| Drug |
prednisone |
163 |
2014 |
| Drug |
docetaxel |
162 |
2014 |
| placebo |
placebo |
161 |
2014 |
| Other |
laboratory biomarker analysis |
130 |
2015 |
| Drug |
enzalutamide |
124 |
2015 |
| Drug |
abiraterone acetate |
90 |
2014 |
| Drug |
bicalutamide |
79 |
2015 |
| Radiation |
radiotherapy |
78 |
2009 |
| Other |
quality-of-life assessment |
68 |
2015 |
| Other |
questionnaire administration |
54 |
2018 |
| Drug |
degarelix |
49 |
2015 |
| Drug |
leuprolide acetate |
49 |
2015 |
| Procedure |
radical prostatectomy |
39 |
2010 |
| Drug |
zoledronic acid |
39 |
2017 |
| Drug |
goserelin acetate |
38 |
2015 |
| Drug |
abiraterone |
36 |
2009 |
| Drug |
apalutamide |
34 |
2018 |
| Drug |
flutamide |
34 |
2015 |
| Other |
pharmacological study |
33 |
2010 |
| Drug |
carboplatin |
29 |
2018 |
| Device |
mri |
26 |
2013 |
| Drug |
pembrolizumab |
25 |
2014 |
| Drug |
goserelin |
24 |
2009 |
| Drug |
ct-scan |
21 |
2014 |
| Procedure |
positron emission tomography |
21 |
2018 |
| Drug |
cabazitaxel |
20 |
2018 |
| Drug |
ipilimumab |
20 |
2014 |
| Other |
questionnaire |
20 |
2018 |
| Biological |
sipuleucel-t |
20 |
2011 |
| Other |
standard care |
20 |
2015 |
| Drug |
estramustine phosphate sodium |
19 |
2002 |
| Drug |
nivolumab |
19 |
2018 |
| Procedure |
computed tomography |
18 |
2018 |
| Behavioral |
exercise intervention |
18 |
2018 |
| Drug |
leuprolide |
18 |
2014 |
| Procedure |
magnetic resonance imaging |
18 |
2013 |
| Drug |
dexamethasone |
17 |
2010 |
| Drug |
olaparib |
17 |
2014 |
| Drug |
prednisolone |
17 |
2014 |
| Drug |
dutasteride |
16 |
2012 |
| Radiation |
stereotactic body radiation therapy |
16 |
2017 |
| Drug |
paclitaxel |
15 |
2016 |
| Procedure |
conventional surgery |
14 |
2006 |
| Biological |
bevacizumab |
13 |
2009 |
| Behavioral |
exercise |
13 |
2017 |
| Drug |
metformin |
13 |
2010 |
| Radiation |
radiation |
13 |
2011 |
| Biological |
sargramostim |
13 |
2014 |
| Radiation |
sbrt |
13 |
2019 |
| Radiation |
brachytherapy |
12 |
2018 |
| Drug |
cyclophosphamide |
12 |
2018 |
| Drug |
estramustine |
12 |
2010 |
| Drug |
ketoconazole |
12 |
2009 |
| Procedure |
pet |
12 |
2018 |
| Drug |
18f-dcfpyl |
11 |
2017 |
| Drug |
androgen deprivation therapy |
11 |
2014 |
| Drug |
androgen deprivation therapy (adt) |
11 |
2018 |
| Radiation |
external beam radiation therapy |
11 |
2016 |
| Radiation |
intensity-modulated radiation therapy |
11 |
2019 |
| Biological |
prostvac-v |
11 |
2018 |
| Procedure |
therapeutic conventional surgery |
11 |
2009 |
| Drug |
triptorelin |
11 |
2014 |
| Drug |
cabozantinib |
10 |
2012 |
| Other |
educational intervention |
10 |
2009 |
| Drug |
lhrh agonist |
10 |
2013 |
| Dietary Supplement |
lycopene |
10 |
2013 |
| Drug |
mitoxantrone |
10 |
2010 |
| Drug |
mitoxantrone hydrochloride |
10 |
1999 |
| Procedure |
neoadjuvant therapy |
10 |
2008 |
| Procedure |
prostate biopsy |
10 |
2019 |
| Procedure |
prostatectomy |
10 |
2009 |
| Biological |
prostvac-f |
10 |
2018 |
| Drug |
thalidomide |
10 |
2002 |
| Drug |
doxorubicin hydrochloride |
9 |
2006 |
| Drug |
nilutamide |
9 |
2016 |
| Drug |
radium-223 |
9 |
2019 |
| Drug |
radium-223 dichloride (xofigo, bay88-8223) |
9 |
2010 |
| Drug |
rucaparib |
9 |
2018 |
| Dietary Supplement |
vitamin d |
9 |
2009 |
| Procedure |
adjuvant therapy |
8 |
2008 |
| Procedure |
care |
8 |
2009 |
| Drug |
casodex |
8 |
2014 |
| Drug |
dasatinib |
8 |
2015 |
| Dietary Supplement |
dietary intervention |
8 |
2013 |
| Drug |
etoposide |
8 |
2009 |
| Drug |
gm-csf |
8 |
2011 |
| Procedure |
psychosocial assessment |
8 |
2009 |
| Procedure |
psychosocial assessment/care |
8 |
2009 |
| Drug |
adt |
7 |
2018 |
| Biological |
denosumab |
7 |
2009 |
| Drug |
durvalumab |
7 |
2019 |
| Drug |
gallium ga 68-labeled psma-11 |
7 |
2018 |
| Dietary Supplement |
selenium |
7 |
2008 |
| Drug |
temsirolimus |
7 |
2010 |
| Drug |
zoladex |
7 |
2018 |
| Drug |
arn-509 |
6 |
2013 |
| Procedure |
biopsy |
6 |
2014 |
| Procedure |
bone scan |
6 |
2013 |
| Drug |
buserelin |
6 |
2009 |
| Drug |
cabazitaxel (xrp6258) |
6 |
2012 |
| Dietary Supplement |
calcitriol |
6 |
2005 |
| Dietary Supplement |
cholecalciferol |
6 |
2008 |
| Drug |
cisplatin |
6 |
2009 |
| Other |
control |
6 |
2009 |
| Diagnostic Test |
ct scan |
6 |
2015 |
| Biological |
dendritic cells dcvac |
6 |
2014 |
| Drug |
everolimus |
6 |
2009 |
| Drug |
finasteride |
6 |
2011 |
| Radiation |
imrt |
6 |
2014 |
| Other |
informational intervention |
6 |
2018 |
| Drug |
ixabepilone |
6 |
2009 |
| Radiation |
low-let photon therapy |
6 |
2008 |
| Drug |
niraparib |
6 |
2019 |
| Procedure |
orchiectomy |
6 |
2018 |
| Drug |
orteronel |
6 |
2012 |
| Biological |
pca |
6 |
2018 |
| Radiation |
radium ra 223 dichloride |
6 |
2015 |
| Dietary Supplement |
soy protein isolate |
6 |
2006 |
| Drug |
testosterone cypionate |
6 |
2014 |
| Drug |
therapeutic hydrocortisone |
6 |
2007 |
| Drug |
18f-dcfpyl injection |
5 |
2018 |
| Drug |
antiandrogen therapy |
5 |
2018 |
| Drug |
atrasentan |
5 |
2005 |
| Behavioral |
behavioral dietary intervention |
5 |
2014 |
| Drug |
chemotherapy |
5 |
2017 |
| Procedure |
ct imaging |
5 |
2009 |
| Drug |
curcumin |
5 |
2014 |
| Biological |
dendritic cells dcvac/pca |
5 |
2014 |
| Radiation |
external beam radiotherapy |
5 |
2018 |
| Drug |
gefitinib |
5 |
2008 |
| Procedure |
high-intensity focused ultrasound ablation |
5 |
2010 |
| Radiation |
hypofractionated radiation therapy |
5 |
2017 |
| Drug |
imatinib mesylate |
5 |
2007 |
| Other |
internet-based intervention |
5 |
2017 |
| Drug |
lenalidomide |
5 |
2009 |
| Drug |
mdv3100 |
5 |
2012 |
| Drug |
odm-201 |
5 |
2017 |
| Biological |
prostvac-v/tricom |
5 |
2013 |
| Biological |
qs21 |
5 |
2007 |
| Drug |
satraplatin |
5 |
2011 |
| Drug |
sunitinib |
5 |
2008 |
| Procedure |
surgery |
5 |
2007 |
| Biological |
trastuzumab |
5 |
2015 |
| Biological |
tricom |
5 |
2013 |
| Dietary Supplement |
vitamin e |
5 |
2009 |
| Diagnostic Test |
18f-dcfpyl pet |
4 |
2018 |
| Radiation |
3-dimensional conformal radiation therapy |
4 |
2009 |
| Procedure |
assessment of therapy complications |
4 |
2010 |
| Drug |
atezolizumab |
4 |
2017 |
| Drug |
avelumab |
4 |
2017 |
| Other |
blood draw |
4 |
2008 |
| Drug |
cabazitaxel xrp6258 |
4 |
2014 |
| Drug |
capecitabine |
4 |
2005 |
| Drug |
celecoxib |
4 |
2010 |
| Drug |
custirsen sodium |
4 |
2012 |
| Drug |
cyproterone acetate |
4 |
2009 |
| Drug |
docetaxel (xrp6976) |
4 |
2012 |
| Drug |
docetaxel 75 mg |
4 |
2016 |
| Drug |
exisulind |
4 |
2006 |
| Biological |
filgrastim |
4 |
2015 |
| Drug |
gemcitabine hydrochloride |
4 |
2009 |
| Genetic |
gene expression analysis |
4 |
2009 |
| Radiation |
hdr brachytherapy |
4 |
2018 |
| Radiation |
image-guided radiation therapy |
4 |
2008 |
| Biological |
immunotherapy allogeneic gm-csf secreting cellular vaccine |
4 |
2005 |
| Drug |
ipatasertib |
4 |
2017 |
| Drug |
leuprorelin |
4 |
2013 |
| Drug |
lhrha |
4 |
2013 |
| Drug |
lupron |
4 |
2020 |
| Drug |
m2 |
4 |
2014 |
| Procedure |
management of therapy complications |
4 |
2012 |
| Other |
medical chart review |
4 |
2017 |
| Drug |
midazolam |
4 |
2016 |
| Device |
multi-parametric mri |
4 |
2014 |
| Device |
multiparametric mri |
4 |
2013 |
| Device |
pet scan |
4 |
2010 |
| Procedure |
pet/mri |
4 |
2019 |
| Drug |
prednisone/prednisolone |
4 |
2014 |
| Biological |
prostvac-f/tricom |
4 |
2013 |
| Drug |
psma adc |
4 |
2011 |
| Drug |
radium-223 dichloride |
4 |
2015 |
| Drug |
radium-223 dichloride (bay88-8223) |
4 |
2012 |
| Procedure |
robot-assisted laparoscopic surgery |
4 |
2014 |
| Drug |
saline |
4 |
2016 |
| Drug |
shr3680 |
4 |
2018 |
| Radiation |
stereotactic ablative radiotherapy |
4 |
2015 |
| Radiation |
stereotactic body radiation therapy (sbrt) |
4 |
2014 |
| Drug |
sunitinib malate |
4 |
2006 |
| Drug |
suramin |
4 |
1999 |
| Drug |
tak-700 |
4 |
2010 |
| Drug |
taxotere |
4 |
2014 |
| Behavioral |
telephone-based intervention |
4 |
2018 |
| Drug |
testosterone enanthate |
4 |
2014 |
| Biological |
tremelimumab |
4 |
2017 |
| Drug |
177lu-psma |
3 |
2019 |
| Drug |
177lu-psma-617 |
3 |
2018 |
| Drug |
18f-dcfbc |
3 |
2010 |
| Drug |
18f-dcfpyl pet/ct |
3 |
2018 |
| Drug |
68ga-psma-11 |
3 |
2018 |
| Procedure |
active surveillance |
3 |
2012 |
| Drug |
alvocidib |
3 |
1999 |
| Drug |
androgen deprivation |
3 |
2012 |
| Drug |
antagonist |
3 |
2018 |
| Drug |
antiandrogen |
3 |
2016 |
| Drug |
aspirin |
3 |
2019 |
| Drug |
at-101 |
3 |
2006 |
| Other |
blood sample |
3 |
2014 |
| Drug |
bortezomib |
3 |
2008 |
| Dietary Supplement |
calcium |
3 |
2006 |
| Drug |
ciprofloxacin |
3 |
2012 |
| Other |
counseling intervention |
3 |
2013 |
| Procedure |
cryoablation |
3 |
2010 |
| Radiation |
cyberknife stereotactic radiosurgery |
3 |
2014 |
| Other |
demographic variables |
3 |
2009 |
| Other |
diagnostic laboratory biomarker analysis |
3 |
2009 |
| Procedure |
diffusion-weighted magnetic resonance imaging |
3 |
2013 |
| Drug |
enzalutamide (xtandi) |
3 |
2018 |
| Procedure |
external beam radiation |
3 |
2013 |
| Drug |
facbc |
3 |
2012 |
| Procedure |
fatigue assessment |
3 |
2009 |
| Procedure |
fatigue assessment/management |
3 |
2009 |
| Drug |
fluciclovine f18 |
3 |
2018 |
| Radiation |
fluorine f 18 sodium fluoride |
3 |
2009 |
| Device |
focal laser ablation |
3 |
2015 |
| Drug |
fulvestrant |
3 |
2017 |
| Drug |
ga-68 psma-hbed-cc pet |
3 |
2017 |
| Drug |
gnrh agonist |
3 |
2004 |
| Drug |
hc1119 |
3 |
2018 |
| Drug |
histrelin acetate |
3 |
2014 |
| Drug |
hydrocortisone |
3 |
2009 |
| Radiation |
hypofractionated radiotherapy |
3 |
2010 |
| Radiation |
igrt |
3 |
2014 |
| Radiation |
igrt 24 gy single dose |
3 |
2019 |
| Other |
immunohistochemistry staining method |
3 |
2007 |
| Radiation |
intensity modulated radiation therapy (imrt) |
3 |
2013 |
| Drug |
lapatinib ditosylate |
3 |
2005 |
| Procedure |
magnetic resonance spectroscopic imaging |
3 |
2018 |
| Procedure |
management |
3 |
2009 |
| Drug |
mdx-010 |
3 |
2006 |
| Drug |
metformin hydrochloride |
3 |
2015 |
| Drug |
methylprednisolone |
3 |
2018 |
| Drug |
mifepristone |
3 |
2013 |
| Drug |
motexafin gadolinium |
3 |
2012 |
| Device |
mpmri |
3 |
2016 |
| Device |
mr |
3 |
2019 |
| Device |
mri scan |
3 |
2017 |
| Device |
ms3tmri |
3 |
2013 |
| Drug |
niclosamide |
3 |
2016 |
| Procedure |
nutritional support |
3 |
2013 |
| Drug |
palbociclib |
3 |
2016 |
| Drug |
panobinostat |
3 |
2009 |
| Drug |
pioglitazone |
3 |
2013 |
| Genetic |
polymerase chain reaction |
3 |
2009 |
| Genetic |
polymorphism analysis |
3 |
2010 |
| Drug |
prednisone 5 mg |
3 |
2016 |
| Radiation |
proton beam radiation therapy |
3 |
2013 |
| Drug |
prx302 |
3 |
2015 |
| Biological |
ptvg-hp |
3 |
2011 |
| Drug |
pyruvate (13c) |
3 |
2016 |
| Drug |
r |
3 |
2019 |
| Drug |
rad001 |
3 |
2008 |
| Radiation |
radiation therapy treatment planning |
3 |
2015 |
| Radiation |
radiation therapy treatment planning/simulation |
3 |
2015 |
| Biological |
recombinant vaccinia prostate-specific antigen vaccine |
3 |
1999 |
| Genetic |
reverse transcriptase-polymerase chain reaction |
3 |
2011 |
| Drug |
rhpsma-7.3 (18f) injection |
3 |
2019 |
| Genetic |
rna analysis |
3 |
2009 |
| Drug |
sildenafil citrate |
3 |
2004 |
| Radiation |
simulation |
3 |
2015 |
| Drug |
sorafenib tosylate |
3 |
2007 |
| Dietary Supplement |
soy isoflavones |
3 |
2006 |
| Radiation |
stereotactic body radiotherapy |
3 |
2014 |
| Radiation |
stereotactic radiosurgery |
3 |
2014 |
| Other |
study of socioeconomic |
3 |
2009 |
| Other |
study of socioeconomic/demographic variables |
3 |
2009 |
| Other |
survivorship care plan |
3 |
2017 |
| Procedure |
systematic biopsies |
3 |
2017 |
| Drug |
tanespimycin |
3 |
2005 |
| Drug |
tasquinimod |
3 |
2014 |
| Procedure |
therapeutic dietary intervention |
3 |
2008 |
| Drug |
trametinib |
3 |
2015 |
| Drug |
triptorelin pamoate |
3 |
2015 |
| Device |
trus guided biopsy |
3 |
2013 |
| Device |
ultrasound |
3 |
2019 |
| Procedure |
ultrasound imaging |
3 |
2013 |
| Drug |
valacyclovir |
3 |
2016 |
| Drug |
vinorelbine tartrate |
3 |
2008 |
| Drug |
vorinostat |
3 |
2007 |
| Drug |
warfarin |
3 |
2013 |
| Device |
whole body mri |
3 |
2013 |
| Diagnostic Test |
[18f]psma-11 |
2 |
2019 |
| Diagnostic Test |
[68ga]psma-11 |
2 |
2017 |
| Biological |
[89zr]df-iab2m |
2 |
2015 |
| Drug |
123-i-mip-1072 |
2 |
2009 |
| Drug |
177lu-j591 |
2 |
2009 |
| Device |
18f-choline pet |
2 |
2014 |
| Drug |
18f-fluciclovine pet ct |
2 |
2016 |
| Drug |
18f-naf |
2 |
2017 |
| Drug |
68-ga psma11 |
2 |
2020 |
| Diagnostic Test |
68ga-hbed-cc-psma pet |
2 |
2018 |
| Drug |
68ga-psma |
2 |
2018 |
| Drug |
68ga-psma-617 pet |
2 |
2018 |
| Drug |
68ga-psma-617 pet/ct |
2 |
2018 |
| Drug |
68ga-psma-hbed-cc |
2 |
2016 |
| Drug |
68ga-rm2 pet |
2 |
2018 |
| Drug |
68ga-rm2 pet/ct |
2 |
2018 |
| Drug |
80 mg |
2 |
2008 |
| Drug |
99mtc-mip-1404 |
2 |
2011 |
| Drug |
abiraterone acetate 1000 mg |
2 |
2016 |
| Drug |
abiraterone/prednisone |
2 |
2018 |
| Behavioral |
acceptance |
2 |
2012 |
| Other |
acupuncture |
2 |
2019 |
| Drug |
adavosertib |
2 |
2017 |
| Biological |
adenovirus |
2 |
2007 |
| Biological |
adenovirus/psa vaccine |
2 |
2007 |
| Drug |
akt inhibitor mk2206 |
2 |
2011 |
| Biological |
aldesleukin |
2 |
1999 |
| Biological |
alecsat |
2 |
2009 |
| Drug |
alendronate |
2 |
2005 |
| Drug |
amg 162 |
2 |
2009 |
| Drug |
amifostine trihydrate |
2 |
1999 |
| Drug |
androgen-deprivation therapy (adt) |
2 |
2017 |
| Drug |
androgen blockade |
2 |
2005 |
| Drug |
androgen suppression |
2 |
2014 |
| Drug |
androgen suppression therapy |
2 |
2011 |
| Biological |
ap1903 |
2 |
2009 |
| placebo |
apc-placebo |
2 |
2010 |
| Drug |
atrasentan hydrochloride |
2 |
2005 |
| Behavioral |
attention control |
2 |
2014 |
| Device |
auroshell particle infusion |
2 |
2016 |
| Drug |
avodart |
2 |
2008 |
| Drug |
axitinib |
2 |
2011 |
| Drug |
azd2171 |
2 |
2007 |
| Drug |
azd3514 |
2 |
2010 |
| Drug |
azd4635 |
2 |
2016 |
| Drug |
azd5363 |
2 |
2017 |
| Other |
best available therapy |
2 |
2017 |
| Drug |
bibf 1120 |
2 |
2014 |
| Drug |
bkm120 |
2 |
2012 |
| Other |
blood |
2 |
2018 |
| Biological |
blood test |
2 |
2015 |
| Drug |
br55 |
2 |
2014 |
| Drug |
capivasertib |
2 |
2015 |
| Drug |
cc-115 |
2 |
2016 |
| Device |
ceevra reveal |
2 |
2019 |
| Drug |
cemiplimab |
2 |
2020 |
| Drug |
cetrelimab 480 mg |
2 |
2018 |
| Biological |
cetuximab |
2 |
2008 |
| Device |
choline pet |
2 |
2014 |
| Drug |
cilengitide |
2 |
2005 |
| Biological |
cixutumumab |
2 |
2009 |
| Device |
claricore system |
2 |
2016 |
| Other |
clinical observation |
2 |
2010 |
| Biological |
cnto 328 |
2 |
2007 |
| Behavioral |
cognitive behavior therapy |
2 |
2017 |
| Device |
confocal laser endomicroscopy |
2 |
2018 |
| Device |
continuumâ„¢ |
2 |
2009 |
| Drug |
copanlisib |
2 |
2020 |
| Radiation |
copper cu 64 tp3805 |
2 |
2016 |
| Other |
counseling |
2 |
2018 |
| Drug |
crizotinib |
2 |
2015 |
| Drug |
crlx101 |
2 |
2018 |
| Device |
ct) |
2 |
2019 |
| Drug |
ctt1057 |
2 |
2016 |
| Radiation |
cyberknife boost |
2 |
2011 |
| Radiation |
cyberknife radiosurgery |
2 |
2014 |
| Other |
cytology specimen collection procedure |
2 |
2015 |
| Drug |
cytoxan |
2 |
2016 |
| Drug |
darolutamide |
2 |
2017 |
| Other |
decision aid |
2 |
2014 |
| Drug |
degarelix acetate |
2 |
2019 |
| Drug |
dexmedetomidine |
2 |
2018 |
| Behavioral |
diet |
2 |
2016 |
| Other |
diffuse optical imaging |
2 |
2014 |
| Drug |
digoxin |
2 |
2010 |
| Drug |
docetaxel 75 mg/m2 |
2 |
2019 |
| Drug |
docetaxel/prednisone |
2 |
2018 |
| Drug |
doxil |
2 |
2006 |
| Radiation |
ebrt |
2 |
2018 |
| Drug |
eflornithine |
2 |
2004 |
| Drug |
eligard |
2 |
2014 |
| Biological |
emd 525797 |
2 |
2009 |
| Drug |
endocrine-modulating drug therapy |
2 |
1999 |
| Behavioral |
endurance training |
2 |
2012 |
| Drug |
enzalutamide capsule |
2 |
2013 |
| Drug |
enzastaurin |
2 |
2007 |
| Other |
enzyme-linked immunosorbent assay |
2 |
2011 |
| Behavioral |
epic sf-12 questionnaire |
2 |
2011 |
| Biological |
epoetin alfa |
2 |
2006 |
| Drug |
erdafitinib |
2 |
2015 |
| Drug |
erlotinib hydrochloride |
2 |
2004 |
| Drug |
estetrol |
2 |
2017 |
| Biological |
f |
2 |
2016 |
| Drug |
fenretinide |
2 |
2004 |
| Drug |
fentanyl |
2 |
2015 |
| Dietary Supplement |
fish oil |
2 |
2008 |
| Drug |
fludarabine |
2 |
2019 |
| Drug |
flutamide (eulexin) |
2 |
2007 |
| Device |
focal cryotherapy |
2 |
2008 |
| Device |
focal irreversible electroporation of the prostate cancer |
2 |
2019 |
| Drug |
foxy-5 |
2 |
2016 |
| Drug |
ga-68 psma ligand |
2 |
2019 |
| Drug |
genistein |
2 |
2011 |
| Other |
geriatric assessment |
2 |
2013 |
| Drug |
gleevec |
2 |
2005 |
| Drug |
glucocorticoid |
2 |
2012 |
| Drug |
gnrh |
2 |
2017 |
| Biological |
gnrh agonist/antagonist |
2 |
2018 |
| Drug |
gnrh analog |
2 |
2019 |
| Biological |
gonadotrophin releasing hormone |
2 |
2019 |
| Biological |
gonadotropin-releasing hormone analog |
2 |
2017 |
| Dietary Supplement |
green tea |
2 |
2008 |
| Dietary Supplement |
green tea extract |
2 |
2013 |
| Drug |
gt0918 |
2 |
2016 |
| Biological |
gti-2040 |
2 |
2004 |
| Behavioral |
guided imagery |
2 |
2011 |
| Radiation |
hdr |
2 |
2013 |
| Radiation |
hdr brachytherapy boost |
2 |
2004 |
| Radiation |
high-dose rate brachytherapy |
2 |
2020 |
| Radiation |
high dose rate prostate brachytherapy |
2 |
2018 |
| Device |
high intensity focused ultrasound |
2 |
2008 |
| Behavioral |
home-based exercise |
2 |
2014 |
| Behavioral |
home based exercise |
2 |
2016 |
| Drug |
hsv-tk |
2 |
2018 |
| Drug |
huj591 |
2 |
2016 |
| Drug |
hydroxychloroquine |
2 |
2011 |
| Device |
hyperthermia |
2 |
2015 |
| Procedure |
hyperthermia treatment |
2 |
2016 |
| Radiation |
hypofractionated imrt boost radiotherapy |
2 |
2014 |
| Radiation |
hypofractionated radiation |
2 |
2011 |
| Radiation |
hypofractionated radiosurgery |
2 |
2018 |
| Radiation |
hypofractionation |
2 |
2014 |
| Combination Product |
iadt |
2 |
2018 |
| Radiation |
igrt 45 gy in 5 fractions of 9 gy |
2 |
2015 |
| Biological |
imc-a12 |
2 |
2008 |
| Drug |
immu-132 |
2 |
2018 |
| Other |
immunoenzyme technique |
2 |
2007 |
| Drug |
imp4297 |
2 |
2018 |
| Biological |
incomplete freund’s adjuvant |
2 |
2005 |
| Drug |
indomethacin |
2 |
2016 |
| Drug |
inhalation anesthesia |
2 |
2017 |
| Procedure |
intensity modulated external beam radiation therapy |
2 |
2010 |
| Radiation |
intensity modulated radiation therapy |
2 |
2012 |
| Behavioral |
international prostate symptom score |
2 |
2014 |
| Diagnostic Test |
interview |
2 |
2019 |
| Radiation |
iodine i 125 |
2 |
1999 |
| Behavioral |
ipss questionnaire |
2 |
2011 |
| Drug |
irofulven |
2 |
2018 |
| Dietary Supplement |
isoflavone |
2 |
2008 |
| Drug |
jnj-56021927 |
2 |
2014 |
| Drug |
kg |
2 |
2017 |
| Procedure |
laparoscopic radical prostatectomy |
2 |
2016 |
| Radiation |
ldr |
2 |
2013 |
| Drug |
leuprolide 7.5 mg |
2 |
2006 |
| Drug |
leuprolide mesylate |
2 |
2017 |
| Drug |
leuprorelin acetate |
2 |
2006 |
| Drug |
lfa102 |
2 |
2011 |
| Radiation |
low dose rate prostate brachytherapy |
2 |
2018 |
| Drug |
luteinizing hormone-releasing hormone (lhrh) agonist |
2 |
2011 |
| Dietary Supplement |
lycopene, vitamin d3, selenium, green tea extract, vitamin e |
2 |
2008 |
| Drug |
m^2 |
2 |
2016 |
| Behavioral |
max-pc questionnaire |
2 |
2011 |
| Biological |
me tarp vaccine |
2 |
2015 |
| Other |
medical examination |
2 |
2008 |
| Behavioral |
memorial anxiety scale for prostate cancer patients |
2 |
2014 |
| Drug |
methylphenidate |
2 |
2011 |
| Dietary Supplement |
methylselenocysteine |
2 |
2012 |
| Drug |
mln2704 (dm1 conjugated monoclonal antibody mln591) |
2 |
2003 |
| Drug |
modradoc006 |
2 |
2019 |
| Drug |
modradoc006/r |
2 |
2019 |
| Biological |
monoclonal antibody muj591 |
2 |
1999 |
| Device |
mri-guided biopsy |
2 |
2014 |
| Other |
mri imaging |
2 |
2012 |
| Procedure |
mri prostate |
2 |
2005 |
| Device |
mri) |
2 |
2019 |
| Device |
ms3tmri / trus guided biopsy |
2 |
2013 |
| Biological |
muc-2-globo h-klh conjugate vaccine |
2 |
2002 |
| Diagnostic Test |
multiparametric magnetic resonance imaging |
2 |
2010 |
| Dietary Supplement |
multivitamin |
2 |
2005 |
| Biological |
mva-bn-brachyury |
2 |
2018 |
| Procedure |
needle biopsy |
2 |
2008 |
| Biological |
oblimersen sodium |
2 |
2004 |
| Drug |
oleclumab |
2 |
2016 |
| placebo |
orteronel placebo |
2 |
2012 |
| Drug |
osteodex |
2 |
2016 |
| Drug |
oxaliplatin |
2 |
2011 |
| Procedure |
pain therapy |
2 |
1999 |
| Biological |
panitumumab |
2 |
2003 |
| Drug |
patupilone |
2 |
2006 |
| Drug |
pazopanib hydrochloride |
2 |
2007 |
| Procedure |
pd-103 |
2 |
2005 |
| Drug |
pegfilgrastim |
2 |
2011 |
| Drug |
pegylated liposomal doxorubicin hydrochloride |
2 |
1999 |
| Radiation |
pelvic sabr with intra-prostatic sabr |
2 |
2019 |
| Diagnostic Test |
pet/ct imaging |
2 |
2016 |
| Other |
phone counseling with dietitian |
2 |
2019 |
| Procedure |
physical therapy |
2 |
2006 |
| Behavioral |
pictograph |
2 |
2015 |
| Drug |
pimonidazole |
2 |
2014 |
| Dietary Supplement |
pomegranate juice |
2 |
2006 |
| Drug |
propofol |
2 |
2014 |
| Behavioral |
prostate cancer education |
2 |
2007 |
| Behavioral |
prostate cancer screening education |
2 |
2011 |
| Device |
prostatic artery embolization |
2 |
2017 |
| Procedure |
prostatic biopsies |
2 |
2018 |
| Biological |
prostvac-v/f |
2 |
2016 |
| Genetic |
proteomic profiling |
2 |
2008 |
| Radiation |
proton beam therapy |
2 |
2012 |
| Biological |
psa |
2 |
2014 |
| Biological |
psa dosage |
2 |
2018 |
| Biological |
psa prostate cancer vaccine |
2 |
2002 |
| Biological |
psa vaccine |
2 |
2007 |
| Diagnostic Test |
psma -pet |
2 |
2018 |
| Diagnostic Test |
psma pet |
2 |
2019 |
| Biological |
ptvg-ar |
2 |
2019 |
| Biological |
ptvg-hp with rhgm-csf |
2 |
2009 |
| Drug |
rebimastat |
2 |
2002 |
| Biological |
recombinant ephb4-hsa fusion protein |
2 |
2016 |
| Drug |
recombinant fowlpox-gm-csf |
2 |
2006 |
| Biological |
recombinant fowlpox-prostate specific antigen vaccine |
2 |
2002 |
| Biological |
recombinant fowlpox-psa(l155) |
2 |
2005 |
| Biological |
recombinant interleukin-12 |
2 |
1999 |
| Biological |
recombinant vaccinia-b7.1 vaccine |
2 |
2002 |
| Biological |
recombinant vaccinia-tricom vaccine |
2 |
2007 |
| Behavioral |
reiki |
2 |
2003 |
| Drug |
releasing hormone agonist therapy |
2 |
2002 |
| Drug |
relugolix |
2 |
2017 |
| Drug |
revlimid |
2 |
2008 |
| Biological |
rhgm-csf |
2 |
2011 |
| Drug |
ribociclib |
2 |
2015 |
| Drug |
risedronate |
2 |
2009 |
| Drug |
romidepsin |
2 |
2012 |
| Drug |
rosuvastatin |
2 |
2019 |
| Biological |
rv001v |
2 |
2019 |
| Procedure |
salvage lymph node dissection |
2 |
2016 |
| Other |
screening questionnaire administration |
2 |
2009 |
| Dietary Supplement |
selenomethionine |
2 |
2010 |
| Drug |
shr3162 |
2 |
2019 |
| Drug |
sirolimus |
2 |
2012 |
| Drug |
sorafenib |
2 |
2006 |
| Drug |
standard of care adt |
2 |
2012 |
| Device |
steep pulse device |
2 |
2017 |
| Radiation |
stereotactic body radiotherapy (sbrt) |
2 |
2017 |
| Behavioral |
stretching |
2 |
2018 |
| Radiation |
strontium chloride sr 89 |
2 |
2007 |
| Drug |
su011248 |
2 |
2005 |
| Drug |
sulforadex |
2 |
2013 |
| Dietary Supplement |
sulforaphane |
2 |
2010 |
| Behavioral |
supervised group exercise |
2 |
2016 |
| Drug |
tadalafil |
2 |
2009 |
| Drug |
tak-385 |
2 |
2014 |
| Drug |
talazoparib |
2 |
2019 |
| Drug |
tamoxifen |
2 |
2008 |
| Diagnostic Test |
targeted biopsies |
2 |
2019 |
| Drug |
taxotere (docetaxel) |
2 |
2010 |
| Drug |
temozolomide |
2 |
2019 |
| Drug |
tisotumab vedotin (humax-tf-adc) |
2 |
2013 |
| Dietary Supplement |
tomato-soy juice |
2 |
2009 |
| Drug |
tookadâ® soluble |
2 |
2011 |
| Drug |
total intravenous anesthesia |
2 |
2017 |
| Procedure |
transrectal prostate biopsy |
2 |
2010 |
| Drug |
trc105 |
2 |
2010 |
| Procedure |
treatment with focal hifu |
2 |
2018 |
| Drug |
tricom) |
2 |
2006 |
| Procedure |
trus biopsy |
2 |
2017 |
| Procedure |
ultrasound-guided prostate biopsy |
2 |
2017 |
| Drug |
vinblastine |
2 |
1999 |
| Drug |
vinorelbine ditartrate |
2 |
2010 |
| Drug |
vismodegib |
2 |
2015 |
| Dietary Supplement |
vitamin c |
2 |
2015 |
| Behavioral |
website |
2 |
2016 |
| Behavioral |
weight loss program |
2 |
2014 |
| Drug |
wst11 |
2 |
2008 |
| Drug |
ym155 |
2 |
2009 |
| Drug |
zd4054 |
2 |
2008 |
| Drug |
zd4054 10 mg |
2 |
2004 |
| Drug |
zd4054 15 mg |
2 |
2004 |
| Drug |
zen003694 |
2 |
2016 |
| Drug |
zometa |
2 |
2007 |
| Drug |
-[18f] dihydro-testosterone |
1 |
2007 |
| Drug |
-pt |
1 |
2016 |
| Device |
"ablatherm foc |
1 |
2012 |
| Device |
“ablatherm foc/dyn”/“focal one” hifu treatment |
1 |
2012 |
| Device |
“focal one” hifu treatment |
1 |
2012 |
| Radiation |
“truebeam” stereotactic body radiosurgery |
1 |
2012 |
| Drug |
(64cu)-labeled psma-targeting particle tracer, |
1 |
2019 |
| Drug |
(64cu)-labeled psma-targeting particle tracer,/64cu-nota-psmai-peg-cy5.5-c’ dots |
1 |
2019 |
| Drug |
(68ga)psma-hbed-cc |
1 |
2016 |
| Drug |
(c-11 acetate) |
1 |
2009 |
| Drug |
(hmb |
1 |
2012 |
| Drug |
.5% bupivacaine |
1 |
2019 |
| Drug |
[18f]-dcfpyl ligand |
1 |
2020 |
| Diagnostic Test |
[18f]-dcfpyl pet |
1 |
2018 |
| Diagnostic Test |
[18f]-dcfpyl pet/ ct scan (psma pet) |
1 |
2018 |
| Drug |
[18f]-fluoro-2-deoxy-d-glucose |
1 |
2007 |
| Drug |
[18f]-fluoro-2-deoxy-d-glucose/-[18f] dihydro-testosterone |
1 |
2007 |
| Drug |
[18f] dihydro-testosterone |
1 |
2014 |
| Drug |
[18f] fluciclovine |
1 |
2017 |
| Diagnostic Test |
[18f] fluciclovine pet |
1 |
2017 |
| Diagnostic Test |
[18f] fluciclovine pet/mri |
1 |
2017 |
| Diagnostic Test |
[18f]dcfpyl pet |
1 |
2017 |
| Diagnostic Test |
[18f]dcfpyl pet/mri scan |
1 |
2017 |
| Device |
[18f]fluorthanatrace |
1 |
2017 |
| Drug |
[f-18] dcfpyl |
1 |
2018 |
| Device |
[ga-68]psma pet |
1 |
2016 |
| Device |
[ga-68]psma pet/mr |
1 |
2016 |
| Radiation |
< 15% risk of |
1 |
2009 |
| Radiation |
< 15% risk of / ln |
1 |
2009 |
| Radiation |
> 15% risk of |
1 |
2009 |
| Radiation |
> 15% risk of / ln |
1 |
2009 |
| Drug |
0,4) |
1 |
2011 |
| Drug |
0.5 ml bolus dose |
1 |
2012 |
| Drug |
1 pomx capsule |
1 |
2010 |
| Procedure |
1 retrograde radical prostatectomy rrp |
1 |
2015 |
| Drug |
1.11gbq of 177lu-eb-psma-617 |
1 |
2018 |
| Drug |
1.85gbq of 177lu-eb-psma-617 |
1 |
2018 |
| Procedure |
10-core prostate biopsy protocol |
1 |
2012 |
| Radiation |
103-palladium |
1 |
2007 |
| Radiation |
110) |
1 |
2003 |
| Drug |
111-in capromab pendetide |
1 |
2009 |
| Drug |
111in-dota-h11b6 |
1 |
2019 |
| Drug |
111in-j591 |
1 |
2009 |
| Drug |
117lu-j591 |
1 |
2007 |
| Procedure |
11c |
1 |
2016 |
| Drug |
11c-acetate |
1 |
2016 |
| Radiation |
11c-choline |
1 |
2013 |
| Drug |
11c-choline injection |
1 |
2014 |
| Procedure |
11c/18f-choline pet/ct |
1 |
2016 |
| Behavioral |
12-week aerobic exercise |
1 |
2018 |
| Behavioral |
12-week aerobic exercise/cognitive-behavioral therapy |
1 |
2018 |
| Procedure |
12 core standard transrectal prostate biopsy |
1 |
2019 |
| Drug |
123-i-mip-1095 |
1 |
2008 |
| Radiation |
125-iodine |
1 |
2007 |
| Drug |
131i-mip-1095 |
1 |
2017 |
| Radiation |
145) |
1 |
2003 |
| Device |
16 french foley catheter |
1 |
2018 |
| Device |
16 french urinary catheter |
1 |
2019 |
| Drug |
177 lu-psma-i&t |
1 |
2019 |
| Radiation |
177lu-psma-i&t radionuclide |
1 |
2019 |
| Drug |
177lu-psma-r2 |
1 |
2018 |
| Other |
177lu-psma617 |
1 |
2017 |
| Drug |
177lu radiolabeled monoclonal antibody huj591 (177lu -j591) |
1 |
2005 |
| Drug |
177lu−j591 |
1 |
2018 |
| Drug |
177lu−psma−617 |
1 |
2018 |
| Device |
18-fdg pet |
1 |
2016 |
| Device |
18-fdg pet/ct |
1 |
2016 |
| Drug |
18f- dcfpyl pet |
1 |
2019 |
| Drug |
18f- dcfpyl pet/ct |
1 |
2019 |
| Drug |
18f-alf-nota-neurotensin |
1 |
2018 |
| Device |
18f-choline pet/ct |
1 |
2014 |
| Diagnostic Test |
18f-dcfpyl iv injection |
1 |
2018 |
| Diagnostic Test |
18f-dcfpyl pet/ct scan |
1 |
2018 |
| Other |
18f-ethylcholine positron emission tomography (fec-pet) |
1 |
2007 |
| Other |
18f-fch pet |
1 |
2013 |
| Other |
18f-fch pet/mri imaging |
1 |
2013 |
| Drug |
18f-fdg |
1 |
2017 |
| Drug |
18f-fluciclovine |
1 |
2017 |
| Drug |
18f-fluciclovine pet scan |
1 |
2019 |
| Other |
18f-fluoroazomycin arabinoside (18f-faza) |
1 |
2012 |
| Drug |
18f-fluorocholine |
1 |
2020 |
| Drug |
18f-fluoromethylcholine (18f-fch) |
1 |
2016 |
| Drug |
18f-naf pet |
1 |
2018 |
| Drug |
18f-naf pet/ct |
1 |
2018 |
| Diagnostic Test |
18f-psma |
1 |
2018 |
| Drug |
18f-sodium fluoride (naf) |
1 |
2013 |
| Drug |
18f dcfbc |
1 |
2014 |
| Biological |
1b) |
1 |
2015 |
| Biological |
1mg ino-9012 |
1 |
2015 |
| Other |
2-days discharge |
1 |
2018 |
| Drug |
2-hydroxyflutamide |
1 |
2009 |
| Drug |
2-hydroxyflutamide (2-hof) |
1 |
2014 |
| Drug |
2-hydroxyflutamide (2-hof) [liproca depot] |
1 |
2009 |
| Drug |
2-hydroxyflutamide depot |
1 |
2017 |
| Procedure |
2 anterograde radical prostatectomy rrp2a |
1 |
2015 |
| Drug |
2 î¼g |
1 |
2012 |
| Other |
20 core-biopsy fragments |
1 |
2016 |
| Procedure |
20 fractions in 4 weeks |
1 |
2006 |
| Procedure |
20 fractions over 28 days |
1 |
2005 |
| Device |
20 french urinary catheter |
1 |
2019 |
| Drug |
225ac−j591 |
1 |
2017 |
| Biological |
2b) |
1 |
2015 |
| Radiation |
2d radiotherapy |
1 |
2017 |
| Biological |
2mg ino-5150 |
1 |
2015 |
| Biological |
2mg ino-5150/1mg ino-9012/electroporation device cellectraâ®-5p |
1 |
2015 |
| Biological |
2mg ino-5150/electroporation device cellectraâ®-5p |
1 |
2015 |
| Drug |
2nd generation adt (abiraterone |
1 |
2018 |
| Drug |
2nd generation adt (abiraterone/enzalutamide) |
1 |
2018 |
| Radiation |
3-dimensional ultrasound-guided radiation therapy |
1 |
2015 |
| Procedure |
3-tesla magnetic resonance imaging |
1 |
2013 |
| Procedure |
3-tesla magnetic resonance imaging (3t mri) |
1 |
2012 |
| Drug |
3 pomx capsules |
1 |
2010 |
| Drug |
3.70gbq of 177lu-eb-psma-617 |
1 |
2018 |
| Radiation |
30gy (gray) planning target volume (ptv) |
1 |
2018 |
| Procedure |
33 fractions over 45 days |
1 |
2005 |
| Radiation |
36.25 gy imrt |
1 |
2011 |
| Procedure |
39 fractions in 8 weeks |
1 |
2006 |
| Radiation |
3d-crt |
1 |
1999 |
| Device |
3d prostate ultrasound |
1 |
2015 |
| Device |
3d ultrasound-guided biopsy |
1 |
2013 |
| Procedure |
3t mr imaging |
1 |
2008 |
| Procedure |
3t mr spectroscopy |
1 |
2008 |
| Device |
3t mri (magnetom verio 3t, erlangen, germany) |
1 |
2013 |
| Device |
3t multiparametric mri |
1 |
2015 |
| Drug |
400mg bid) |
1 |
2006 |
| Radiation |
46 gy in 23 fractions |
1 |
2015 |
| Radiation |
5 |
1 |
2020 |
| Drug |
5-azacitidine |
1 |
2018 |
| Radiation |
51.6 gy imrt |
1 |
2011 |
| Procedure |
5250 cgy |
1 |
2005 |
| Procedure |
5250 cgy/20 fractions over 28 days |
1 |
2005 |
| Procedure |
6000 cgy |
1 |
2006 |
| Procedure |
6000 cgy/20 fractions in 4 weeks |
1 |
2006 |
| Drug |
64cu-nota-psmai-peg-cy5.5-c’ dots |
1 |
2019 |
| Procedure |
6600 cgy |
1 |
2005 |
| Procedure |
6600 cgy/33 fractions over 45 days |
1 |
2005 |
| Drug |
68-ga rm2 |
1 |
2019 |
| Drug |
68-ga rm2. |
1 |
2020 |
| Drug |
68ga- psma |
1 |
2016 |
| Drug |
68ga- psma-hbed-cc |
1 |
2016 |
| Drug |
68ga-dota-bombesin |
1 |
2015 |
| Drug |
68ga-hbed-cc-psma (dkfz-11) pet |
1 |
2016 |
| Drug |
68ga-hbed-cc-psma (dkfz-11) pet/ct |
1 |
2016 |
| Diagnostic Test |
68ga-hbed-cc-psma pet / ct |
1 |
2018 |
| Drug |
68ga-hbed-cc-psma pet/ct |
1 |
2016 |
| Drug |
68ga-labeled psma |
1 |
2019 |
| Drug |
68ga-nota-ae105 |
1 |
2017 |
| Diagnostic Test |
68ga-psma-11 pet-mri |
1 |
2018 |
| Drug |
68ga-psma-r2 |
1 |
2018 |
| Diagnostic Test |
68ga-psma pet |
1 |
2018 |
| Diagnostic Test |
68ga-psma pet/ct |
1 |
2018 |
| Radiation |
68ga-rm2 (rm2) |
1 |
2015 |
| Drug |
68ga psma-11 injection |
1 |
2019 |
| Drug |
68ga rm2 |
1 |
2019 |
| Drug |
68ga−psma−hbed−cc |
1 |
2018 |
| Drug |
7-hydroxystaurosporine |
1 |
2002 |
| Drug |
7-hydroxystaurosporine (ucn-01) |
1 |
1999 |
| Radiation |
70 gy |
1 |
2011 |
| Radiation |
70 gy/cge |
1 |
2011 |
| Radiation |
70.2 gy 3d-crt |
1 |
2002 |
| Radiation |
70.2 gy 3d-crt/imrt |
1 |
2002 |
| Radiation |
72.5 gy |
1 |
2011 |
| Radiation |
72.5 gy/cge |
1 |
2011 |
| Radiation |
74-80 grays (units of radiation) |
1 |
2015 |
| Procedure |
7800 cgy |
1 |
2006 |
| Procedure |
7800 cgy/39 fractions in 8 weeks |
1 |
2006 |
| Radiation |
79.2 gy 3d-crt |
1 |
2002 |
| Radiation |
79.2 gy 3d-crt/imrt |
1 |
2002 |
| Biological |
8.5mg ino-5150 |
1 |
2015 |
| Biological |
8.5mg ino-5150/1mg ino-9012/electroporation device cellectraâ®-5p |
1 |
2015 |
| Biological |
8.5mg ino-5150/electroporation device cellectraâ®-5p |
1 |
2015 |
| Drug |
89zr- dfo-mstp2109a |
1 |
2013 |
| Drug |
89zr-df-iab2m |
1 |
2016 |
| Drug |
89zr-dfo-huj591 |
1 |
2012 |
| Drug |
89zr dfo-mstp2109a |
1 |
2013 |
| Drug |
89zr−j591 |
1 |
2016 |
| Diagnostic Test |
99mtc-hmdp planar bone scintigraphy (bs) |
1 |
2018 |
| Diagnostic Test |
99mtc-hmdp single photon emission computer tomography |
1 |
2018 |
| Diagnostic Test |
99mtc-hmdp single photon emission computer tomography/computer tomography |
1 |
2018 |
| Procedure |
99mtc-medronate whole body bone scan with spect |
1 |
2013 |
| Drug |
99mtc-mip-1404 injection |
1 |
2015 |
| Drug |
99mtc mip 1404 |
1 |
2012 |
| Diagnostic Test |
a shared decision making |
1 |
2020 |
| Drug |
a166 |
1 |
2018 |
| Drug |
aa normal dose-fasting conditions (c) |
1 |
2015 |
| Drug |
aa reduced dose-fat diet (b) |
1 |
2015 |
| Drug |
aa reduced dose-normal diet (a) |
1 |
2015 |
| Drug |
ab680 |
1 |
2020 |
| Drug |
ab928 |
1 |
2020 |
| Drug |
abarelix |
1 |
2009 |
| Drug |
abemaciclib |
1 |
2018 |
| Biological |
abi-007 |
1 |
1999 |
| Biological |
abi-007/carboplatin/trastuzumab |
1 |
1999 |
| Drug |
abi-008 |
1 |
2007 |
| Drug |
abiraterone - group 1 |
1 |
2015 |
| Drug |
abiraterone - group 2 |
1 |
2015 |
| Drug |
abiraterone / prednisone |
1 |
2015 |
| Drug |
abiraterone 1000 mg |
1 |
2014 |
| Drug |
abiraterone acetate (cohort b = closed to accrual) |
1 |
2014 |
| Drug |
abiraterone acetate / prednisone |
1 |
2013 |
| Drug |
abiraterone acetate / prednisone / lhrh-therapy |
1 |
2013 |
| Drug |
abiraterone acetate 1000 mg po daily |
1 |
2014 |
| Drug |
abiraterone acetate escalated dose |
1 |
2018 |
| Drug |
abiraterone acetate in combination with prednisone |
1 |
2011 |
| Drug |
abiraterone acetate mtd |
1 |
2007 |
| placebo |
abiraterone acetate placebo |
1 |
2012 |
| Drug |
abiraterone acetate standard dose |
1 |
2018 |
| Drug |
abiraterone acetate with methylprednisolone |
1 |
2016 |
| Drug |
abiraterone acetate with prednisone |
1 |
2015 |
| Drug |
abiraterone acetate, prednisolone |
1 |
2014 |
| Drug |
abiraterone acetate/degarelix |
1 |
2012 |
| Drug |
abiraterone acetate/enzalutamide |
1 |
2019 |
| Drug |
abiraterone acetate/enzalutamide/docetaxel |
1 |
2016 |
| Drug |
abiraterone acetate/prednisone |
1 |
2012 |
| Drug |
abiraterone oral tablet [zytiga] |
1 |
2019 |
| Drug |
abiraterone/shr3162 |
1 |
2019 |
| Radiation |
ablative radiation therapy |
1 |
2018 |
| Drug |
abr-215050, tasquinimod |
1 |
2007 |
| Drug |
abraxane |
1 |
2006 |
| Device |
absorbable perirectal spacer |
1 |
2007 |
| Drug |
abt-888 |
1 |
2010 |
| Drug |
abx-egf |
1 |
2003 |
| Behavioral |
academic detailing |
1 |
2018 |
| Drug |
acai juice product |
1 |
2012 |
| Radiation |
accelerated hypofractionation radiotherapy |
1 |
2013 |
| Behavioral |
acceptance/commitment therapy |
1 |
2012 |
| Behavioral |
acceptance/commitment therapy for erectile dysfunction (act-ed) |
1 |
2016 |
| Procedure |
access needle |
1 |
2016 |
| Drug |
ace inhibitor |
1 |
2016 |
| Dietary Supplement |
acetogenins |
1 |
2013 |
| Drug |
acetylsalicylic acid |
1 |
2006 |
| Drug |
acide zoledronic |
1 |
2010 |
| Procedure |
acquisition of images |
1 |
2017 |
| Genetic |
acth |
1 |
2013 |
| Device |
actigraph |
1 |
2018 |
| Other |
active monitoring |
1 |
2014 |
| Device |
activity actigraph |
1 |
2018 |
| Other |
acupressure |
1 |
2019 |
| Drug |
acyclovir |
1 |
2014 |
| Drug |
ad5-sge-reic |
1 |
2013 |
| Drug |
ad5-sge-reic/dkk3 |
1 |
2013 |
| Biological |
ad5-ycd |
1 |
2007 |
| Biological |
ad5-ycd/muttksr39rep-adp |
1 |
2007 |
| Drug |
adaptive androgen deprivation therapy (adt) |
1 |
2018 |
| Drug |
adi-peg 20 |
1 |
2011 |
| Device |
adjustment of mechanical ventilator inspiratory to expiratory time ratio (1:1 to 1:2) |
1 |
2016 |
| Device |
adjustment of mechanical ventilator inspiratory to expiratory time ratio (1:2 to 1:1) |
1 |
2016 |
| Radiation |
adjuvant external beam radiation therapy |
1 |
2018 |
| Radiation |
adjuvant radiotherapy |
1 |
2009 |
| Other |
administration of common sage |
1 |
2007 |
| Drug |
administration of radium-223 |
1 |
2014 |
| Genetic |
adnrgm |
1 |
2016 |
| Drug |
adt (androgen deprivation therapy) |
1 |
2019 |
| Drug |
adt (androgen deprivation therapy) (i.e. leuprolide) |
1 |
2015 |
| Drug |
adt (androgen deprivation therapy) (i.e. leuprolide)/an androgen receptor inhibitor (i.e. bicalutamide) |
1 |
2015 |
| Diagnostic Test |
adult physical activity questionnaire (apaq) |
1 |
2018 |
| Procedure |
advanced imaging for radiotherapy planning |
1 |
2009 |
| Procedure |
advanced imaging for radiotherapy planning/guidance |
1 |
2009 |
| Behavioral |
advanced pelvic floor muscle exercise (apfx) |
1 |
2014 |
| Drug |
adxs31-142 |
1 |
2014 |
| Drug |
adxs31-142 / pembrolizumab (mk-3475) |
1 |
2014 |
| Behavioral |
aerobic cardiovascular exercise program |
1 |
2005 |
| Behavioral |
aerobic exercise training |
1 |
2015 |
| Drug |
afatinib |
1 |
2015 |
| Drug |
afatinib dimaleate |
1 |
2015 |
| Drug |
aflibercept |
1 |
2007 |
| Drug |
afuresertib |
1 |
2019 |
| Radiation |
agility system. |
1 |
2019 |
| Biological |
aglatimagene besadenovec |
1 |
2016 |
| Drug |
ags-1c4d4 |
1 |
2007 |
| Other |
ah-ha tool in the epic ehr |
1 |
2019 |
| Device |
aixplorerâ® shearwave elastography (sweâ„¢) |
1 |
2017 |
| Biological |
alhydrogelâ® vaccine |
1 |
2008 |
| Drug |
alimta (pemetrexed) |
1 |
2010 |
| Drug |
alisertib |
1 |
2013 |
| Drug |
all trans retinoic acid |
1 |
2018 |
| Dietary Supplement |
allin |
1 |
2019 |
| Biological |
allostim |
1 |
2010 |
| Drug |
alpha-cyclodextrin |
1 |
2014 |
| Drug |
alpha cyclodextrin |
1 |
2013 |
| Drug |
alpharadin |
1 |
2014 |
| Drug |
alprostadil (e1) |
1 |
2004 |
| Drug |
alt-803 |
1 |
2018 |
| Procedure |
alternative medicine procedure |
1 |
2006 |
| Drug |
alvespimycin hydrochloride |
1 |
2004 |
| Drug |
amg 102 |
1 |
2008 |
| Drug |
amg 160 |
1 |
2019 |
| Drug |
amg 386 |
1 |
2012 |
| Drug |
amg 509 |
1 |
2019 |
| Drug |
amifostine |
1 |
2004 |
| Drug |
amonafide l-malate (drug) |
1 |
2004 |
| Procedure |
amount of pneumoperitoneum pressure applied during rarp |
1 |
2017 |
| Drug |
an androgen receptor inhibitor (i.e. bicalutamide) |
1 |
2015 |
| Other |
an ultrasound-based technique to identify prostate cancer |
1 |
2010 |
| Radiation |
anchorseed iodine 125 brachytherapy prostate implant |
1 |
2010 |
| Drug |
androdermâ® 2.5mg |
1 |
2010 |
| Drug |
androdermâ® 5.0mg |
1 |
2010 |
| Drug |
androdermâ® 7.5mg |
1 |
2010 |
| Drug |
androgen-deprivation therapy |
1 |
2006 |
| Biological |
androgen ablation (aa) |
1 |
2009 |
| Drug |
androgen ablation therapy |
1 |
2012 |
| Drug |
androgen blockade / radiation therapy |
1 |
2005 |
| Drug |
androgen hormonal suppression |
1 |
2005 |
| Drug |
androgen hormonal suppression/radiation |
1 |
2005 |
| Drug |
androgen receptor antagonist arn-509 |
1 |
2016 |
| Drug |
androgen suppression therapy/radiation therapy |
1 |
2005 |
| Device |
angel concentrated platelet rich plasma system |
1 |
2016 |
| Drug |
angelica sinensis |
1 |
2005 |
| Drug |
anti-androgen therapy: bicalutamide |
1 |
2011 |
| Drug |
anti-ox40 |
1 |
2010 |
| Biological |
anti-ox40 antibody pf-04518600 |
1 |
2017 |
| Biological |
anti-psma monoclonal antibody mdx1201-a488 |
1 |
2014 |
| Drug |
antiandrogen/docetaxel |
1 |
2016 |
| Drug |
antibiotic prophylaxis |
1 |
2011 |
| Other |
antiemetic |
1 |
2017 |
| Other |
antihistamine |
1 |
2017 |
| Drug |
antiplatelet agent, such as aspirin, |
1 |
2016 |
| Drug |
antiplatelet agent, such as aspirin,/other low-dose antiplatelet agent |
1 |
2016 |
| Combination Product |
apalutamid |
1 |
2018 |
| Drug |
apalutamide 240 mg |
1 |
2018 |
| placebo |
apalutamide placebo |
1 |
2015 |
| Biological |
apc8015f |
1 |
2009 |
| Procedure |
apex local anesthesia |
1 |
2016 |
| Drug |
apitolisib |
1 |
2011 |
| Drug |
approved gnrh agonist |
1 |
2016 |
| Drug |
apr-246 |
1 |
2009 |
| Drug |
ar antagonist (bms-641988) |
1 |
2006 |
| Drug |
aranesp |
1 |
2005 |
| Drug |
ard6562, docetaxel |
1 |
2006 |
| Drug |
arginine |
1 |
2012 |
| Other |
arm a: 3d-conformal radiation |
1 |
2006 |
| Radiation |
arm b: helical tomotherapy intensity modulated radiotherapy |
1 |
2006 |
| Dietary Supplement |
arm i soy bread |
1 |
2012 |
| Dietary Supplement |
arm ii soy-almond bread |
1 |
2012 |
| Drug |
arn-509 (phase 1) |
1 |
2010 |
| Drug |
arn-509 (phase 2) |
1 |
2010 |
| Drug |
arsenic trioxide |
1 |
1999 |
| Device |
artemia |
1 |
2020 |
| Device |
artemisâ„¢ software system |
1 |
2017 |
| Drug |
arv-110 |
1 |
2019 |
| Drug |
as1404 (dmxaa) |
1 |
2005 |
| Behavioral |
ascent |
1 |
2018 |
| Drug |
ascorbic acid (vitamin c) |
1 |
2010 |
| Drug |
asg-5me |
1 |
2010 |
| Drug |
asp3550 |
1 |
2007 |
| placebo |
aspirin placebo, vitamin d |
1 |
2016 |
| placebo |
aspirin placebo, vitamin d placebo |
1 |
2016 |
| Genetic |
assessment of serum corticosteroid intermediates |
1 |
2013 |
| Genetic |
assessment of serum corticosteroid intermediates/acth |
1 |
2013 |
| Drug |
at-101, prednisone |
1 |
2007 |
| Drug |
at-101, prednisone/docetaxel |
1 |
2007 |
| Drug |
at13387 |
1 |
2012 |
| Drug |
atezolizumab1200 mg iv |
1 |
2017 |
| Drug |
atorvastatin |
1 |
2013 |
| Drug |
atorvastatin 80mg |
1 |
2018 |
| Drug |
atorvastatin calcium |
1 |
2010 |
| Drug |
atypical type-1 |
1 |
2018 |
| Drug |
atypical type-2 |
1 |
2018 |
| Behavioral |
audio program |
1 |
2018 |
| Behavioral |
audit |
1 |
2018 |
| Behavioral |
audit/feedback |
1 |
2018 |
| Drug |
augmentin |
1 |
2017 |
| Biological |
autologous anti-psca-car-4-1bb |
1 |
2019 |
| Biological |
autologous anti-psca-car-4-1bb/tcrzeta-cd19t-expressing t-lymphocytes |
1 |
2019 |
| Biological |
autologous dendritic cell |
1 |
2010 |
| Biological |
autologous dendritic cell vaccine (dc |
1 |
2006 |
| Biological |
autologous dendritic cell vaccine (dc/pc3) |
1 |
2006 |
| Other |
autologous platelet-rich plasma |
1 |
2016 |
| placebo |
autologus elutriated monocyte placebo vaccine |
1 |
2015 |
| Other |
automated messaging |
1 |
2019 |
| Drug |
axumin pet |
1 |
2017 |
| Drug |
axumin pet/ct |
1 |
2017 |
| Drug |
azacitidine |
1 |
2000 |
| Drug |
azacitidine for injectable suspension |
1 |
2006 |
| Drug |
azd0530 |
1 |
2007 |
| Drug |
azd2014 |
1 |
2014 |
| Drug |
azd5069 |
1 |
2017 |
| Drug |
azd5153 |
1 |
2017 |
| Drug |
azd6738 |
1 |
2018 |
| Drug |
b-dim |
1 |
2009 |
| Drug |
bafetinib |
1 |
2010 |
| Other |
balance sheet task |
1 |
2012 |
| Device |
balloon catheter for suprapubic bladder-drainage |
1 |
2014 |
| Device |
balloon catheter for transurethral bladder-drainage |
1 |
2014 |
| Device |
balloon implant |
1 |
2009 |
| Procedure |
balloon implantation |
1 |
2009 |
| Procedure |
base |
1 |
2016 |
| Procedure |
base/apex local anesthesia |
1 |
2016 |
| Drug |
bay 1841788(odm-201) |
1 |
2015 |
| Drug |
bay 2315497 injection |
1 |
2018 |
| Drug |
bay 43-9006 |
1 |
2004 |
| Drug |
bay1075553 |
1 |
2011 |
| Drug |
bay1841788 |
1 |
2016 |
| Drug |
bay1841788 (darolutamide) |
1 |
2017 |
| Drug |
bay1841788 / darolutamide (odm-201) |
1 |
2016 |
| Biological |
bay2010112 |
1 |
2012 |
| Biological |
bcl-xl_42-caf09b vaccine |
1 |
2018 |
| Other |
behavioral activity counseling |
1 |
2014 |
| Behavioral |
behavioral counseling |
1 |
2017 |
| Behavioral |
behavioral dietary |
1 |
2006 |
| Behavioral |
behavioral dietary/exercise intervention |
1 |
2006 |
| Behavioral |
behavioral intervention |
1 |
2019 |
| Behavioral |
behavioral medicine strategies |
1 |
2014 |
| Behavioral |
behavioral: psychosexual intervention |
1 |
2013 |
| Dietary Supplement |
beneforte broccoli soup |
1 |
2013 |
| Dietary Supplement |
beneforte extra broccoli soup |
1 |
2013 |
| Drug |
berzosertib |
1 |
2018 |
| Drug |
best standard of care (bsoc) |
1 |
2008 |
| Other |
best supportive |
1 |
2018 |
| Other |
best supportive/best standard of care |
1 |
2018 |
| Drug |
best systemic therapy |
1 |
2015 |
| Other |
best systemic therapy (bst) |
1 |
2012 |
| Other |
best systemic therapy (bst) / surgery/radiation therapy |
1 |
2012 |
| Dietary Supplement |
beta-carotene |
1 |
2005 |
| Drug |
bevacizumab, bicalutamide |
1 |
2006 |
| Drug |
bevacizumab, bicalutamide/goserelin |
1 |
2006 |
| Drug |
bez235 |
1 |
2012 |
| Behavioral |
bf |
1 |
2011 |
| Behavioral |
bf/phone |
1 |
2011 |
| Behavioral |
bf/support |
1 |
2011 |
| Diagnostic Test |
bi-parametric mri |
1 |
2018 |
| Drug |
bi 2536 |
1 |
2008 |
| Drug |
bi 836845 |
1 |
2014 |
| Drug |
bibf 1120 high dose |
1 |
2014 |
| Drug |
bibf 1120 low dose |
1 |
2014 |
| Drug |
bibw 2992 |
1 |
2008 |
| Drug |
bibw 2992 (afatinib) |
1 |
2011 |
| Drug |
bicalutamide (casodex), goserelin (zoladex) |
1 |
2006 |
| placebo |
bicalutamide placebo |
1 |
2015 |
| Drug |
bicalutamide/calcium/ vitamin d supplementation |
1 |
2007 |
| Procedure |
bilateral epididymal-sparing orchidectomy |
1 |
2018 |
| Procedure |
bilateral pelvic ln dissection |
1 |
2019 |
| Procedure |
bilateral rectus sheath catheter |
1 |
2018 |
| Procedure |
bilateral simple orchidectomy (bso) |
1 |
2018 |
| Procedure |
bilateral subcapsular orchidectomy |
1 |
2018 |
| Drug |
bind-014 |
1 |
2013 |
| Drug |
binimetinib |
1 |
2015 |
| Procedure |
biofeedback |
1 |
2008 |
| Device |
biograph mmr, siemens |
1 |
2016 |
| Other |
biological collection |
1 |
2019 |
| Device |
biomarker analysis |
1 |
2014 |
| Behavioral |
biomedical component |
1 |
2014 |
| Device |
biomedical tato3â® microwave needle thermoablation device (koelis, grenoble, france) |
1 |
2019 |
| Device |
biopsies using apollo |
1 |
2014 |
| Device |
biopsies using apollo/urostationâ® |
1 |
2014 |
| Procedure |
biopsies using image fusion |
1 |
2011 |
| Procedure |
biopsies using urostationâ® (image fusion) |
1 |
2014 |
| Procedure |
biopsy of prostate |
1 |
2017 |
| Device |
biopsy sample performed after the sonovueâ® injection |
1 |
2014 |
| Procedure |
biopsy sponge pad |
1 |
2012 |
| Procedure |
biospecimen collection |
1 |
2020 |
| Device |
biparametric mri before biopsy |
1 |
2015 |
| Procedure |
bipolar radiofrequency focal ablation |
1 |
2014 |
| Other |
blood draws |
1 |
2019 |
| Procedure |
blood samples for psa |
1 |
2015 |
| Procedure |
blood samples for psa/immune assays |
1 |
2015 |
| Other |
blood/urine sampling |
1 |
2019 |
| Drug |
bms-641988 (ar#2) |
1 |
2008 |
| Drug |
bms-986253 |
1 |
2018 |
| Drug |
bmtp-11 |
1 |
2009 |
| Drug |
bn83495 (cohort 1) |
1 |
2008 |
| Drug |
bn83495 (cohort 2) |
1 |
2008 |
| Drug |
bn83495 (cohort 3) |
1 |
2008 |
| Behavioral |
body mind training (bmt) |
1 |
2017 |
| Behavioral |
body training (bt): |
1 |
2017 |
| Drug |
bombesin (68ga) labeled (bay86-7548) |
1 |
2010 |
| Behavioral |
bone health care coordinator |
1 |
2014 |
| Procedure |
bone marrow biopsy |
1 |
2005 |
| Biological |
bone marrow sampling |
1 |
2014 |
| Procedure |
bone marrow transplantation |
1 |
2016 |
| Drug |
bortezomib (ps-341) |
1 |
2003 |
| Biological |
bpx-101 |
1 |
2009 |
| Biological |
bpx-201 vaccine |
1 |
2013 |
| Biological |
bpx-201 vaccine/ap1903 |
1 |
2013 |
| Drug |
br-dim |
1 |
2006 |
| Radiation |
brachytherapy (100 |
1 |
2003 |
| Radiation |
brachytherapy (100/110) |
1 |
2003 |
| Radiation |
brachytherapy (125 |
1 |
2003 |
| Radiation |
brachytherapy (125/145) |
1 |
2003 |
| Radiation |
brachytherapy boost |
1 |
2000 |
| Radiation |
brachytherapy boost with external beam radiotherapy |
1 |
2014 |
| Radiation |
brachytherapy boost) |
1 |
2015 |
| Radiation |
brachytherapy remedial |
1 |
2013 |
| Radiation |
brachytherapy, external beam radiotherapy |
1 |
2018 |
| Procedure |
brachytherapy] |
1 |
2019 |
| Radiation |
brachytherapy(iodine i 125) |
1 |
2008 |
| Dietary Supplement |
brassica vegetable |
1 |
2008 |
| Drug |
brimonidine tartrate 0.2% |
1 |
2016 |
| Dietary Supplement |
broccomaxâ® |
1 |
2018 |
| Drug |
bromodeoxyuridine |
1 |
1999 |
| Drug |
bryostatin 1 |
1 |
2000 |
| Drug |
btp-114 |
1 |
2016 |
| Drug |
bupivacaine |
1 |
2018 |
| Procedure |
c-11 acetate pet scan |
1 |
2005 |
| Drug |
c-11 choline |
1 |
2015 |
| Procedure |
c-choline pet scanning |
1 |
2008 |
| Drug |
c) |
1 |
2019 |
| Drug |
c11-sodium acetate |
1 |
2012 |
| Procedure |
c11 methionine pet scan |
1 |
2005 |
| Drug |
cabacitaxel |
1 |
2011 |
| Drug |
cabazitaxel (xrp6258) (rpr116258) |
1 |
2006 |
| Drug |
cabazitaxel 10 mg |
1 |
2012 |
| Drug |
cabazitaxel 10 mg/m2 |
1 |
2012 |
| Drug |
cabazitaxel 25 mg |
1 |
2014 |
| Drug |
cabazitaxel 25 mg/m2 iv |
1 |
2014 |
| Drug |
cabazitaxel 60 mg solution for injection |
1 |
2019 |
| Drug |
cabazitaxel with peg-filgrastim |
1 |
2015 |
| Drug |
cabazitaxel, docetaxel, mitoxantrone |
1 |
2017 |
| Drug |
cabazitaxel, docetaxel, mitoxantrone/satraplatin |
1 |
2017 |
| Drug |
cabazitaxel/prednisone |
1 |
2018 |
| Drug |
cabergoline |
1 |
2013 |
| Drug |
cabozantinib-s-malate |
1 |
2013 |
| Drug |
cabozantinib s-malate |
1 |
2019 |
| Drug |
caffeine |
1 |
2014 |
| Drug |
calcifidiol |
1 |
2001 |
| Dietary Supplement |
calcium carbonate |
1 |
2002 |
| Drug |
calcium gluconate |
1 |
2003 |
| Dietary Supplement |
calcium supplement |
1 |
2004 |
| Device |
calypso beacon implant |
1 |
2017 |
| Device |
calypsoâ® 4d localization system |
1 |
2005 |
| Device |
camprobe |
1 |
2018 |
| Behavioral |
cancer information mentor |
1 |
2007 |
| Biological |
cancer macrobead placement in abdominal cavity |
1 |
2010 |
| Behavioral |
cancer: thriving |
1 |
2009 |
| Behavioral |
cancer: thriving/surviving online workshop |
1 |
2009 |
| Other |
carbohydrate restricted diet |
1 |
2018 |
| Procedure |
carbon-11 acetate pet scan |
1 |
2005 |
| Drug |
carbon-11 labeled acetate |
1 |
2010 |
| Device |
carbon-ion radiotherapy |
1 |
2016 |
| Radiation |
carbon ions boost followed by pelvic photon radiotherapy |
1 |
2016 |
| Other |
carboxymethylcellulose eye drops |
1 |
2016 |
| Drug |
carfilzomib |
1 |
2014 |
| Drug |
carlumab |
1 |
2009 |
| Drug |
carmustine |
1 |
1999 |
| Biological |
cart-psma-tgfî²rdn |
1 |
2019 |
| Biological |
cart t cells |
1 |
2017 |
| Dietary Supplement |
casein proteins |
1 |
2002 |
| Drug |
casodex 150mg |
1 |
2007 |
| Drug |
casodex/zoladex (or lupron) |
1 |
2008 |
| Drug |
cc-1, psmaxcd3 |
1 |
2019 |
| Drug |
cc-4047 |
1 |
2003 |
| Drug |
ccs1477 |
1 |
2018 |
| Drug |
ccw702 |
1 |
2019 |
| Behavioral |
cd-rom-based prostate ca treatment education |
1 |
2005 |
| Behavioral |
cd-rom-based prostate ca treatment education/decision tools |
1 |
2005 |
| Behavioral |
cd-rom-based prostate cancer treatment education |
1 |
2005 |
| Behavioral |
cdc brochure condition |
1 |
2013 |
| Behavioral |
cdc brochure only condition |
1 |
2013 |
| Drug |
cdx-301 (cohort b |
1 |
2019 |
| Drug |
cdx-301 (cohort b/c) |
1 |
2019 |
| Drug |
cediranib |
1 |
2016 |
| Drug |
cediranib maleate |
1 |
2010 |
| Drug |
cefazolin |
1 |
2018 |
| Device |
cellectra 2000 |
1 |
2019 |
| Drug |
cep-701 |
1 |
2004 |
| Drug |
cetrelimab 240 mg |
1 |
2018 |
| Other |
ceus |
1 |
2016 |
| Other |
ceus/targeted biopsies |
1 |
2016 |
| Drug |
cfi-400945 |
1 |
2017 |
| Radiation |
cge |
1 |
2011 |
| Biological |
chadox1-mva 5t4 vaccine |
1 |
2019 |
| Biological |
chadox1.5t4 |
1 |
2015 |
| Behavioral |
champion |
1 |
2017 |
| Behavioral |
chess system |
1 |
2007 |
| Drug |
chitosan |
1 |
2018 |
| Device |
choline pet/ct/dual time point fdg pet/ct |
1 |
2014 |
| Drug |
choline pet/mr |
1 |
2015 |
| Drug |
ciforadenant |
1 |
2016 |
| Drug |
ciforadenant / atezolizumab |
1 |
2016 |
| Drug |
cinacalcet hydrochloride |
1 |
2010 |
| Radiation |
civasheet 60 gy |
1 |
2018 |
| Radiation |
civasheet 75 gy |
1 |
2018 |
| Device |
claricore optical biopsy system |
1 |
2018 |
| Behavioral |
clinical order check |
1 |
2018 |
| Behavioral |
clipp |
1 |
2018 |
| Drug |
clodronate disodium |
1 |
1999 |
| Behavioral |
coaching |
1 |
2017 |
| Behavioral |
coaching intervention |
1 |
2015 |
| Behavioral |
cognitive-behavioral therapy |
1 |
2018 |
| Behavioral |
cognitive affective preparation |
1 |
2014 |
| Other |
cognitive behavioral therapy (cbt) |
1 |
2011 |
| Behavioral |
cognitive behavioural therapy (cbt) |
1 |
2017 |
| Behavioral |
cognitive remediation therapy |
1 |
2017 |
| Diagnostic Test |
cognitive vs software |
1 |
2020 |
| Drug |
cohort 1 |
1 |
2011 |
| Drug |
cohort 2 |
1 |
2011 |
| Drug |
cohort 3 |
1 |
2011 |
| Drug |
cohort 4 |
1 |
2011 |
| Device |
coils in pet |
1 |
2019 |
| Other |
collection of data concerning their sexuality |
1 |
2018 |
| Radiation |
combined, intensified |
1 |
2017 |
| Radiation |
combined, intensified/modulated adjuvant radiotherapy |
1 |
2017 |
| Other |
commercially-available tomato food product |
1 |
2014 |
| Behavioral |
commitment therapy |
1 |
2012 |
| Behavioral |
commitment therapy for erectile dysfunction (act-ed) |
1 |
2016 |
| Other |
communication intervention |
1 |
2013 |
| Other |
communication skills training |
1 |
2017 |
| Drug |
comparator: mk0429 |
1 |
2006 |
| placebo |
comparator: placebo |
1 |
2008 |
| placebo |
comparator: placebo (unspecified) |
1 |
2003 |
| Procedure |
comparison of screening methods |
1 |
2009 |
| Device |
comparison systematic light exposure |
1 |
2018 |
| Procedure |
complementary |
1 |
2006 |
| Procedure |
complementary/alternative medicine procedure |
1 |
2006 |
| Behavioral |
comprehensive health enhancement support system |
1 |
2005 |
| Other |
compression |
1 |
2018 |
| Drug |
computed tomography (ct) |
1 |
2014 |
| Procedure |
computed tomography scan |
1 |
2016 |
| Other |
computer-assisted intervention |
1 |
2016 |
| Diagnostic Test |
computer tomography |
1 |
2018 |
| Behavioral |
computer with internet |
1 |
2005 |
| Drug |
concurrent use of radium ra 223 dichloride |
1 |
2014 |
| Drug |
concurrent use of radium ra 223 dichloride/abiraterone acetate/prednisone |
1 |
2014 |
| Device |
cone-beam computed tomography |
1 |
2015 |
| Radiation |
conebeam ct |
1 |
2018 |
| Procedure |
conformal intensity modulated radiotherapy (imrt) |
1 |
2005 |
| Radiation |
conformal radiation therapy |
1 |
2014 |
| Procedure |
control position by 3dobi before the fraction |
1 |
2007 |
| Other |
control protein diet |
1 |
2017 |
| Radiation |
convention |
1 |
2016 |
| Radiation |
conventional 3d-crt |
1 |
2006 |
| Radiation |
conventional 3d-crt/imrt |
1 |
2006 |
| Radiation |
conventional external beam therapy |
1 |
2005 |
| Radiation |
conventional fractionated imrt boost radiotherapy |
1 |
2014 |
| Radiation |
conventional fractionated intensity modulated radiotherapy |
1 |
2008 |
| Radiation |
conventional imrt |
1 |
2019 |
| Drug |
conventional nsaa |
1 |
2015 |
| Procedure |
conventional open retropubic radical prostectomy |
1 |
2015 |
| Radiation |
conventional radiotherapy (crt) prostate boost |
1 |
2017 |
| Radiation |
conventional radiotherapy 74 gy delivered in 37 fractions |
1 |
2006 |
| Radiation |
conventionally-fractionated wprt |
1 |
2019 |
| Radiation |
conventionally fractionated prostate radiotherapy |
1 |
2012 |
| Radiation |
conventionally fractionated versus hypofractionated boost |
1 |
2018 |
| Drug |
copanlisib hydrochloride |
1 |
2015 |
| Behavioral |
coping skills training |
1 |
2007 |
| Other |
correlative studies |
1 |
2014 |
| Drug |
cort125281 |
1 |
2018 |
| Other |
corticosteroid |
1 |
2017 |
| Behavioral |
counseling sessions |
1 |
2011 |
| Behavioral |
counselling based on yoga |
1 |
2018 |
| Drug |
cp-461 |
1 |
2002 |
| Drug |
cp-675,206 |
1 |
2004 |
| Drug |
cp-675,206 (tremelimumab) |
1 |
2006 |
| Drug |
cp-675,206/leuprolide acetate/bicalutamide |
1 |
2004 |
| Drug |
cp-751,871 |
1 |
2006 |
| Biological |
cpg |
1 |
2006 |
| Drug |
cpi-1205 |
1 |
2018 |
| Dietary Supplement |
creatine monohydrate |
1 |
2019 |
| Device |
cross-linked hyaluronan gel |
1 |
2009 |
| Procedure |
cryoablation/external beam radiation |
1 |
2007 |
| Biological |
cryopreserved umbilical cord allograft |
1 |
2020 |
| Procedure |
cryosurgery |
1 |
2015 |
| Procedure |
cryosurgical freezing (cryosurgery) |
1 |
2019 |
| Procedure |
cryotherapy |
1 |
2014 |
| Procedure |
ct (computed tomography) |
1 |
2018 |
| Procedure |
ct fusion |
1 |
2019 |
| Procedure |
ct fusion / transrectal u/s guided prostate biopsy |
1 |
2019 |
| Diagnostic Test |
ct scan (psma pet) |
1 |
2018 |
| Procedure |
ct scan/bone scan |
1 |
2015 |
| Diagnostic Test |
ct scanning |
1 |
2018 |
| Radiation |
ct simulation |
1 |
2018 |
| Drug |
ct with gallium-68 labeled psma-hbed-cc |
1 |
2018 |
| Device |
ct, pet |
1 |
2013 |
| Drug |
ctap101 capsules |
1 |
2014 |
| Drug |
ctt1403 |
1 |
2019 |
| Behavioral |
cultural cbt |
1 |
2017 |
| Behavioral |
current care |
1 |
2018 |
| Drug |
custirsen |
1 |
2010 |
| Drug |
custirsen (ogx-011) |
1 |
2006 |
| Drug |
custirsen (ogx-011)/docetaxel |
1 |
2006 |
| Drug |
custirsen (ogx-011)/mitoxantrone |
1 |
2006 |
| Biological |
cv301 |
1 |
2017 |
| Biological |
cv787 (cg7870) |
1 |
2005 |
| Biological |
cv9103 |
1 |
2009 |
| Drug |
cva21 |
1 |
2008 |
| Radiation |
cyberknife |
1 |
2013 |
| Radiation |
cyberknife boost 18 gy |
1 |
2017 |
| Radiation |
cyberknife boost 21 gy |
1 |
2017 |
| Radiation |
cyberknife sbrt |
1 |
2019 |
| Drug |
cyclophosphamide 1g |
1 |
2017 |
| Drug |
cyclophosphamide 1g/m^2 |
1 |
2017 |
| Drug |
cyclophosphamide/zyc300 (zyc300 with cyclophosphamide pre-dosing) |
1 |
2006 |
| Drug |
cyproterone acetate 15 |
1 |
2005 |
| Drug |
cyproterone acetate 25 |
1 |
2005 |
| Drug |
cyproterone acetate 5 |
1 |
2005 |
| Procedure |
cystoprostatectomy |
1 |
2018 |
| Drug |
cytarabine |
1 |
2007 |
| Drug |
d |
1 |
2014 |
| Drug |
dabigatran etexilate |
1 |
2017 |
| Drug |
dabrafenib |
1 |
2015 |
| Drug |
dabrafenib mesylate |
1 |
2015 |
| Procedure |
daily cone beam ct for imaging guidance for radiotherapy |
1 |
2005 |
| Procedure |
daily vacuum therapy |
1 |
2012 |
| Procedure |
daily xray volume imaging for planning radiotherapy |
1 |
2005 |
| Drug |
dalteparin |
1 |
1999 |
| Biological |
daratumumab |
1 |
2017 |
| Drug |
darolutamide (nubeqa, bay1841788) |
1 |
2014 |
| Drug |
darolutamide (odm-201) |
1 |
2016 |
| Drug |
darolutamide(nubeqa, bay1841788) |
1 |
2019 |
| Biological |
dc |
1 |
2006 |
| Biological |
dc-tn-muc1: autologous dendritic cells expressing tn-muc1 |
1 |
2009 |
| Biological |
dc/lncap |
1 |
2006 |
| Biological |
dc1 vaccine |
1 |
2009 |
| Drug |
dcfpyl-pet |
1 |
2016 |
| Drug |
dcfpyl-pet/mri/-pt/ct |
1 |
2016 |
| Biological |
dcvac |
1 |
2018 |
| Biological |
dcvac/pca |
1 |
2018 |
| Biological |
dec-205 |
1 |
2012 |
| Biological |
dec-205/ny-eso-1 fusion protein cdx-1401 |
1 |
2012 |
| Dietary Supplement |
decaffeinated black tea |
1 |
2008 |
| Other |
decipher |
1 |
2014 |
| Other |
decipher prostate cancer classifier |
1 |
2016 |
| Other |
decision aid for men with localized prostate cancer |
1 |
2020 |
| Behavioral |
decision support intervention (dsi) |
1 |
2017 |
| Behavioral |
decision tools |
1 |
2005 |
| Drug |
defactinib |
1 |
2015 |
| Drug |
defactinib hydrochloride |
1 |
2015 |
| Dietary Supplement |
defined green tea catechin extract |
1 |
2007 |
| Procedure |
definitive treatment |
1 |
2016 |
| Drug |
degarelix (lhrh antagonist) |
1 |
2015 |
| Drug |
degarelix 120 mg [firmagon] |
1 |
2019 |
| Drug |
degarelix 160 mg |
1 |
2007 |
| Drug |
degarelix 160 mg / degarelix 160 mg |
1 |
2007 |
| Drug |
degarelix 240 |
1 |
2010 |
| Drug |
degarelix 240 mg |
1 |
2008 |
| Drug |
degarelix 240 mg / 80 mg |
1 |
2008 |
| Drug |
degarelix 240/80 mg |
1 |
2010 |
| Drug |
degarelix 80 mg |
1 |
2007 |
| Drug |
degarelix 80 mg / degarelix 80 mg |
1 |
2007 |
| Drug |
degarelix acetate, leuprolide acetate |
1 |
2011 |
| Drug |
degarelix injection |
1 |
2012 |
| Behavioral |
delayed diet |
1 |
2013 |
| Behavioral |
delayed diet/exercise intervention |
1 |
2013 |
| Procedure |
delayed orchiectomy |
1 |
2013 |
| Procedure |
delayed orchiectomy/depot lhrh |
1 |
2013 |
| Biological |
dendritic cell application |
1 |
2013 |
| Biological |
dendritic cell based cryoimmunotherapy |
1 |
2015 |
| Biological |
dendritic cell vaccine |
1 |
2010 |
| Biological |
dendritic cells (dc) prostate |
1 |
2011 |
| Drug |
denosumab (reduced dosing) |
1 |
2014 |
| Drug |
denosumab (standard dosing) |
1 |
2014 |
| Procedure |
depot lhrh |
1 |
2013 |
| Device |
derma vaxâ„¢ intradermal dna delivery system |
1 |
2009 |
| Drug |
desflurane |
1 |
2014 |
| Drug |
dexamethasone 0.5 mg once daily |
1 |
2013 |
| Other |
dexamethasone 8 mg |
1 |
2016 |
| Drug |
dexamethasone/radium-223 |
1 |
2018 |
| Drug |
dexchlorpheniramine |
1 |
2015 |
| Drug |
dexchlorpheniramine/diphenhydramine |
1 |
2015 |
| Drug |
dextromethorphan |
1 |
2014 |
| Drug |
dextromethorphan hydrobromide |
1 |
2009 |
| Behavioral |
diabetes prevention program |
1 |
2008 |
| Device |
diagnostic imaging: c11 choline pet; c11 acetate pet; |
1 |
2007 |
| Device |
diagnostic imaging: c11 choline pet; c11 acetate pet;/mri spectroscopy |
1 |
2007 |
| Procedure |
diagnostic mri |
1 |
2018 |
| Diagnostic Test |
diagnostic performance 3d t1 |
1 |
2017 |
| Procedure |
diagnostic prostate biopsy |
1 |
2018 |
| Drug |
diclofenac suppository |
1 |
2013 |
| Drug |
diclofenac suppository/lidocaine gel |
1 |
2013 |
| Behavioral |
diet/nutrition coaching |
1 |
2016 |
| Other |
dietary education |
1 |
2010 |
| Other |
dietary education/counseling |
1 |
2010 |
| Dietary Supplement |
dietary intervention (red tomato juice) |
1 |
2014 |
| Dietary Supplement |
dietary intervention (tangerine tomato juice) |
1 |
2014 |
| Other |
dietary intervention first |
1 |
2012 |
| Other |
dietary interview |
1 |
2008 |
| Drug |
diethylstilbestrol |
1 |
2006 |
| Drug |
diethylstilbestrol (des) |
1 |
2005 |
| Device |
diffuse optical tomography (dot) system |
1 |
2017 |
| Procedure |
diffusion mri |
1 |
2014 |
| Procedure |
digital rectal exam |
1 |
2014 |
| Procedure |
digital rectal examination |
1 |
2015 |
| Drug |
diindolylmethane |
1 |
2007 |
| Drug |
diphenhydramine |
1 |
2015 |
| Other |
discrete choice task |
1 |
2012 |
| Drug |
disulfiram |
1 |
2010 |
| Drug |
dkk3 |
1 |
2013 |
| Drug |
dkn-01 150 mg |
1 |
2019 |
| Drug |
dkn-01 300 mg |
1 |
2019 |
| Drug |
dkn-01 600 mg |
1 |
2019 |
| Genetic |
dna analysis |
1 |
2009 |
| Genetic |
dna methylation analysis |
1 |
2009 |
| Biological |
dna vaccine |
1 |
2012 |
| Drug |
docetaxel (taxotereâ®) chemotherapy |
1 |
2006 |
| Biological |
docetaxel / prednisone* / zoledronic acid |
1 |
2003 |
| Drug |
docetaxel 60 mg |
1 |
2018 |
| Drug |
docetaxel 60 mg/m2 |
1 |
2018 |
| Drug |
docetaxel 75 mg/m^2 |
1 |
2016 |
| Drug |
docetaxel 75 mg/m2 / prednisone 10 mg/d |
1 |
2014 |
| Drug |
docetaxel 75 mg/m2 / prednisone 10 mg/d / abiraterone 1000 mg/d |
1 |
2014 |
| Drug |
docetaxel every 3 weeks |
1 |
2010 |
| Drug |
docetaxel every 3 weeks / prednisone |
1 |
2010 |
| Drug |
docetaxel in parenteral dosage form |
1 |
2019 |
| Drug |
docetaxel injectable solution |
1 |
2019 |
| Drug |
docetaxel weekly |
1 |
2010 |
| Drug |
docetaxel weekly/ prednisone |
1 |
2010 |
| Drug |
docetaxel(xrp6976) |
1 |
2009 |
| Drug |
docetaxel(xrp6976) / modafinil |
1 |
2009 |
| Drug |
docetaxel, carboplatin |
1 |
2008 |
| Drug |
docetaxel, reolysin |
1 |
2012 |
| Drug |
docetaxel, reolysin/prednisone |
1 |
2012 |
| Drug |
docetaxel/diethylstilbestrol (des) |
1 |
2005 |
| Drug |
docetaxel/gm-csf |
1 |
2007 |
| Drug |
docetaxel/imrt |
1 |
2006 |
| Drug |
dolastatin 10 |
1 |
1999 |
| Radiation |
dose escalation |
1 |
2018 |
| Radiation |
dose escalation using stereotactic boost |
1 |
2013 |
| Drug |
dose level 2a: ipatasertib |
1 |
2019 |
| Drug |
dose level 2b: rucaparib |
1 |
2019 |
| Drug |
dose level 3: ipatasertib |
1 |
2019 |
| Drug |
dose level 3: rucaparib |
1 |
2019 |
| Radiation |
dose to prostate bed |
1 |
2017 |
| Radiation |
dose to prostate bed with integrated boost |
1 |
2017 |
| Dietary Supplement |
doxercalciferol |
1 |
2001 |
| Drug |
doxorubicin-gnrh agonist conjugate aezs-108 |
1 |
2010 |
| Biological |
dpx-0907 consists of 7 tumor-specific hla-a2-restricted peptides, a universal t helper peptide, a polynucleotide adjuvant, a liposome |
1 |
2010 |
| Biological |
dpx-0907 consists of 7 tumor-specific hla-a2-restricted peptides, a universal t helper peptide, a polynucleotide adjuvant, a liposome/montanide isa51 vg |
1 |
2010 |
| Drug |
drug (dutasteride) intervention first |
1 |
2012 |
| Drug |
drug cocktail |
1 |
2015 |
| Procedure |
drug resistance inhibition treatment |
1 |
1999 |
| Drug |
drug: 99mtc-mip-1404 |
1 |
2012 |
| Drug |
dst-2970 (abiraterone) |
1 |
2019 |
| Drug |
dstp3086s |
1 |
2011 |
| Device |
dual time point fdg pet |
1 |
2014 |
| Procedure |
dual x-ray absorptiometry |
1 |
2015 |
| Drug |
dupilumab |
1 |
2019 |
| Device |
duraseal |
1 |
2012 |
| Drug |
durvalumab/tremelimumab |
1 |
2017 |
| Behavioral |
dvd decision aid |
1 |
2013 |
| Device |
dyn" |
1 |
2012 |
| Procedure |
dynamic contrast-enhanced magnetic resonance imaging |
1 |
2012 |
| Device |
dynamic contrast-enhanced mri (dce) |
1 |
2014 |
| Drug |
e7389 |
1 |
2006 |
| Procedure |
early dvc ligation |
1 |
2017 |
| Other |
early palliative care |
1 |
2017 |
| Radiation |
early salvage radiotherapy |
1 |
2009 |
| Radiation |
ebrt / hdr brachytherapy boost |
1 |
2014 |
| Other |
ec0652 |
1 |
2014 |
| Drug |
ec1169 |
1 |
2014 |
| Device |
echolaser x4 system |
1 |
2019 |
| Behavioral |
education (eme) |
1 |
2016 |
| Behavioral |
education counseling session for psa screening |
1 |
2018 |
| Behavioral |
educational cd-rom |
1 |
2005 |
| Procedure |
educational handout about prostate cancer screening |
1 |
2005 |
| Behavioral |
educational internet site on prostate cancer screening |
1 |
2008 |
| Behavioral |
educational intervention to increase informed decision making for prostate cancer screening |
1 |
2005 |
| Behavioral |
educational print booklet |
1 |
2008 |
| Other |
educational program |
1 |
2017 |
| Other |
educational supplement |
1 |
2017 |
| Other |
educational video |
1 |
2015 |
| Other |
elastography |
1 |
2012 |
| Biological |
electroporation device cellectraâ®-5p |
1 |
2015 |
| Device |
electroporation using cellectraâ®-5p |
1 |
2015 |
| Drug |
elesclomol sodium |
1 |
2008 |
| Drug |
eligard (tm) |
1 |
2010 |
| Drug |
eligard 22.5mg |
1 |
2012 |
| Device |
em tracking |
1 |
2005 |
| Other |
email |
1 |
2012 |
| Behavioral |
email message |
1 |
2018 |
| Procedure |
embolization |
1 |
2018 |
| Behavioral |
empower |
1 |
2020 |
| Behavioral |
empty bladder |
1 |
2019 |
| Other |
emri |
1 |
2007 |
| Other |
emri/mrsi |
1 |
2007 |
| Drug |
enantone |
1 |
2018 |
| Drug |
endocrine therapy |
1 |
2005 |
| Device |
endomicroscopy |
1 |
2008 |
| Device |
endopat2000 |
1 |
2015 |
| Procedure |
endorectal coil magnetic resonance images |
1 |
2005 |
| Other |
endorectal magnetic resonance imaging (1.5tesla) (emri) |
1 |
2007 |
| Biological |
engineered autologous t cells |
1 |
2010 |
| Behavioral |
enhanced monitoring |
1 |
2016 |
| Behavioral |
enhanced monitoring/education (eme) |
1 |
2016 |
| Other |
enhanced survivorship care plan |
1 |
2020 |
| Drug |
enoblituzumab |
1 |
2016 |
| Drug |
entinostat |
1 |
2019 |
| Drug |
enzalutamide (cohort a = closed to accrual) |
1 |
2014 |
| Drug |
enzalutamide 160 mg |
1 |
2016 |
| Drug |
enzalutamide 40 mg |
1 |
2017 |
| Drug |
enzalutamide 40 mg oral capsule [xtandi] |
1 |
2019 |
| Biological |
enzalutamide combo |
1 |
2016 |
| Drug |
enzalutamide liquid |
1 |
2018 |
| Drug |
enzalutamide oral capsule [xtandi] |
1 |
2019 |
| placebo |
enzalutamide placebo |
1 |
2019 |
| placebo |
enzalutamide placebo to match (ptm) |
1 |
2014 |
| Drug |
enzalutamide tablet |
1 |
2013 |
| Drug |
enzalutamide) |
1 |
2018 |
| Combination Product |
enzalutamide/abiraterone/apalutamid |
1 |
2018 |
| Drug |
enzalutamide/dutasteride |
1 |
2014 |
| Drug |
eovist |
1 |
2013 |
| Dietary Supplement |
epa |
1 |
2014 |
| Drug |
epacadostat |
1 |
2018 |
| Other |
epic questionnaire |
1 |
2018 |
| Drug |
epidural 250ml of 0.2% ropivacaine |
1 |
2012 |
| Drug |
epidural 250ml of 0.2% ropivacaine/2 î¼g/ml of fentanyl, 5 ml/hr continuous infusion/0.5 ml bolus dose |
1 |
2012 |
| Procedure |
epidural anesthesia |
1 |
2011 |
| Drug |
epidural infusion of saline, ropivecaine, |
1 |
2010 |
| Drug |
epidural infusion of saline, ropivecaine,/ropivacaine/sufentanil |
1 |
2010 |
| Drug |
epothilone b |
1 |
2002 |
| Device |
equivalent) |
1 |
2015 |
| Drug |
erapa (encapsulated rapamycin) |
1 |
2018 |
| Device |
erectaid |
1 |
2005 |
| Behavioral |
erectile dysfunction |
1 |
2005 |
| Drug |
eribulin in combination |
1 |
2013 |
| Drug |
eribulin mesylate |
1 |
2006 |
| Drug |
erlotinib |
1 |
2005 |
| Drug |
erlotinib (tarceva) |
1 |
2005 |
| Drug |
erlotinib / bevacizumab |
1 |
2005 |
| Drug |
erythropoietin (epo) |
1 |
2008 |
| Biological |
es414 |
1 |
2014 |
| Drug |
escalating dose of casodex from 50mg daily to 150 mg daily |
1 |
2007 |
| Drug |
esk981 |
1 |
2018 |
| Drug |
estradiol |
1 |
2006 |
| Drug |
estrogen antagonists |
1 |
2002 |
| Drug |
estrogen transdermal patch |
1 |
2007 |
| Drug |
et 743 |
1 |
2005 |
| Biological |
etbx-051; adenoviral brachyury vaccine |
1 |
2018 |
| Biological |
etbx-061; adenoviral muc1 vaccine |
1 |
2018 |
| Biological |
etbx-071; adenoviral psa vaccine |
1 |
2018 |
| Drug |
etoricoxib |
1 |
2007 |
| Drug |
eulexin |
1 |
2000 |
| Drug |
everolimus (rad001) |
1 |
2012 |
| Other |
evidence-based information |
1 |
2018 |
| Device |
exablate 2100; insightec |
1 |
2012 |
| Device |
exablate mrgfus |
1 |
2016 |
| Device |
exablate mrgfus for prostate cancer |
1 |
2008 |
| Device |
exablate prostate treatment |
1 |
2019 |
| Drug |
exatecan mesylate |
1 |
1999 |
| Radiation |
exclusive external beam radiotherapy |
1 |
2014 |
| Radiation |
exclusive single-fraction irradiation |
1 |
2014 |
| Drug |
exemestane |
1 |
2002 |
| Drug |
exemestane/bicalutamide |
1 |
2002 |
| Behavioral |
exercise counseling |
1 |
2017 |
| Behavioral |
exercise program |
1 |
2016 |
| Other |
exercise programme |
1 |
2016 |
| Behavioral |
exercise training |
1 |
2005 |
| Behavioral |
exercise/diet |
1 |
2019 |
| Drug |
exisulind therapy |
1 |
2005 |
| Diagnostic Test |
exodx prostate (intelliscore) |
1 |
2017 |
| Behavioral |
expanded prostate cancer index composite |
1 |
2014 |
| Behavioral |
expanded prostate cancer index composite-short form 12 |
1 |
2014 |
| Behavioral |
expanded prostate cancer index composite sf-12 |
1 |
2013 |
| Behavioral |
expanded prostate cancer index composite sf12 questionnaire |
1 |
2014 |
| Behavioral |
experimental: arm 1 (aerobic exercise) |
1 |
2015 |
| Behavioral |
experimental: arm 2 (resist. exercise) |
1 |
2015 |
| Procedure |
explantation |
1 |
2019 |
| Behavioral |
exrecise intervention |
1 |
2017 |
| Other |
extended biopsy |
1 |
2019 |
| Radiation |
extended hypofractionation radiotherapy |
1 |
2013 |
| Procedure |
extended pelvic lymphadenectomy |
1 |
2018 |
| Radiation |
external beam radiotherapy (78 gy in 39 fractions |
1 |
2015 |
| Radiation |
external beam radiotherapy (78 gy in 39 fractions/46 gy in 23 fractions/brachytherapy boost) |
1 |
2015 |
| Radiation |
external radiation therapy |
1 |
2016 |
| Radiation |
external radiotherapy |
1 |
2010 |
| Drug |
ezetimibe 10mg-simvastatin 40mg |
1 |
2015 |
| Drug |
f-18-fluorocholine |
1 |
2019 |
| Drug |
f-18-psma-1007 |
1 |
2019 |
| Diagnostic Test |
f-18 fluciclovine-pet |
1 |
2018 |
| Diagnostic Test |
f-18 fluciclovine-pet/ct scan |
1 |
2018 |
| Drug |
f-18 naf |
1 |
2010 |
| Diagnostic Test |
f18-fluciclovine pet |
1 |
2020 |
| Diagnostic Test |
f18-fluciclovine pet/ct |
1 |
2020 |
| Diagnostic Test |
f18-psma |
1 |
2019 |
| Diagnostic Test |
f18-psma-1007 pet |
1 |
2020 |
| Diagnostic Test |
f18-psma-1007 pet/ct |
1 |
2020 |
| Procedure |
facbc pet |
1 |
2015 |
| Drug |
facbc pet-ct |
1 |
2016 |
| Drug |
facbc pet-ct imaging |
1 |
2017 |
| Drug |
facbc pet-ct scan |
1 |
2016 |
| Procedure |
facbc pet/mri in a subset of participants |
1 |
2015 |
| Diagnostic Test |
faecal immunochemical test |
1 |
2019 |
| Behavioral |
family history: number |
1 |
2015 |
| Behavioral |
family history: number / pictograph |
1 |
2015 |
| Behavioral |
family history: number format |
1 |
2015 |
| Procedure |
fascial suturing, qol forms |
1 |
2009 |
| Other |
fasting |
1 |
2016 |
| Biological |
fecal microbiota transplant |
1 |
2019 |
| Procedure |
fecal samples |
1 |
2018 |
| Behavioral |
feedback |
1 |
2018 |
| Drug |
fentanile |
1 |
2016 |
| Drug |
ferrotranâ® (ferumoxtran-10) |
1 |
2020 |
| Drug |
ferumoxytol |
1 |
2011 |
| Drug |
fgfr inhibitor azd4547 |
1 |
2015 |
| Procedure |
fiducial marker placement |
1 |
2003 |
| Procedure |
fiducials placement |
1 |
2011 |
| Other |
first exercise session |
1 |
2018 |
| Other |
first exercise session - compression |
1 |
2018 |
| Other |
first exercise session / compression |
1 |
2018 |
| Radiation |
first part of treatment : conformal irradiation |
1 |
2011 |
| Dietary Supplement |
fish oil supplement |
1 |
2006 |
| Drug |
fk228 (romidepsin) |
1 |
2005 |
| Radiation |
flame boost |
1 |
2010 |
| Dietary Supplement |
flaxseed |
1 |
2002 |
| Other |
fleet enema |
1 |
2017 |
| Behavioral |
flexibility training |
1 |
2008 |
| Other |
flow cytometry |
1 |
2008 |
| Diagnostic Test |
fluciclovine pet |
1 |
2018 |
| Other |
fluciclovine pet scan added to mri |
1 |
2019 |
| Diagnostic Test |
fluciclovine pet/mri |
1 |
2018 |
| Drug |
fludarabine phosphate |
1 |
2019 |
| Radiation |
fludeoxyglucose f 18 |
1 |
1999 |
| Procedure |
fluid loading of volulyte 300 ml |
1 |
2016 |
| Diagnostic Test |
fluorine-18-prostate specific membrane antigen-1007- positron emission tomography |
1 |
2018 |
| Diagnostic Test |
fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography |
1 |
2018 |
| Radiation |
fluorine f 18 d-fmau |
1 |
2013 |
| Drug |
fluorocholine (18f-fch) injection |
1 |
2013 |
| Diagnostic Test |
fluorocholine pet |
1 |
2017 |
| Diagnostic Test |
fluorocholine pet/ct |
1 |
2017 |
| Drug |
fluorothymidine f 18 |
1 |
2012 |
| Device |
fluourine-18 fluoromethylcholine pet |
1 |
2009 |
| Device |
fluourine-18 fluoromethylcholine pet/ct imaging |
1 |
2009 |
| Drug |
flutamide (eulexin)/lupron/zoladex |
1 |
2005 |
| Drug |
fluvastatin |
1 |
2013 |
| Drug |
fms inhibitor jnj-40346527 |
1 |
2017 |
| Radiation |
focal brachytherapy |
1 |
2013 |
| Radiation |
focal brachytherapy boost to sbrt |
1 |
2019 |
| Device |
focal hifu treatment using focal one (edap tms) |
1 |
2018 |
| Device |
focal high intensity focused ultrasound (hifu) treatment |
1 |
2016 |
| Procedure |
focal laser ablation of the prostate |
1 |
2015 |
| Procedure |
focal phothtermal ablation |
1 |
2008 |
| Radiation |
focal prostate brachytherapy with cesium-131 |
1 |
2014 |
| Radiation |
focal salvage hdr prostate brachytherapy |
1 |
2012 |
| Procedure |
focal therapy |
1 |
2019 |
| Procedure |
focal therapy after bicalutamide 50mg tablets for 12 weeks |
1 |
2019 |
| Procedure |
focal therapy after finasteride 5mg tablets for 12 weeks |
1 |
2019 |
| Behavioral |
focus program |
1 |
2008 |
| Dietary Supplement |
folic acid |
1 |
2005 |
| Behavioral |
food frequency questionnaire |
1 |
2014 |
| Behavioral |
football |
1 |
2015 |
| Drug |
for46 |
1 |
2018 |
| Other |
formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy |
1 |
2018 |
| Drug |
fosfomycin |
1 |
2017 |
| Biological |
fowlpox virus vaccine vector |
1 |
1999 |
| Biological |
fpv-brachyury |
1 |
2018 |
| Radiation |
fractionation |
1 |
2014 |
| Procedure |
frozen glove |
1 |
2009 |
| Behavioral |
fruit |
1 |
2011 |
| Behavioral |
fruit/vegetable intake education |
1 |
2011 |
| Behavioral |
full bladder |
1 |
2019 |
| Device |
functional magnetic resonance imaging |
1 |
2015 |
| Procedure |
fusion biopsies |
1 |
2017 |
| Procedure |
fusion biopsy |
1 |
2016 |
| Drug |
g-202 |
1 |
2015 |
| Drug |
g-csf (granulocyte colony-stimulating factor) |
1 |
2012 |
| Drug |
ga-68-psma-11 |
1 |
2017 |
| Drug |
ga-68 labeled hbed-cc psma |
1 |
2015 |
| Drug |
ga-68 labeled psma-11 |
1 |
2019 |
| Drug |
ga-68 labeled psma-11 pet |
1 |
2016 |
| Drug |
ga-68 p16-093 pet |
1 |
2018 |
| Drug |
ga-68 p16-093 pet/ct scan |
1 |
2018 |
| Drug |
ga-68 psma11 |
1 |
2018 |
| Drug |
ga-hbed-ipsma pet |
1 |
2017 |
| Drug |
gabapentin |
1 |
2002 |
| Radiation |
gadopentetate dimeglumine |
1 |
2015 |
| Drug |
gadoxetate sodium |
1 |
2019 |
| Drug |
galeterone |
1 |
2012 |
| Drug |
gallium-68 citrate pet |
1 |
2015 |
| Drug |
gallium-68 thp-psma |
1 |
2018 |
| Drug |
gallium ga 68-dotatate |
1 |
2018 |
| Drug |
gallium ga 68-labeled grpr antagonist bay86-7548 |
1 |
2017 |
| Drug |
gallium ga 68-labeled psma ligand glu-urea-lys(ahx) |
1 |
2015 |
| Drug |
gallium ga 68-labeled psma ligand glu-urea-lys(ahx)-hbed-cc |
1 |
2016 |
| Drug |
gallium ga 68-psma-11 |
1 |
2016 |
| Biological |
ganitumab |
1 |
2007 |
| Other |
gas chromatography-mass spectrometry |
1 |
2008 |
| Drug |
gcp - genistein |
1 |
2007 |
| Drug |
gcp - genistein/polysaccharide |
1 |
2007 |
| Drug |
gefitinib, radiotherapy |
1 |
2005 |
| Dietary Supplement |
gelatin capsule containing microcrystalline cellulose. |
1 |
2010 |
| Drug |
gemcitabine |
1 |
2005 |
| Drug |
gemox |
1 |
2011 |
| Biological |
gene-modified tumor cell vaccine therapy |
1 |
1999 |
| Procedure |
gene rearrangement |
1 |
2008 |
| Behavioral |
general health counseling coaching |
1 |
2018 |
| Behavioral |
general health education |
1 |
2014 |
| Genetic |
genetic risk assessment |
1 |
2012 |
| Genetic |
genetic risk score: number |
1 |
2015 |
| Genetic |
genetic risk score: number / pictograph |
1 |
2015 |
| Genetic |
genetic risk score: number format |
1 |
2015 |
| Drug |
genistein/polysaccharide (gcp) |
1 |
2005 |
| Other |
geriatric assessment/quality of life |
1 |
2016 |
| Other |
geriatrician review |
1 |
2014 |
| Drug |
gleevec / sorafenib |
1 |
2007 |
| Drug |
glutamine) |
1 |
2012 |
| Biological |
glycosylated recombinant human interleukin-7 |
1 |
2013 |
| placebo |
gm-csf placebo |
1 |
2011 |
| Drug |
gm csf |
1 |
2006 |
| Drug |
gnrh (agonist) |
1 |
2015 |
| Drug |
gnrh (leuprolide) |
1 |
2007 |
| Drug |
gnrh antagonist |
1 |
2019 |
| Procedure |
gold standard biopsy |
1 |
2011 |
| Drug |
gonal f rff pen 900 unt per 1.5 ml pen injector |
1 |
2019 |
| Drug |
goserelin 10.8 mg |
1 |
2020 |
| Drug |
goserelin acetate 10.8 mg subcutaneous implant |
1 |
2019 |
| Drug |
goserelin with bicalutamide |
1 |
2006 |
| Drug |
goserelin with bicalutamide/dutasteride |
1 |
2006 |
| Drug |
goserelin with bicalutamide/dutasteride/ketoconazole |
1 |
2006 |
| Drug |
goserelin with dutasteride |
1 |
2006 |
| Drug |
goserelin/bicalutamide |
1 |
2009 |
| Biological |
gpi-0100 |
1 |
2001 |
| Drug |
gpi 1485 |
1 |
2004 |
| Drug |
granulocyte colony-stimulating factor (g-csf) |
1 |
2016 |
| Dietary Supplement |
grape seed extract |
1 |
2017 |
| Drug |
grape skin extract |
1 |
2011 |
| Radiation |
gray |
1 |
2005 |
| Device |
green indocianine |
1 |
2017 |
| Dietary Supplement |
green tea capsules |
1 |
2010 |
| Dietary Supplement |
green tea catechin extract |
1 |
2005 |
| Behavioral |
green tea drink |
1 |
2010 |
| placebo |
green tea placebo capsules |
1 |
2010 |
| Behavioral |
group based exercise |
1 |
2015 |
| Drug |
gs-5829 |
1 |
2015 |
| Drug |
gsk2636771 |
1 |
2014 |
| Drug |
gsk525762 |
1 |
2017 |
| Drug |
guadecitabine |
1 |
2016 |
| Procedure |
guidance |
1 |
2009 |
| Other |
guided imagery/progressive muscle relaxation |
1 |
2011 |
| Behavioral |
guided lifestyle program intervention |
1 |
2019 |
| Drug |
gvax |
1 |
2012 |
| Biological |
gx301 |
1 |
2014 |
| Other |
h2 antagonist |
1 |
2017 |
| Procedure |
haematology |
1 |
2007 |
| Drug |
hc-1119 |
1 |
2018 |
| Drug |
hdac inhibitor sb939 |
1 |
2010 |
| Radiation |
hdr-brachytherapy |
1 |
2014 |
| Radiation |
hdr (19gy) |
1 |
2017 |
| Radiation |
hdr (19gy)/sbrt (35-40gy) |
1 |
2017 |
| Radiation |
hdr brachytherapy / ebrt / stad |
1 |
2018 |
| Radiation |
hdr brachytherapy as monotherapy |
1 |
2018 |
| Radiation |
hdr brachytherapy monotherapy |
1 |
2014 |
| Radiation |
hdr partial prostate brachytherapy |
1 |
2017 |
| Radiation |
hdr prostate brachytherapy |
1 |
2010 |
| Drug |
he3235 |
1 |
2008 |
| Behavioral |
health promotion |
1 |
2016 |
| Behavioral |
healthy bones pamphlet |
1 |
2014 |
| Radiation |
height rt |
1 |
2014 |
| Behavioral |
help with decision making on prostate cancer treatment |
1 |
2001 |
| Device |
hemopatch |
1 |
2019 |
| Biological |
her2bi-armed activated t cells |
1 |
2017 |
| Device |
hifu |
1 |
2017 |
| Device |
hifu (sonablateâ® 500) |
1 |
2008 |
| Radiation |
high-dose-rate prostate brachytherapy |
1 |
2015 |
| Drug |
high-dose mpx |
1 |
2011 |
| Radiation |
high-dose rate (hdr) radiotherapy |
1 |
2012 |
| Behavioral |
high-intensity aerobic interval training (hiit) |
1 |
2017 |
| Procedure |
high-intensity focused ultrasound |
1 |
2019 |
| Radiation |
high-let heavy ion therapy |
1 |
1999 |
| Device |
high-resolution micro-ultrasound guided prostate biopsy |
1 |
2017 |
| Device |
high-resolution ultrasound guided prostate biopsy |
1 |
2014 |
| Dietary Supplement |
high-selenium baker’s yeast |
1 |
2009 |
| Procedure |
high dose-rate brachytherapy |
1 |
2005 |
| Drug |
high dose aspirin |
1 |
2016 |
| placebo |
high dose aspirin, vitamin d placebo |
1 |
2016 |
| Drug |
high dose aspirin/vitamin d |
1 |
2016 |
| Radiation |
high dose rate (hdr) brachytherapy using iridium 192 radioactive seeds |
1 |
2008 |
| Radiation |
high dose rate brachytherapy |
1 |
2016 |
| Dietary Supplement |
high dose selenized-yeast |
1 |
2010 |
| Behavioral |
high intensity aerobic |
1 |
2016 |
| Behavioral |
high intensity aerobic/resistance training |
1 |
2016 |
| Behavioral |
high intensity exercise |
1 |
2014 |
| Procedure |
high intensity focused ultrasound (hifu) treatment |
1 |
2020 |
| Behavioral |
high intensity interval training |
1 |
2016 |
| Behavioral |
high intensity interval training bout |
1 |
2018 |
| Other |
high performance liquid chromatography |
1 |
2007 |
| Other |
high quality volume ct scan; mri scan |
1 |
2012 |
| Diagnostic Test |
high resolution mri (hrmri) |
1 |
2017 |
| Drug |
high sulforaphane extract (broccoli sprout extract) |
1 |
2009 |
| Procedure |
higher peep ventilation |
1 |
2015 |
| Procedure |
histology (gold standard) |
1 |
2014 |
| Other |
histoscanningâ„¢ |
1 |
2012 |
| Other |
histoscanningâ„¢/multiparametric mri |
1 |
2012 |
| Drug |
histrelin hydrogel implant |
1 |
2011 |
| Procedure |
holmium laser enucleation of prostate (holep) |
1 |
2019 |
| Other |
home-based exercise program |
1 |
2018 |
| Behavioral |
home based training using the xbox kinect system |
1 |
2012 |
| Drug |
hormonal therapy (lhrh agonist and |
1 |
2016 |
| Drug |
hormonal therapy (lhrh agonist and/or antiandrogens) |
1 |
2016 |
| Biological |
hormone |
1 |
2018 |
| Drug |
hormone suppressors |
1 |
2016 |
| Drug |
hormone therapy |
1 |
2019 |
| Biological |
hormone/radiation therapy |
1 |
2018 |
| Biological |
hpn424 |
1 |
2018 |
| Drug |
hr |
1 |
2019 |
| Drug |
hr continuous infusion |
1 |
2012 |
| Drug |
hsp90 inhibitor sta-9090 |
1 |
2011 |
| Drug |
hsv-tk /valacyclovir in combination with brachytherapy |
1 |
2013 |
| Radiation |
htimrt |
1 |
2011 |
| Device |
hyaluronic acid |
1 |
2013 |
| Device |
hybrid pet-ct imaging system |
1 |
2006 |
| Drug |
hydromorphone hydrochloride |
1 |
1999 |
| Drug |
hydroxychloroquine sulfate 200mg tab |
1 |
2019 |
| Biological |
hyperacute-prostate cancer vaccine |
1 |
2005 |
| Drug |
hyperpolarized carbon c 13 pyruvate |
1 |
2018 |
| Other |
hyperpolarized pyruvate (13c) |
1 |
2016 |
| Drug |
hyperpolarized pyruvate (13c) injection |
1 |
2010 |
| Radiation |
hypo-flame 2.0 study |
1 |
2019 |
| Radiation |
hypo-flame study |
1 |
2016 |
| Radiation |
hypo-fractionated postoperative imrt-sib |
1 |
2017 |
| Procedure |
hypo-fractionated radiotherapy |
1 |
2009 |
| Radiation |
hypofraction |
1 |
2016 |
| Radiation |
hypofractionated 3d-crt |
1 |
2006 |
| Radiation |
hypofractionated 3d-crt/imrt |
1 |
2006 |
| Radiation |
hypofractionated dose escalation radiotherapy |
1 |
2014 |
| Radiation |
hypofractionated helical imrt |
1 |
2012 |
| Radiation |
hypofractionated imrt radiation treatment |
1 |
2019 |
| Radiation |
hypofractionated imrt using helical tomotherapy. |
1 |
2019 |
| Radiation |
hypofractionated intensity modulated radiotherapy |
1 |
2008 |
| Radiation |
hypofractionated proton therapy |
1 |
2014 |
| Radiation |
hypofractionated radiation therapy 57 gy in 19 fractions |
1 |
2006 |
| Radiation |
hypofractionated radiation therapy 60 gy in 20 fractions |
1 |
2006 |
| Radiation |
hypofractionated radiation treatment |
1 |
2011 |
| Radiation |
hypofractionated radiotherapy with photons |
1 |
2019 |
| Radiation |
hypofractionated radiotherapy with protons |
1 |
2019 |
| Radiation |
hypofractionated rt 5 x 7,25 gy |
1 |
2013 |
| Radiation |
hypofractionated therapy |
1 |
2013 |
| Radiation |
hypofractionated wprt |
1 |
2019 |
| Radiation |
hypofractionated, image-guided, intensity-modulated external beam radiation |
1 |
2009 |
| Radiation |
hypofractionation proton beam therapy with concurrent treatment of the prostate |
1 |
2016 |
| Radiation |
hypofractionation proton beam therapy with concurrent treatment of the prostate/pelvic nodes |
1 |
2016 |
| Procedure |
hypoxia measurement |
1 |
2005 |
| Drug |
i-131-1095 |
1 |
2019 |
| Combination Product |
iadt / radiotherapy |
1 |
2018 |
| Drug |
ibandronate sodium |
1 |
2004 |
| Drug |
ibrance |
1 |
2014 |
| Drug |
ibrutinib |
1 |
2015 |
| Procedure |
icg |
1 |
2014 |
| Radiation |
igrt/vmat focal therapy boost to dil |
1 |
2017 |
| Biological |
ii peptide vaccine |
1 |
2008 |
| Genetic |
il-12 gene |
1 |
2006 |
| Biological |
il-2 |
1 |
2014 |
| Drug |
il2 |
1 |
2006 |
| Drug |
ilx651 |
1 |
2004 |
| Radiation |
image-guided radiotherapy |
1 |
2011 |
| Procedure |
image-guided, volumetric intensity-modulated arc radiotherapy (igrt-vmat) |
1 |
2019 |
| Radiation |
image guided radiation therapy |
1 |
2012 |
| Procedure |
imaging in trimodality |
1 |
2018 |
| Other |
imaging panel |
1 |
2018 |
| Other |
imaging: diffusion-weighted mri |
1 |
2008 |
| Biological |
imc-1121b (ramucirumab) |
1 |
2008 |
| Drug |
imc-a12 (cixutumumab) |
1 |
2007 |
| Drug |
imexon |
1 |
2006 |
| Behavioral |
immediate diet |
1 |
2013 |
| Behavioral |
immediate diet/exercise intervention |
1 |
2013 |
| Procedure |
immediate orchiectomy |
1 |
2013 |
| Procedure |
immediate orchiectomy/depot lhrh |
1 |
2013 |
| Procedure |
immune assays |
1 |
2015 |
| Other |
immunologic technique |
1 |
2008 |
| Other |
immunological diagnostic method |
1 |
2006 |
| Radiation |
imrt followed by mpmri guided sbrt boost with sib to intraprostatic lesions |
1 |
2018 |
| Radiation |
imrt technique |
1 |
2012 |
| Radiation |
imrt to 45 gy; prostate bed proton boost of 21.6 cge |
1 |
2009 |
| Radiation |
imrt to 45 gy; proton boost to prostate bed to 25.2 cge |
1 |
2009 |
| Procedure |
in vitro-treated peripheral blood stem cell transplantation |
1 |
2001 |
| Biological |
inactivated influenza vaccine |
1 |
2008 |
| Biological |
inactivated influenza vaccine/the 23- valent pneumococcal vaccine |
1 |
2008 |
| Biological |
inactivated influenza vaccine/the ppv23 vaccine (pneumovax) |
1 |
2008 |
| Drug |
indocyanine green solution |
1 |
2014 |
| Drug |
indole-3-carbinol |
1 |
2008 |
| Biological |
indoximod |
1 |
2012 |
| Behavioral |
informal interview |
1 |
2017 |
| Other |
information gathering |
1 |
2008 |
| Other |
information support program |
1 |
2020 |
| Drug |
inject of autologous adipose-derived stem cells |
1 |
2012 |
| Device |
injectable rectal spacer (spaceoar, duraseal |
1 |
2015 |
| Device |
injectable rectal spacer (spaceoar, duraseal/equivalent) |
1 |
2015 |
| Other |
injection of 64cu-dota-ae105 |
1 |
2014 |
| Drug |
ino-5151 (cohort c) |
1 |
2019 |
| Radiation |
intensity-modulated radiation therapy (imrt) |
1 |
2006 |
| Radiation |
intensity-modulated radiotherapy of the pelvic lymph nodes using sib |
1 |
2013 |
| Radiation |
intensity modulated radiotherapy |
1 |
2017 |
| Behavioral |
interactive voice response (ivr) reminders |
1 |
2014 |
| Behavioral |
interactive voice response symptom management |
1 |
2013 |
| Radiation |
intermediate risk proton radiation |
1 |
2008 |
| Drug |
intermittent dosing of azd5363 |
1 |
2012 |
| Radiation |
internal radiation therapy |
1 |
2015 |
| Behavioral |
internet-delivered mindfulness-based cognitive therapy |
1 |
2017 |
| Behavioral |
intervention session |
1 |
2008 |
| Device |
intervention systematic light exposure |
1 |
2018 |
| Other |
interview with a sociologist |
1 |
2015 |
| Other |
interviews |
1 |
2017 |
| Other |
interviews with stakeholders |
1 |
2017 |
| Biological |
intetumumab |
1 |
2007 |
| Biological |
intramuscular (im) poly iclc |
1 |
2017 |
| Other |
intraoperative complication management |
1 |
2012 |
| Other |
intraoperative complication management/prevention |
1 |
2012 |
| Other |
intrarectal povidone-iodine cleansing |
1 |
2018 |
| Other |
intrarectal povidone-iodine cleansing/formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy |
1 |
2018 |
| Biological |
intratumoral (it) poly iclc 0.5 mg |
1 |
2017 |
| Biological |
intratumoral (it) poly iclc 1.0 mg |
1 |
2017 |
| Device |
investigational pet scanner coils |
1 |
2019 |
| Device |
investigational pet scanner coils/software |
1 |
2019 |
| Device |
investigational software |
1 |
2019 |
| Device |
investigational software/coils in pet/mr scan |
1 |
2019 |
| Radiation |
iodine 125 standard loose brachytherapy seeds |
1 |
2010 |
| Radiation |
iodine i 131 monoclonal antibody muj591 |
1 |
2000 |
| Drug |
ipi-504 |
1 |
2007 |
| Drug |
ipilimumab 5 mg |
1 |
2019 |
| Drug |
ipilimumab 5 mg/ml |
1 |
2019 |
| Drug |
iressa |
1 |
2006 |
| Procedure |
iridium implant |
1 |
2007 |
| Drug |
irinotecan hydrochloride |
1 |
2002 |
| Radiation |
irradiation therapy |
1 |
2017 |
| Procedure |
irreversible electroporation |
1 |
2013 |
| Device |
irreversible electroporation (nanoknife) |
1 |
2013 |
| Drug |
isis eif4e rx |
1 |
2010 |
| Drug |
isotretinoin |
1 |
2000 |
| Drug |
ispinesib |
1 |
2004 |
| Procedure |
issue of information booklet |
1 |
2005 |
| Drug |
itraconazole |
1 |
2013 |
| Drug |
itraconazole 200 mg |
1 |
2009 |
| Drug |
itraconazole 300mg |
1 |
2009 |
| Drug |
iv administration of fluorine-18 fluorocholine followed by pet |
1 |
2009 |
| Drug |
iv administration of fluorine-18 fluorocholine followed by pet/ct imaging |
1 |
2009 |
| Drug |
iv fluorine-18 labeled methylcholine before pet |
1 |
2009 |
| Drug |
iv fluorine-18 labeled methylcholine before pet/ct |
1 |
2009 |
| Drug |
jnj-212082 |
1 |
2010 |
| Biological |
jnj-64041809 (cohort 1a |
1 |
2015 |
| Biological |
jnj-64041809 (cohort 1a/1b) |
1 |
2015 |
| Biological |
jnj-64041809 (cohort 2a |
1 |
2015 |
| Biological |
jnj-64041809 (cohort 2a/2b) |
1 |
2015 |
| Drug |
jnj 56021927 |
1 |
2015 |
| Drug |
ketaconazole |
1 |
2002 |
| Drug |
ketamine |
1 |
2016 |
| Drug |
ketoconazole, hydrocortisone |
1 |
2008 |
| Drug |
ketoconazole, hydrocortisone/dutasteride |
1 |
2008 |
| Biological |
keyhole limpet hemocyanin |
1 |
1999 |
| Drug |
kpt-8602 |
1 |
2016 |
| Radiation |
kv x-ray images |
1 |
2018 |
| Drug |
kx2-391 |
1 |
2010 |
| Drug |
l-377202 |
1 |
2009 |
| Drug |
l-selenomethionine |
1 |
2002 |
| placebo |
l-selenomethionine placebo |
1 |
2002 |
| Other |
laboratory biomarker |
1 |
2014 |
| Drug |
lae001 |
1 |
2019 |
| Biological |
lage-1 hla class i |
1 |
2008 |
| Procedure |
laparoscopic radical prostatectomy/bilateral pelvic ln dissection |
1 |
2019 |
| Drug |
lapatinib |
1 |
2006 |
| Procedure |
laproscopic prostatectomy |
1 |
2012 |
| Drug |
larotrectinib |
1 |
2015 |
| Drug |
larotrectinib sulfate |
1 |
2015 |
| Procedure |
laser-based thermotherapy |
1 |
2010 |
| Radiation |
lattice extreme ablative dose radiation therapy |
1 |
2011 |
| Drug |
lbh589 (i.v. panobinostat) |
1 |
2008 |
| Behavioral |
lcnc |
1 |
2014 |
| Drug |
lde225 |
1 |
2014 |
| Radiation |
ldr-brachytherapy with i125 seeds |
1 |
2013 |
| Radiation |
ldr brachytherapy |
1 |
2018 |
| Radiation |
ldr brachytherapy/external beam radiation therapy |
1 |
2018 |
| Radiation |
ldr/hdr |
1 |
2017 |
| Radiation |
lead rt |
1 |
2014 |
| Other |
lecture |
1 |
2018 |
| Drug |
leflunomide |
1 |
1999 |
| Drug |
letrozole |
1 |
2018 |
| Behavioral |
letter to gp |
1 |
2014 |
| Procedure |
leukapheresis |
1 |
2018 |
| Drug |
leuprolide 7.5 mg / degarelix 160 mg |
1 |
2007 |
| Drug |
leuprolide 7.5 mg / degarelix 80 mg |
1 |
2007 |
| Drug |
leuprolide acetate - formulation a |
1 |
2008 |
| Drug |
leuprolide acetate - formulation b |
1 |
2008 |
| Drug |
leuprolide acetate ( eligardâ®) hormonal therapy |
1 |
2006 |
| Drug |
leuprolide acetate 22.5 mg depot, gp-pharm sa |
1 |
2011 |
| Drug |
leuprolide acetate fluidcrystalâ® injection depot |
1 |
2014 |
| Drug |
leuprolide acetate for injectable suspension |
1 |
2008 |
| Drug |
leuprolide acetate for injectable suspension 22.5 mg |
1 |
2004 |
| Drug |
leuprolide acetate/bicalutamide |
1 |
2004 |
| Drug |
leuprolide/goserelin |
1 |
2005 |
| Drug |
leuprolide/goserelin acetate |
1 |
2001 |
| Drug |
leuprorelin acetate 45mg powder for injection suspension vial |
1 |
2019 |
| Drug |
leuprorelin sr |
1 |
2010 |
| Drug |
lhrh |
1 |
2006 |
| Drug |
lhrh-therapy |
1 |
2013 |
| Other |
lhrh agent |
1 |
2008 |
| Drug |
lhrh agonist/antagonist |
1 |
2018 |
| Drug |
lhrh agonists (goserelin acetate) |
1 |
2007 |
| Drug |
lhrh agonists (goserelin acetate)/calcium/ vitamin d supplementation |
1 |
2007 |
| Drug |
lhrh analogue |
1 |
2017 |
| Drug |
lhrha/surgical castration |
1 |
2015 |
| Drug |
lidocaine |
1 |
2007 |
| Drug |
lidocaine gel |
1 |
2013 |
| Drug |
lidocaine gel only |
1 |
2013 |
| Behavioral |
lifestyle counseling |
1 |
2011 |
| Behavioral |
lifestyle intervention |
1 |
2015 |
| Other |
light touch intervention |
1 |
2017 |
| Drug |
linsitinib |
1 |
2012 |
| Drug |
liplacis |
1 |
2013 |
| Drug |
lithium carbonate |
1 |
2014 |
| Drug |
lmis 50 mg |
1 |
2016 |
| Radiation |
ln |
1 |
2009 |
| Biological |
lncap |
1 |
2006 |
| Procedure |
local anesthesia |
1 |
2007 |
| Other |
long-term follow-up |
1 |
2017 |
| Drug |
lovastatin |
1 |
2007 |
| Behavioral |
low |
1 |
2014 |
| Drug |
low-dose mpx |
1 |
2011 |
| Dietary Supplement |
low-fat diet |
1 |
2008 |
| Procedure |
low-intensity bodywork therapy |
1 |
2002 |
| Radiation |
low-let cobalt-60 gamma ray therapy |
1 |
2008 |
| Behavioral |
low carbohydrate diet |
1 |
2012 |
| Drug |
low dose aspirin , vitamin d |
1 |
2016 |
| placebo |
low dose aspirin, vitamin d placebo |
1 |
2016 |
| Radiation |
low dose rate brachytherapy |
1 |
2016 |
| Dietary Supplement |
low dose selenized-yeast |
1 |
2010 |
| Other |
low protein diet |
1 |
2017 |
| Radiation |
low risk proton radiation |
1 |
2008 |
| Behavioral |
low/medium intensity exercise |
1 |
2014 |
| Drug |
lu-177 psma-617 |
1 |
2019 |
| Drug |
lu177-psma-617 |
1 |
2017 |
| Combination Product |
lum imaging system |
1 |
2018 |
| Drug |
luminal type-1 |
1 |
2018 |
| Drug |
luminal type-2 |
1 |
2018 |
| Drug |
lupron depot |
1 |
2014 |
| Drug |
luteinizing hormone-releasing hormone analog |
1 |
2019 |
| Drug |
luteinizing hormone releasing hormone [lhrh] agonist |
1 |
1999 |
| Drug |
lutetium lu 177-psma-617 |
1 |
2019 |
| Radiation |
lutetium lu 177 monoclonal antibody j591 |
1 |
2004 |
| Drug |
lutrate |
1 |
2018 |
| Drug |
ly01005 |
1 |
2018 |
| Drug |
ly2157299 |
1 |
2015 |
| Drug |
ly2181308 sodium |
1 |
2008 |
| Drug |
ly2452473 |
1 |
2015 |
| Drug |
ly2606368 |
1 |
2014 |
| Drug |
ly3023414 |
1 |
2015 |
| Drug |
lycopene 30mg |
1 |
2011 |
| Dietary Supplement |
lycopene capsules |
1 |
2010 |
| placebo |
lycopene placebo capsules |
1 |
2010 |
| Dietary Supplement |
lycopene supplement |
1 |
2006 |
| Drug |
lycopene/docetaxel |
1 |
2013 |
| Procedure |
lymph nod detection |
1 |
2011 |
| Procedure |
lymph node biopsy |
1 |
2014 |
| Procedure |
lymph node dissection |
1 |
2020 |
| Procedure |
lymph node template |
1 |
2011 |
| Drug |
lyophilized black raspberry confection |
1 |
2013 |
| Drug |
m2 iv |
1 |
2014 |
| Drug |
m2) |
1 |
2017 |
| Biological |
m7824 |
1 |
2018 |
| Other |
machine learning planning |
1 |
2016 |
| Dietary Supplement |
mag-epa |
1 |
2018 |
| Drug |
magnesium sulfate |
1 |
2016 |
| Other |
magnetic nanoparticle injection |
1 |
2014 |
| Procedure |
magnetic resonance imaging (dce-mri) |
1 |
2007 |
| Diagnostic Test |
magnetic resonance imaging (mri) |
1 |
2019 |
| Procedure |
magnetic resonance imaging (mri) scan |
1 |
2015 |
| Device |
magnetic resonance imaging, siemens |
1 |
2011 |
| Other |
magnetic resonance imaging; spectroscopic imaging, contrast enhanced imaging |
1 |
2007 |
| Device |
magnetic resonance spectroscopy (3tesla) |
1 |
2006 |
| Procedure |
magnetic resonance spectroscopy imaging |
1 |
2005 |
| Procedure |
magnetic resonance whole body diffusion-weighted imaging |
1 |
2017 |
| Diagnostic Test |
mammogram |
1 |
2019 |
| Radiation |
mapped tumor salvage rt (mtsrt) |
1 |
2011 |
| Drug |
masitinib |
1 |
2018 |
| Other |
mass spectrometry |
1 |
2007 |
| placebo |
matching placebo |
1 |
2006 |
| placebo |
matching placebo (normal saline) |
1 |
2014 |
| Procedure |
maximization of cardiac stroke volume with fluid infusion |
1 |
2008 |
| Drug |
maximum androgen blockade |
1 |
2020 |
| Biological |
mdc |
1 |
2015 |
| Biological |
mdc vaccination |
1 |
2015 |
| Biological |
mdc/pdc vaccination |
1 |
2015 |
| Drug |
mdx-010 / mdx-010 / docetaxel |
1 |
2002 |
| Biological |
mdx-1106 |
1 |
2007 |
| Biological |
medi-522 |
1 |
2003 |
| Biological |
medi3726 |
1 |
2016 |
| Biological |
medi3726 post-chemo |
1 |
2016 |
| Biological |
medi3726 pre-chemo |
1 |
2016 |
| Biological |
medi3726/enzalutamide combo |
1 |
2016 |
| Drug |
medi7247 |
1 |
2018 |
| Behavioral |
meditation |
1 |
2018 |
| Behavioral |
medium intensity exercise |
1 |
2014 |
| Drug |
meloxicam |
1 |
2005 |
| Drug |
melphalan |
1 |
1999 |
| Drug |
memantine hydrochloride |
1 |
2012 |
| Device |
memokath 028sw urethral stent |
1 |
2005 |
| Behavioral |
memory anxiety scale for prostate cancer patients |
1 |
2014 |
| Drug |
mepivacaãne |
1 |
2016 |
| Procedure |
metastasectomy |
1 |
2019 |
| Radiation |
metastasis-directed treatment |
1 |
2018 |
| Other |
metastasis biopsy |
1 |
2012 |
| Drug |
metformin hydrochloride extended release 750mg |
1 |
2014 |
| Drug |
metformin/bicalutamide |
1 |
2015 |
| Dietary Supplement |
methionine-restricted diet |
1 |
2018 |
| Radiation |
methionine c 11 |
1 |
1999 |
| Drug |
methyl cellulose blend |
1 |
2009 |
| Drug |
metoclopramide, granisetron, |
1 |
2015 |
| Drug |
metoclopramide, granisetron,/ondansetron |
1 |
2015 |
| Biological |
mga271 |
1 |
2011 |
| Drug |
mge |
1 |
2018 |
| Diagnostic Test |
micro-ultrasound targeted biopsy |
1 |
2018 |
| Genetic |
microarray analysis |
1 |
2007 |
| placebo |
microcrystalline cellulose nf (placebo) |
1 |
2009 |
| Device |
microwave trans rectal focal treatment |
1 |
2017 |
| Drug |
mifepristone/eribulin in combination |
1 |
2013 |
| Dietary Supplement |
mikei red reishi essence ex |
1 |
2018 |
| Behavioral |
mindfulness-based therapy |
1 |
2017 |
| Other |
mindfulness-based therapy group for couples |
1 |
2017 |
| Behavioral |
mindfulness program |
1 |
2018 |
| Procedure |
minimally invasive ablative therapy (miat) |
1 |
2018 |
| Other |
minipdx group |
1 |
2018 |
| Drug |
mirabegron |
1 |
2018 |
| Drug |
mitotane |
1 |
2014 |
| Drug |
mitoxantrone (novantrone) |
1 |
2003 |
| Drug |
ml of fentanyl, 5 ml |
1 |
2012 |
| Drug |
mln0128 |
1 |
2014 |
| Drug |
mln8237 |
1 |
2013 |
| Drug |
mobilan (m-vm3) |
1 |
2015 |
| Drug |
modafinil |
1 |
2009 |
| Procedure |
moderate-intensity |
1 |
2002 |
| Procedure |
moderate-intensity/low-intensity bodywork therapy |
1 |
2002 |
| Radiation |
modulated adjuvant radiotherapy |
1 |
2017 |
| Other |
molecular imaging |
1 |
2016 |
| Diagnostic Test |
molecular markers |
1 |
2018 |
| Biological |
monoclonal antibody huj591 |
1 |
2001 |
| Drug |
monoclonal antibody j591 |
1 |
2002 |
| Dietary Supplement |
monosodium glutamate |
1 |
2020 |
| Biological |
montanide isa51 vg |
1 |
2010 |
| Behavioral |
monthly phone calls |
1 |
2016 |
| Drug |
motexafin gadolinium injection |
1 |
2004 |
| Procedure |
mpmr guided mr-us fusion transrectal prostate biopsy |
1 |
2019 |
| Diagnostic Test |
mpmri for pc detection |
1 |
2017 |
| Device |
mpmri guided prostate examination using pi-rads v2 |
1 |
2017 |
| Diagnostic Test |
mpmri scanning |
1 |
2020 |
| Diagnostic Test |
mpmri targeted biopsy |
1 |
2018 |
| Radiation |
mr-based image-guided, intensity-modulated radiotherapy |
1 |
2017 |
| Diagnostic Test |
mr-guided biopsy |
1 |
2018 |
| Device |
mr-guided focal laser ablation |
1 |
2014 |
| Device |
mr-guided in-bore prostate biopsy |
1 |
2014 |
| Radiation |
mr-guided prostate sbrt |
1 |
2020 |
| Device |
mr-guided transurethral us ablation of prostate tissue |
1 |
2012 |
| Other |
mr-spectroscopy |
1 |
2011 |
| Procedure |
mr-ultrasound guided fusion biopsy |
1 |
2017 |
| Drug |
mr - gallium-68 labeled psma-hbed-cc |
1 |
2020 |
| Radiation |
mr guided linear accelerator |
1 |
2019 |
| Device |
mr linac |
1 |
2018 |
| Device |
mr scan |
1 |
2019 |
| Procedure |
mr us fusion guided prostate biopsy |
1 |
2019 |
| Device |
mr/trus fusion guided prostate biopsy |
1 |
2019 |
| Device |
mrgfus treatment |
1 |
2010 |
| Procedure |
mri- us fusion prostate biopsy (fpb) |
1 |
2019 |
| Device |
mri-guided transurethral ultrasound ablation |
1 |
2016 |
| Procedure |
mri-targeted biopsy |
1 |
2015 |
| Procedure |
mri-targeted prostate biopsy |
1 |
2019 |
| Device |
mri-tulsa |
1 |
2019 |
| Device |
mri / trus-guided biopsy |
1 |
2015 |
| Radiation |
mri assisted focal boost with hdr monotherapy |
1 |
2015 |
| Procedure |
mri contrast agent combidex (ferumoxtran-10) |
1 |
2005 |
| Device |
mri guided biopsy |
1 |
2017 |
| Procedure |
mri guided needles to deliver hdr brachytherapy |
1 |
2009 |
| Device |
mri guided prostate biopsy |
1 |
2012 |
| Device |
mri guided prostate biopsy/trus guided biopsy |
1 |
2012 |
| Device |
mri guided transurethral hifu ablation of prostatic tissue |
1 |
2017 |
| Procedure |
mri in a subset of participants |
1 |
2015 |
| Device |
mri spectroscopy |
1 |
2007 |
| Procedure |
mri targeted focal laser thermal therapy |
1 |
2010 |
| Procedure |
mri targeted focal thermal therapy of prostate cancer |
1 |
2007 |
| Diagnostic Test |
mri ultrasound fusion guided biopsy |
1 |
2017 |
| Device |
mri with dbsi analysis |
1 |
2020 |
| Drug |
mri with gallium-68 labeled psma-hbed-cc |
1 |
2018 |
| Other |
mri, ct, |
1 |
2016 |
| Other |
mri, ct,/bone scan |
1 |
2016 |
| Device |
mri, mpmri |
1 |
2013 |
| Procedure |
mri/fusion biopsies |
1 |
2017 |
| Other |
mri/targeted biopsies |
1 |
2016 |
| Diagnostic Test |
mri/targeted biopsies/stockholm3-test |
1 |
2019 |
| Device |
mri/ultrasound transperineal prostate biopsy |
1 |
2017 |
| Device |
mri/us fusion-guided prostate biopsy |
1 |
2014 |
| Biological |
mrna transfected dendritic cell |
1 |
2011 |
| Other |
mrsi |
1 |
2007 |
| Drug |
msb0011359c (m7824) |
1 |
2017 |
| Other |
msg drink |
1 |
2018 |
| Biological |
muc-2-klh |
1 |
2008 |
| Biological |
muc-2-klh vaccine |
1 |
2000 |
| Drug |
muc_1 |
1 |
2006 |
| Biological |
muc1-klh vaccine |
1 |
2000 |
| Biological |
muc1-klh vaccine/qs21 |
1 |
2000 |
| Radiation |
multi-fraction sabr |
1 |
2015 |
| Other |
multi-parametic mri |
1 |
2014 |
| Device |
multi-parametric mri(mp-mri) |
1 |
2014 |
| Other |
multiphoton microscopy |
1 |
2008 |
| Drug |
multiple pet |
1 |
2018 |
| Drug |
multiple pet/mri with gallium-68 labeled psma-hbed-cc |
1 |
2018 |
| Drug |
muscadine |
1 |
2011 |
| Drug |
muscadine/grape skin extract |
1 |
2011 |
| Biological |
muttksr39rep-adp |
1 |
2007 |
| Biological |
mv |
1 |
2015 |
| Biological |
mva-bn-pro |
1 |
2008 |
| Biological |
mva.5t4 |
1 |
2015 |
| Procedure |
naf pet |
1 |
2013 |
| Procedure |
naf pet/ct imaging |
1 |
2013 |
| Drug |
nanopacâ® |
1 |
2017 |
| Drug |
nanoparticle albumin-bound rapamycin |
1 |
2016 |
| Device |
navigo bxâ„¢ |
1 |
2012 |
| Behavioral |
nci website |
1 |
2018 |
| Drug |
neoadjuvant hormonal therapy |
1 |
2010 |
| Biological |
neoantigen dna vaccine |
1 |
2018 |
| Procedure |
nerve-sparing radical prostatectomy |
1 |
2013 |
| Drug |
neuroendocrine type-1 |
1 |
2018 |
| Drug |
neuroendocrine type-2 |
1 |
2018 |
| Other |
neuropsychologic evaluation |
1 |
2016 |
| Procedure |
neurosafe procedure |
1 |
2017 |
| Other |
next-day discharge |
1 |
2018 |
| Drug |
nicotine |
1 |
1999 |
| Drug |
nicotine replacement patch |
1 |
2011 |
| Device |
nim-eclipse |
1 |
2015 |
| Drug |
niraparib 200 mg |
1 |
2018 |
| Drug |
niraparib tosylate monohydrate |
1 |
2019 |
| Drug |
nitrocamptothecin |
1 |
2000 |
| Drug |
nivolumab (cohort a, b |
1 |
2019 |
| Drug |
nivolumab (cohort a, b/c) |
1 |
2019 |
| Drug |
nivolumab 10 mg |
1 |
2019 |
| Drug |
nivolumab 10 mg/ml |
1 |
2019 |
| Drug |
nivolumab infusion [opdivo] |
1 |
2019 |
| Drug |
nivolumab/ipilimumab |
1 |
2017 |
| Drug |
nktr-214 (cohort a) |
1 |
2019 |
| Other |
no active treatment - completed prior radiation |
1 |
2012 |
| Drug |
no epidural drug administered |
1 |
2012 |
| Other |
no weight loss group |
1 |
2007 |
| Drug |
non-labeled psma |
1 |
2019 |
| Other |
non-restricted diet |
1 |
2018 |
| Other |
normal diet |
1 |
2016 |
| Radiation |
normofractionated radiotherapy with photons |
1 |
2019 |
| Procedure |
novel pet tracer facbc |
1 |
2008 |
| Drug |
nox66 |
1 |
2017 |
| Drug |
nrx 194204 |
1 |
2011 |
| Drug |
nsaa |
1 |
2015 |
| Behavioral |
nutrition |
1 |
2016 |
| Behavioral |
nutrition coaching |
1 |
2016 |
| Other |
nutrition intervention |
1 |
2013 |
| Other |
nutritional assessment |
1 |
2019 |
| Dietary Supplement |
nutritional supplementation |
1 |
2013 |
| Drug |
nx-1207 15 mg |
1 |
2012 |
| Drug |
nx-1207 2.5 mg |
1 |
2012 |
| Biological |
ny-eso-1 |
1 |
2008 |
| Biological |
ny-eso-1 fusion protein cdx-1401 |
1 |
2012 |
| Biological |
ny-eso-1 protein |
1 |
2006 |
| Biological |
ny-eso-1 protein/cpg |
1 |
2006 |
| Biological |
ny-eso-1/lage-1 hla class i/ii peptide vaccine |
1 |
2008 |
| Drug |
obi-3424 |
1 |
2018 |
| Other |
observation-post rp |
1 |
2016 |
| Other |
observational (no sbrt) |
1 |
2016 |
| Other |
obtaining biospecimen |
1 |
2015 |
| Drug |
octreotide lar |
1 |
2005 |
| Drug |
odm-201 capsule formulation |
1 |
2013 |
| Drug |
odm-201 tablet a |
1 |
2013 |
| Drug |
odm-201 tablet b |
1 |
2013 |
| Drug |
odm-204 |
1 |
2014 |
| Drug |
odm-208 |
1 |
2018 |
| Drug |
odm-209 |
1 |
2019 |
| Biological |
ogx-011 |
1 |
2005 |
| Drug |
ogx-427 |
1 |
2010 |
| Drug |
olaparib 300 mg |
1 |
2016 |
| Drug |
olaparib 400 mg |
1 |
2016 |
| Drug |
olaparib pill |
1 |
2017 |
| Biological |
olaratumab |
1 |
2010 |
| Dietary Supplement |
olive oil |
1 |
2010 |
| Dietary Supplement |
omega-3 |
1 |
2017 |
| Dietary Supplement |
omega-3 fatty acid |
1 |
2014 |
| Drug |
omeprazole |
1 |
2013 |
| Drug |
onc1-0013b |
1 |
2017 |
| Other |
oncogeriatric evaluation |
1 |
2016 |
| Other |
oncotype dx results |
1 |
2016 |
| Dietary Supplement |
oncoxin-viusid |
1 |
2018 |
| Drug |
ondansetron |
1 |
2015 |
| Behavioral |
online spaced education |
1 |
2010 |
| Other |
online training module |
1 |
2018 |
| Other |
online tutorial |
1 |
2015 |
| Drug |
onvansertib |
1 |
2018 |
| Drug |
opaganib |
1 |
2019 |
| Other |
opc |
1 |
2016 |
| Drug |
opdivo injectable product |
1 |
2019 |
| Drug |
open-label ridaforolimus (mk8669) |
1 |
2008 |
| Procedure |
opening (endopelvic fascia) |
1 |
2015 |
| Behavioral |
opioid reduction intervention |
1 |
2018 |
| Radiation |
optimal booster |
1 |
2017 |
| Radiation |
optimal sbrt |
1 |
2017 |
| Behavioral |
option grid decision aid |
1 |
2020 |
| Drug |
or antiandrogens) |
1 |
2016 |
| Drug |
or dutasteride |
1 |
2005 |
| Other |
or surgery (metastasectomy) |
1 |
2019 |
| placebo |
oral bicalutamide placebo |
1 |
2004 |
| placebo |
oral eflornithine placebo |
1 |
2004 |
| Drug |
oral l-arginine |
1 |
2010 |
| Drug |
oral triamcinalone |
1 |
2005 |
| Biological |
orca-010 |
1 |
2019 |
| Drug |
oric-101 |
1 |
2019 |
| Drug |
orteronel/prednisone |
1 |
2012 |
| Drug |
osimertinib |
1 |
2015 |
| Drug |
other low-dose antiplatelet agent |
1 |
2016 |
| Procedure |
oxygen measurement - eppendorf machine |
1 |
2005 |
| Drug |
ozarelix |
1 |
2010 |
| Biological |
p-psma-101 car-t cells |
1 |
2020 |
| Behavioral |
p4 |
1 |
2008 |
| Biological |
p501-as15 vaccine |
1 |
2005 |
| Drug |
pace with cabazitaxel (15 mg |
1 |
2017 |
| Drug |
pace with cabazitaxel (15 mg/m2) |
1 |
2017 |
| Drug |
pace with cabazitaxel (20 mg |
1 |
2017 |
| Drug |
pace with cabazitaxel (20 mg/m2) |
1 |
2017 |
| Drug |
paclitaxel (taxol) |
1 |
2002 |
| Drug |
paclitaxel polyglumex (xyotax) |
1 |
2007 |
| Radiation |
palliative radiotherapy |
1 |
2018 |
| Drug |
pamidronate |
1 |
2016 |
| Drug |
pamiparib 60 mg po bid |
1 |
2018 |
| Biological |
pan-301-1 |
1 |
2017 |
| Drug |
pantoprazole |
1 |
2012 |
| Drug |
panzemâ® ncd |
1 |
2006 |
| Drug |
papaverine |
1 |
2004 |
| Radiation |
part-trial |
1 |
2017 |
| Drug |
part 1, dose level 1 |
1 |
2019 |
| Drug |
part 1, dose level 1/dose level 2a: ipatasertib |
1 |
2019 |
| Drug |
part 1, dose level 1/dose level 2b: rucaparib |
1 |
2019 |
| Drug |
part 1, dose level 2a |
1 |
2019 |
| Drug |
part 1, dose level 2a/dose level 3: rucaparib |
1 |
2019 |
| Drug |
part 1, dose level 2b |
1 |
2019 |
| Drug |
part 1, dose level 2b/dose level 3: ipatasertib |
1 |
2019 |
| Drug |
part a: azd8186 monotherapy |
1 |
2013 |
| Drug |
part b: azd8186 monotherapy |
1 |
2013 |
| Drug |
part c1: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part c2: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part d1: azd2014 combination with azd8186 |
1 |
2013 |
| Drug |
part d2 azd2014 combination with azd8186 |
1 |
2013 |
| Other |
participation |
1 |
2018 |
| Behavioral |
partner |
1 |
2013 |
| Other |
partner-assisted coping skills training |
1 |
2009 |
| Behavioral |
partner/cdc brochure condition |
1 |
2013 |
| Drug |
pasireotide |
1 |
2013 |
| Behavioral |
patient-centered communication of life expectancy |
1 |
2018 |
| Drug |
patient controlled analgesia (pca) |
1 |
2011 |
| Drug |
patient controlled opioid analgesia (pca) |
1 |
2018 |
| Other |
patient decision aid |
1 |
2018 |
| Behavioral |
patient decision aid (print-based) |
1 |
2005 |
| Procedure |
patient discharge in the day of surgery |
1 |
2013 |
| Procedure |
patient discharge on postoperative day 1 |
1 |
2013 |
| Procedure |
patient discharge on postoperative day 2 |
1 |
2013 |
| Other |
patient preference results |
1 |
2008 |
| Behavioral |
patients: questions to ask your doctor: a workbook for patient-doctor teams |
1 |
2016 |
| Drug |
pazopanib |
1 |
2011 |
| Behavioral |
pc-pep |
1 |
2018 |
| Behavioral |
pc-pep - prostate cancer patient education program |
1 |
2009 |
| Biological |
pc3) |
1 |
2006 |
| Other |
pca3 assay |
1 |
2009 |
| Drug |
pck3145 |
1 |
2008 |
| Biological |
pd-1 knockout t cells |
1 |
2018 |
| Procedure |
pd-103 with 20 vs 44 gy supplemental beam xrt |
1 |
2007 |
| Biological |
pdc vaccination |
1 |
2015 |
| Other |
pearl |
1 |
2016 |
| Dietary Supplement |
pectasol-c modified citrus pectin (mcp) |
1 |
2012 |
| Other |
peep |
1 |
2017 |
| Other |
peer training |
1 |
2018 |
| Drug |
peg-g-csf |
1 |
2015 |
| Device |
peg hydrogel (spaceoar) |
1 |
2012 |
| Drug |
pelvic dcfpyl pet-mri fusion |
1 |
2015 |
| Drug |
pelvic dcfpyl pet-mri fusion/pet/mri |
1 |
2015 |
| Behavioral |
pelvic floor muscle training |
1 |
2013 |
| Diagnostic Test |
pelvic mri |
1 |
2018 |
| Radiation |
pelvic nodes |
1 |
2016 |
| Radiation |
pelvic radiation |
1 |
2017 |
| Diagnostic Test |
pelvic spect |
1 |
2015 |
| Radiation |
pelvis imrt |
1 |
2011 |
| Biological |
pembrolizumab 200 mg |
1 |
2016 |
| Drug |
pemetrexed |
1 |
2005 |
| Drug |
pemetrexed disodium |
1 |
2011 |
| Biological |
peptide vaccine |
1 |
2008 |
| Radiation |
percutaneous radiation therapy |
1 |
2012 |
| Drug |
perflutren lipid microsphere intravenous suspension |
1 |
2016 |
| Procedure |
perfusion magnetic resonance imaging |
1 |
2015 |
| Drug |
perifosine |
1 |
2003 |
| Drug |
perillyl alcohol |
1 |
1999 |
| Behavioral |
perioperative care |
1 |
2013 |
| Behavioral |
perioperative care/wetness management |
1 |
2013 |
| Procedure |
peripheral blood stem cell transplantation |
1 |
1999 |
| Procedure |
periprostatic block |
1 |
2013 |
| Procedure |
periprostatic nerve block |
1 |
2019 |
| Radiation |
permanent iodine-125 seed implant |
1 |
2015 |
| Procedure |
permanent prostate implant |
1 |
2005 |
| Radiation |
permanent seed implantation |
1 |
2012 |
| Behavioral |
personal patient profile - prostate (p3p) |
1 |
2013 |
| Other |
personalised treatment |
1 |
2016 |
| Behavioral |
personalized risk model |
1 |
2015 |
| Behavioral |
personalized risk model/website/coaching intervention |
1 |
2015 |
| Biological |
pertuzumab |
1 |
2015 |
| Drug |
pet-ct scans supplemented with 11c-choline tracer |
1 |
2008 |
| Procedure |
pet-mr 18f-facbc |
1 |
2014 |
| Radiation |
pet acetate scan |
1 |
2010 |
| Device |
pet scan ou tep-tdm |
1 |
2016 |
| Radiation |
pet scan/ultrasound |
1 |
2010 |
| Diagnostic Test |
pet/ct |
1 |
2017 |
| Device |
pet/ct scan |
1 |
2015 |
| Drug |
pet/ct with gallium-68 labeled psma-hbed-cc |
1 |
2018 |
| Device |
pet/ct, pet/mri, mpmri |
1 |
2013 |
| Procedure |
pet/mr-ultrasound guided fusion biopsy |
1 |
2017 |
| Drug |
pet/mri with gallium-68 labeled psma-hbed-cc |
1 |
2018 |
| Biological |
pf-06753512 |
1 |
2015 |
| Biological |
pf-06755990 |
1 |
2015 |
| Biological |
pf-06755992 |
1 |
2015 |
| Biological |
pf-06801591 |
1 |
2015 |
| Drug |
pf-06821497 |
1 |
2018 |
| Drug |
pf-06952229 |
1 |
2018 |
| Drug |
pf00562271 |
1 |
2008 |
| Other |
pfmt |
1 |
2020 |
| Drug |
pha-739358 |
1 |
2008 |
| Drug |
phase i |
1 |
2019 |
| Drug |
phase i/phase ii: lae001/prednisone / afuresertib |
1 |
2019 |
| Drug |
phase ii: lae001 |
1 |
2019 |
| Drug |
phenelzine sulfate |
1 |
2014 |
| Drug |
phenoxodiol |
1 |
2007 |
| Drug |
phentolamine mesylate |
1 |
2004 |
| Behavioral |
phone |
1 |
2011 |
| Other |
phone call |
1 |
2012 |
| Other |
phone call/email |
1 |
2012 |
| Other |
physical activity program |
1 |
2018 |
| Behavioral |
physician behavior related to patient preference survey |
1 |
2008 |
| Behavioral |
physicians: educational module |
1 |
2016 |
| Dietary Supplement |
phytochemical |
1 |
2009 |
| Other |
phytoestrogen-rich foods |
1 |
2016 |
| Drug |
pi-88 |
1 |
2005 |
| Drug |
pi3k-beta inhibitor gsk2636771 |
1 |
2015 |
| Drug |
pi3kbeta inhibitor azd8186 |
1 |
2017 |
| Drug |
pivmecillinam |
1 |
2017 |
| Drug |
pivmecillinam/augmentin |
1 |
2017 |
| placebo |
placebo (for aflibercept) |
1 |
2007 |
| Biological |
placebo / valacyclovir |
1 |
2011 |
| placebo |
placebo daily for one year |
1 |
2009 |
| placebo |
placebo drink |
1 |
2018 |
| placebo |
placebo for enzalutamide |
1 |
2013 |
| placebo |
placebo group |
1 |
2018 |
| placebo |
placebo of modafinil |
1 |
2009 |
| placebo |
placebo risedronate oral tablet |
1 |
2009 |
| placebo |
placebo surveillance |
1 |
2015 |
| Behavioral |
placebo surveillance/written exercise guidelines |
1 |
2015 |
| placebo |
placebo tablets |
1 |
2005 |
| Drug |
placebo tablets/questionaires |
1 |
2005 |
| placebo |
placebo, prednisone |
1 |
2007 |
| Drug |
placebo, prednisone/docetaxel |
1 |
2007 |
| Drug |
placebo/prednisone |
1 |
2012 |
| Procedure |
placement of sling |
1 |
2013 |
| Radiation |
plan adaptation of radiation treatment in case of anatomical changes |
1 |
2019 |
| Other |
planning |
1 |
2010 |
| Other |
plant- based, olive oil diet |
1 |
2017 |
| Diagnostic Test |
plasma biomarkes. |
1 |
2018 |
| Drug |
plenaxis |
1 |
2004 |
| Behavioral |
pn |
1 |
2014 |
| Behavioral |
pn only |
1 |
2014 |
| Behavioral |
pn/lcnc |
1 |
2014 |
| Drug |
pnt2258 |
1 |
2010 |
| Drug |
poly-iclc (cohort b) |
1 |
2019 |
| Drug |
poly ic-lc |
1 |
2008 |
| Drug |
poly(adp ribose) polymerase 1 |
1 |
2017 |
| Drug |
polyphenon e (egcg) |
1 |
2008 |
| Drug |
polysaccharide |
1 |
2007 |
| Drug |
polysaccharide (gcp) |
1 |
2005 |
| Drug |
pomegranate-extract pill |
1 |
2014 |
| Dietary Supplement |
pomegranate pill |
1 |
2008 |
| placebo |
pomegranate pill placebo |
1 |
2008 |
| Device |
poseidon system |
1 |
2019 |
| Device |
positron emission tomography-computed tomography (pet |
1 |
2019 |
| Device |
positron emission tomography-computed tomography (pet/ct) |
1 |
2019 |
| Device |
positron emission tomography-magnetic resonance imaging (pet |
1 |
2019 |
| Device |
positron emission tomography-magnetic resonance imaging (pet/mri) |
1 |
2019 |
| Procedure |
positron emission tomography (pet) |
1 |
2015 |
| Device |
positron emission tomography (pet) image |
1 |
2015 |
| Device |
positron emission tomography (pet) image/with computed tomography (ct) (pet/ct) |
1 |
2015 |
| Device |
positron emission tomography (pet) image/with magnetic resonance imaging (mri) (pet/mri) |
1 |
2015 |
| Procedure |
positron emission tomography (pet) scan |
1 |
2015 |
| Procedure |
positron emission tomography/computed tomography |
1 |
2019 |
| Procedure |
positron emission tomography/computed tomography scan |
1 |
2016 |
| Drug |
post-nsrrp hbo2t |
1 |
2009 |
| Radiation |
post-operative adaptive radiation therapy |
1 |
2013 |
| Other |
post test administration |
1 |
2015 |
| Other |
pre-implant transrectal ultrasound images |
1 |
2010 |
| Other |
pre-implant transrectal ultrasound images/planning |
1 |
2010 |
| Procedure |
pre-operative conformal radiotherapy |
1 |
2005 |
| Procedure |
pre-procedural preparation |
1 |
2009 |
| Diagnostic Test |
pre-surgery ultrasound |
1 |
2017 |
| Other |
pre-test administration |
1 |
2015 |
| Other |
pre-test video education |
1 |
2017 |
| Procedure |
pre-treatment |
1 |
2013 |
| Procedure |
pre-treatment tumour oxygen measurements |
1 |
2005 |
| Procedure |
pre-treatment/progression tumor biopsies |
1 |
2013 |
| Combination Product |
prednisolone 10 mg |
1 |
2018 |
| Drug |
prednisone (or prednisolone) |
1 |
2011 |
| Drug |
prednisone 10 mg |
1 |
2014 |
| Drug |
prednisone 2.5 mg twice daily |
1 |
2013 |
| Drug |
prednisone 5 mg once daily |
1 |
2013 |
| Drug |
prednisone 5 mg po bid |
1 |
2014 |
| Drug |
prednisone 5 mg twice daily |
1 |
2013 |
| Drug |
prednisone 5mg |
1 |
2017 |
| Drug |
prednisone 5mg tab |
1 |
2019 |
| placebo |
prednisone placebo |
1 |
2012 |
| Biological |
prednisone* |
1 |
2003 |
| Drug |
prednisone/prednisolone/dexamethasone |
1 |
2007 |
| Behavioral |
prehabilitation (prehab) |
1 |
2013 |
| Drug |
premarin |
1 |
2005 |
| Other |
preoperative mri |
1 |
2010 |
| Behavioral |
prescription |
1 |
2017 |
| Procedure |
preservation (endopelvic fascia) |
1 |
2015 |
| Other |
pressure controlled ventilation |
1 |
2018 |
| Behavioral |
pretend reiki |
1 |
2003 |
| Dietary Supplement |
prevastein hcâ® |
1 |
2008 |
| Other |
prevention |
1 |
2012 |
| Drug |
preventive administration of rapaflo |
1 |
2014 |
| Drug |
prinomastat |
1 |
1999 |
| Behavioral |
printed material |
1 |
2008 |
| Behavioral |
proactive streamlined genetic education |
1 |
2020 |
| Behavioral |
proactive streamlined genetic education/testing |
1 |
2020 |
| Behavioral |
problem-solving therapy |
1 |
2014 |
| Other |
procase decision-aid |
1 |
2011 |
| Device |
procedure |
1 |
2019 |
| Device |
procedure/surgery: transperineal focal laser ablation (tpla) |
1 |
2019 |
| Other |
processed human nerve tissue scaffold |
1 |
2009 |
| Procedure |
progression tumor biopsies |
1 |
2013 |
| Other |
progressive muscle relaxation |
1 |
2011 |
| Other |
progressive supervised weight training |
1 |
2018 |
| Drug |
propranolol hydrochloride |
1 |
2017 |
| Device |
prospace |
1 |
2018 |
| Device |
prospare |
1 |
2016 |
| Other |
prostascinct |
1 |
2007 |
| Biological |
prostatakâ®(adv-tk) |
1 |
2011 |
| Biological |
prostatakâ®(adv-tk) / valacyclovir |
1 |
2011 |
| Radiation |
prostate |
1 |
2011 |
| Other |
prostate-specific antigen measurement |
1 |
2015 |
| Diagnostic Test |
prostate-specific antigen test |
1 |
2019 |
| Radiation |
prostate alone imrt |
1 |
2011 |
| Procedure |
prostate biopsies |
1 |
2019 |
| Diagnostic Test |
prostate biopsy test |
1 |
2019 |
| Device |
prostate brachytherapy |
1 |
2019 |
| Other |
prostate cancer comorbidity index (pcci) score |
1 |
2019 |
| Behavioral |
prostate cancer decision aid |
1 |
2017 |
| Behavioral |
prostate cancer education/resources for couples (perc) |
1 |
2018 |
| Other |
prostate cancer foundation booklet |
1 |
2010 |
| Other |
prostate cancer foundation diet |
1 |
2017 |
| Procedure |
prostate cancer imaging |
1 |
2012 |
| Radiation |
prostate cancer radiotherapy using real-time tracking |
1 |
2014 |
| Diagnostic Test |
prostate cancer screening |
1 |
2018 |
| Other |
prostate cancer screening decision aid |
1 |
2016 |
| Behavioral |
prostate cancer treatment desi |
1 |
2010 |
| Dietary Supplement |
prostate cancer, phytochemical |
1 |
2007 |
| Dietary Supplement |
prostate cancer, phytochemical/pufa |
1 |
2007 |
| Device |
prostate cryotherapy |
1 |
2017 |
| Drug |
prostate health cocktail |
1 |
2008 |
| Device |
prostate immobilization device |
1 |
2005 |
| Radiation |
prostate radiation |
1 |
2017 |
| Radiation |
prostate radiation / tumor boost irradiation |
1 |
2017 |
| Radiation |
prostate sbrt |
1 |
2012 |
| Radiation |
prostate/pelvis imrt |
1 |
2011 |
| Procedure |
prostatectomy [radiotherapy can be external beam |
1 |
2019 |
| Procedure |
prostatectomy/surgery |
1 |
2014 |
| Biological |
prostatic acid phosphatase-sargramostim fusion protein |
1 |
2001 |
| Device |
prostatic artery embolization (pae) |
1 |
2016 |
| Biological |
prostvac |
1 |
1999 |
| Biological |
prostvac-f/ tricom |
1 |
2007 |
| Biological |
prostvac -v |
1 |
2016 |
| Biological |
prostvacâ®-vf |
1 |
2004 |
| Biological |
prostvacâ®-vf/tricomâ„¢ |
1 |
2004 |
| Other |
protein restrictive diet |
1 |
2012 |
| Radiation |
proton |
1 |
2009 |
| Radiation |
proton (prostate bed) to 70.2 cge |
1 |
2009 |
| Radiation |
proton arm 1: standard proton therapy |
1 |
2018 |
| Radiation |
proton arm 2: hypofractionated proton therapy |
1 |
2018 |
| Radiation |
proton boost |
1 |
2018 |
| Radiation |
proton radiation |
1 |
2009 |
| Radiation |
proton radiation hypofractionation |
1 |
2010 |
| Radiation |
proton radiation standard fractionation |
1 |
2010 |
| Device |
proton therapy |
1 |
2017 |
| Radiation |
proton to 66.6 cge |
1 |
2009 |
| Device |
proxiscan |
1 |
2016 |
| Device |
proxiscan (scintigraphic rectal probe) |
1 |
2011 |
| Drug |
ps-341 (bortezomib) |
1 |
2007 |
| Drug |
ps 341 |
1 |
2005 |
| Drug |
psa-activated psa-pah1 |
1 |
2006 |
| Diagnostic Test |
psa / systematic biopsies |
1 |
2019 |
| Other |
psa assay |
1 |
2009 |
| Other |
psa blood test |
1 |
2013 |
| Other |
psa flyer |
1 |
2012 |
| Biological |
psa rna-pulsed dendritic cell vaccine |
1 |
2000 |
| Other |
psa testing |
1 |
2016 |
| Behavioral |
psa tool |
1 |
2017 |
| Diagnostic Test |
psa, sthlm3 |
1 |
2017 |
| Diagnostic Test |
psa, sthlm3/mpmri for pc detection |
1 |
2017 |
| Biological |
psa/il-2/gm-csf |
1 |
2014 |
| Biological |
psa:154-163(155l) peptide vaccine |
1 |
2005 |
| Biological |
psma-cart cells |
1 |
2019 |
| Diagnostic Test |
psma -pet/ct scanning |
1 |
2018 |
| Radiation |
psma -pet/ct simulation |
1 |
2018 |
| Diagnostic Test |
psma pet/ct |
1 |
2019 |
| Drug |
psma pet/mr - gallium-68 labeled psma-hbed-cc |
1 |
2020 |
| Behavioral |
psychosocial component |
1 |
2014 |
| Behavioral |
psychosocial rehabilitation course |
1 |
2010 |
| Behavioral |
psychosocial support |
1 |
2016 |
| Drug |
ptk787 |
1 |
2005 |
| Biological |
ptvg-hp plasmid dna vaccine |
1 |
2015 |
| Dietary Supplement |
pufa |
1 |
2007 |
| Drug |
purified isoflavones |
1 |
2009 |
| Biological |
pvaxrcpsav53l (dna encoding rhesus psa) |
1 |
2009 |
| Drug |
px-866 |
1 |
2011 |
| Diagnostic Test |
quadratus lumborum block |
1 |
2018 |
| Other |
quality of life |
1 |
2016 |
| Other |
quality of life questionnaires |
1 |
2015 |
| Drug |
quercetin |
1 |
2013 |
| Drug |
questionaires |
1 |
2005 |
| Drug |
quinacrine |
1 |
2006 |
| Radiation |
r/t gating kv intrafraction monitoring |
1 |
2012 |
| Drug |
ra-223 in combination with enzalutamide |
1 |
2017 |
| Drug |
ra-223 therapy |
1 |
2016 |
| Drug |
ra223 |
1 |
2014 |
| Drug |
rad 001 |
1 |
2010 |
| Drug |
rad001, docetaxel, bevacizumab |
1 |
2007 |
| Radiation |
radiation by brachytherapy |
1 |
2019 |
| Radiation |
radiation by sbrt |
1 |
2019 |
| Other |
radiation therapist planning |
1 |
2016 |
| Radiation |
radiation therapy (rt) |
1 |
2008 |
| Device |
radiation therapy positioning system (rtps) |
1 |
2009 |
| Radiation |
radiation: pelvic lymph nodes with boost to prostate |
1 |
2011 |
| Procedure |
radical cystectomy |
1 |
2016 |
| Procedure |
radical prosatectomy |
1 |
2009 |
| Procedure |
radical prostatectomy (rp) followed by eplnd |
1 |
2019 |
| Procedure |
radical prostatectomy (rp) only |
1 |
2019 |
| Procedure |
radical prostatectomy with both urethral irrigation |
1 |
2009 |
| Procedure |
radical prostatectomy with both urethral irrigation/fascial suturing, qol forms |
1 |
2009 |
| Procedure |
radical prostatectomy with fascial suturing but no urethral irrigation, qol forms |
1 |
2009 |
| Procedure |
radical prostatectomy with neither urethral irrigation nor fascial suturing, qol forms |
1 |
2009 |
| Procedure |
radical prostatectomy with urethral irrigation but no fascial suturing, qol forms |
1 |
2009 |
| Procedure |
radical prostatectomy/standard care |
1 |
2019 |
| Procedure |
radical therapy (prostatectomy |
1 |
2018 |
| Procedure |
radical therapy (prostatectomy/radiotherapy) |
1 |
2018 |
| Procedure |
radical therapy (radiotherapy |
1 |
2019 |
| Procedure |
radical therapy (radiotherapy/prostatectomy [radiotherapy can be external beam/brachytherapy] |
1 |
2019 |
| Procedure |
radio-frequency ablation (rfa) |
1 |
2014 |
| Procedure |
radio-frequency ablation (rfa) encageâ„¢ |
1 |
2011 |
| Radiation |
radioimmuniguided intenstiy modulated radiotherapy |
1 |
2009 |
| Diagnostic Test |
radiomics |
1 |
2018 |
| Other |
radiotherapy (sbrt) and |
1 |
2019 |
| Other |
radiotherapy (sbrt) and/or surgery (metastasectomy) |
1 |
2019 |
| Radiation |
radiotherapy 70 gy |
1 |
2005 |
| Radiation |
radiotherapy 76 gy |
1 |
2005 |
| Radiation |
radiotherapy daily verification reduced safety margins |
1 |
2012 |
| Radiation |
radiotherapy imrt |
1 |
2017 |
| Device |
radiotherapy stent |
1 |
2005 |
| Radiation |
radiotherapy to the pelvis |
1 |
2016 |
| Radiation |
radiotherapy to the prostate |
1 |
2005 |
| Radiation |
radiotherapy weekly verification standard safety margins |
1 |
2012 |
| Other |
radiotherapy with adjuvant androgen deprivation therapy |
1 |
2014 |
| Radiation |
radiotherapy with imrt |
1 |
2012 |
| Radiation |
radiotherapy with imrt/cyberknife boost |
1 |
2012 |
| Radiation |
radiotherapy with photons |
1 |
2016 |
| Radiation |
radiotherapy with protons |
1 |
2016 |
| Procedure |
radiotherapy) |
1 |
2018 |
| Drug |
radium-223 chloride |
1 |
2018 |
| Drug |
radium-223 chloride (xofigoâ®, bay88-8223) injection |
1 |
2008 |
| Drug |
radium-223/enzalutamide |
1 |
2014 |
| Radiation |
radium 223 |
1 |
2018 |
| Drug |
radium chloride ra-223 |
1 |
2019 |
| Drug |
raloxifene |
1 |
2010 |
| Drug |
ramosetron |
1 |
2017 |
| Behavioral |
randomized exercise intervention |
1 |
2009 |
| Drug |
ranitidine |
1 |
2015 |
| Other |
ranking task |
1 |
2012 |
| Drug |
ranolazine |
1 |
2013 |
| Drug |
rapamycin 3mg |
1 |
2006 |
| Drug |
rapamycin 6mg |
1 |
2006 |
| Procedure |
rarp |
1 |
2019 |
| Other |
rating |
1 |
2012 |
| Other |
rating/ranking task |
1 |
2012 |
| Drug |
recombinant fowlpox-psa (l155)-tricom (prostvac-f |
1 |
2003 |
| Drug |
recombinant fowlpox-psa (l155)-tricom (prostvac-f/tricom) |
1 |
2003 |
| Drug |
recombinant fowlpox-psa(l155)/tricom (prostvac-f/tricom) |
1 |
2006 |
| Biological |
recombinant fowlpox-psa(l155)/tricom vaccine |
1 |
2005 |
| Biological |
recombinant fowlpox-tricom vaccine |
1 |
2007 |
| Drug |
recombinant human gm-csf |
1 |
2003 |
| Biological |
recombinant interferon alfa |
1 |
2000 |
| Biological |
recombinant interferon alfa-2b |
1 |
2019 |
| Biological |
recombinant interferon gamma |
1 |
1999 |
| Drug |
recombinant interleukin-2 |
1 |
2002 |
| Drug |
recombinant vaccinia-psa (l155)-tricom (prostvac-v |
1 |
2003 |
| Drug |
recombinant vaccinia-psa (l155)-tricom (prostvac-v/tricom) |
1 |
2003 |
| Drug |
recombinant vaccinia-psa(l155) |
1 |
2006 |
| Drug |
recombinant vaccinia-psa(l155)/tricom (prostvac-v/tricom) |
1 |
2006 |
| Biological |
recombinant viral vaccine therapy |
1 |
1999 |
| Behavioral |
recommendations |
1 |
2011 |
| Device |
rectal balloon with air filling |
1 |
2019 |
| Procedure |
rectus sheath block |
1 |
2018 |
| Behavioral |
reduced-exertion high-intensity interval training |
1 |
2017 |
| Other |
reducing your risks in the crash |
1 |
2008 |
| Procedure |
regional lymph node dissection |
1 |
2011 |
| Drug |
regn2810 |
1 |
2019 |
| Drug |
regn5678 |
1 |
2019 |
| Behavioral |
reiki/relaxation response therapy with cognitive restructuring |
1 |
2005 |
| Drug |
relacorilant |
1 |
2018 |
| Behavioral |
relaxation response therapy with cognitive restructuring |
1 |
2005 |
| Drug |
remifentanyl |
1 |
2013 |
| Behavioral |
resistance exercise |
1 |
2008 |
| Behavioral |
resistance exercise program |
1 |
2005 |
| Behavioral |
resistance training |
1 |
2016 |
| Behavioral |
resources for couples (perc) |
1 |
2018 |
| Behavioral |
rest |
1 |
2003 |
| Behavioral |
rest / guided imagery |
1 |
2003 |
| Behavioral |
restore rehabilitation program |
1 |
2017 |
| Behavioral |
revised psa tool |
1 |
2017 |
| Drug |
rf-psa |
1 |
2006 |
| Drug |
rhenium-188-hedp |
1 |
2018 |
| Drug |
rhumab 2c4 (pertuzumab) |
1 |
2003 |
| Drug |
ridaforolimus |
1 |
2005 |
| Drug |
ridaforolimus (mk8669) |
1 |
2008 |
| Biological |
rilimogene galvacirepvec |
1 |
2014 |
| Drug |
rimiducid |
1 |
2020 |
| Drug |
rintatolimod |
1 |
2019 |
| Drug |
risedronate sodium |
1 |
2002 |
| Other |
risetx |
1 |
2017 |
| Device |
risk map dss tool |
1 |
2018 |
| Drug |
ritalin |
1 |
2005 |
| Device |
robot-assisted prostate biopsy |
1 |
2014 |
| Procedure |
robot-assisted radical prostatectomy |
1 |
2020 |
| Procedure |
robotic-assisted radical prostatectomy |
1 |
2016 |
| Procedure |
robotic assisted radical prostatectomy |
1 |
2015 |
| Device |
robotic placement device |
1 |
2006 |
| Procedure |
robotic radical prostatectomy |
1 |
2012 |
| Procedure |
robotic surgery |
1 |
2015 |
| Drug |
rocuronium 0.3mg |
1 |
2019 |
| Drug |
rocuronium 0.3mg/kg/hr |
1 |
2019 |
| Drug |
rocuronium 1.5mg |
1 |
2019 |
| Drug |
rocuronium 1.5mg/kg/hr |
1 |
2019 |
| Drug |
rofecoxib |
1 |
2003 |
| Drug |
ropivacaine |
1 |
2010 |
| Drug |
rosiglitazone |
1 |
2005 |
| Biological |
rspsma protein |
1 |
2008 |
| Biological |
rspsma protein/alhydrogelâ® vaccine |
1 |
2008 |
| Radiation |
rt |
1 |
2016 |
| Genetic |
rtvp-1 gene |
1 |
2006 |
| Drug |
rucaparib camsylate |
1 |
2018 |
| Drug |
rv-b7.1 |
1 |
2006 |
| Drug |
rv-psa |
1 |
2006 |
| Procedure |
s guided prostate biopsy |
1 |
2019 |
| Drug |
sabarubicin |
1 |
2001 |
| Radiation |
sabr |
1 |
2018 |
| Device |
sacral nerve stimulator |
1 |
2019 |
| Device |
sacral nerve stimulator battery |
1 |
2019 |
| Drug |
sagopilone (zk 219477) |
1 |
2006 |
| Drug |
sagopilone (zk 219477) / prednisone |
1 |
2006 |
| Procedure |
salvage lymphnode dissection |
1 |
2020 |
| Radiation |
salvage radiation |
1 |
2017 |
| Radiation |
salvage radiation therapy |
1 |
2017 |
| Radiation |
salvage radiotherapy srt |
1 |
2016 |
| Drug |
samarium-153 |
1 |
2006 |
| Drug |
samarium 153 |
1 |
2007 |
| Radiation |
samarium sm 153 lexidronam pentasodium |
1 |
2007 |
| Other |
same day discharge |
1 |
2018 |
| Drug |
sapanisertib |
1 |
2015 |
| Drug |
saracatinib |
1 |
2007 |
| Drug |
sargramostim (gm-csf, leukine) |
1 |
2007 |
| Drug |
savolitinib |
1 |
2017 |
| Drug |
saw palmetto |
1 |
2012 |
| Radiation |
sbrt (35-40gy) |
1 |
2017 |
| Radiation |
sbrt / adt |
1 |
2018 |
| Combination Product |
sbrt / durvalumab |
1 |
2019 |
| Radiation |
sbrt prostate |
1 |
2009 |
| Radiation |
sbrt to whole prostate |
1 |
2018 |
| Other |
screening |
1 |
2018 |
| Drug |
sd-101 |
1 |
2016 |
| Radiation |
second part : hypofractionated stereotactic boost |
1 |
2011 |
| Procedure |
sedoanalgesia |
1 |
2013 |
| placebo |
selenium placebo |
1 |
2000 |
| Behavioral |
self-care |
1 |
2018 |
| Behavioral |
self-completed implementation intention |
1 |
2011 |
| Behavioral |
self-hypnosis |
1 |
2018 |
| Behavioral |
self-hypnosis / self-care |
1 |
2018 |
| Drug |
semaxanib |
1 |
2000 |
| Other |
semen analysis |
1 |
2010 |
| Procedure |
seminal vesicle-sparing radical prostatectomy |
1 |
2013 |
| Other |
sensate focus exercise |
1 |
2020 |
| Drug |
sequential bibf 1120 |
1 |
2008 |
| Drug |
sequential bibf 1120 / bibw 2992 |
1 |
2008 |
| Other |
serum biomarker assays. |
1 |
2008 |
| Procedure |
serum prostate antigen test |
1 |
2014 |
| Other |
serum specimens obtained will be utilized for proteomic profiling comprising maldi-tof ms, |
1 |
2008 |
| Other |
serum specimens obtained will be utilized for proteomic profiling comprising maldi-tof ms,/serum biomarker assays. |
1 |
2008 |
| Drug |
seviteronel: given orally once daily in 28-day cycles |
1 |
2015 |
| Drug |
seviteronel: given orally once daily in 28 day cycles |
1 |
2013 |
| Drug |
sevoflurane |
1 |
2013 |
| Behavioral |
sexual |
1 |
2014 |
| Other |
sexual health inventory for men (shim) questionnaire administration |
1 |
2012 |
| Behavioral |
sexual/urological intervention |
1 |
2014 |
| Drug |
sfn-rich broccoli sprout extract capsules |
1 |
2010 |
| Procedure |
sfur-rarp |
1 |
2019 |
| Drug |
sgn-15 (cbr96-doxorubicin immunoconjugate) |
1 |
2002 |
| Other |
sham exercise |
1 |
2011 |
| Other |
sham information |
1 |
2018 |
| Procedure |
sham intervention |
1 |
2009 |
| Drug |
sham post-nsrrp hbo2t |
1 |
2009 |
| Procedure |
sham procedure |
1 |
2014 |
| Other |
shareclinic |
1 |
2017 |
| Other |
shear-wave ultrasound elastography (swue) |
1 |
2012 |
| Procedure |
shear wave elastography |
1 |
2017 |
| Drug |
shr2554 |
1 |
2018 |
| placebo |
shr3162(placebo) |
1 |
2019 |
| placebo |
shr3680(placebo) |
1 |
2019 |
| Drug |
shr3680; shr3162 |
1 |
2016 |
| Radiation |
sib dose-escalation radiotherapy |
1 |
2013 |
| Radiation |
sibrt |
1 |
2018 |
| Drug |
sildenafil |
1 |
2007 |
| Drug |
sildenafil citrate/questionaires |
1 |
2005 |
| Drug |
sildenafil therapy |
1 |
2009 |
| Drug |
sildenafil therapy/post-nsrrp hbo2t |
1 |
2009 |
| Drug |
sildenafil therapy/sham post-nsrrp hbo2t |
1 |
2009 |
| Drug |
silibin-phytosome |
1 |
2007 |
| Procedure |
simple cue for patient to talk to doctor |
1 |
2005 |
| Radiation |
simrt |
1 |
2011 |
| Drug |
simvastatin |
1 |
2007 |
| Other |
sinerem (uspio) enhanced mri |
1 |
2008 |
| Drug |
sipt treatment |
1 |
2013 |
| Biological |
sipuleucel-t with booster |
1 |
2008 |
| Biological |
sipuleucel-t without booster |
1 |
2008 |
| Drug |
sm-153 |
1 |
2006 |
| Drug |
sm88 (cohort 1) |
1 |
2016 |
| Drug |
sm88 (cohort 2) |
1 |
2016 |
| Device |
smartbxâ„¢ system. |
1 |
2011 |
| Device |
smartphone |
1 |
2015 |
| Device |
smartphone/tablet |
1 |
2015 |
| Procedure |
smarttarget - biopsy |
1 |
2014 |
| Behavioral |
smoking cessation |
1 |
2016 |
| Behavioral |
soccer training |
1 |
2012 |
| Drug |
sodium (na)18f positron emission tomography (pet) |
1 |
2014 |
| Drug |
sodium (na)18f positron emission tomography (pet)/computed tomography (ct) |
1 |
2014 |
| Drug |
sodium acetate c11 |
1 |
2011 |
| Drug |
sodium chloride 9 mg |
1 |
2011 |
| Drug |
sodium chloride 9 mg/ml |
1 |
2011 |
| Drug |
sodium phenylbutyrate |
1 |
2000 |
| Drug |
sodium selenite |
1 |
2014 |
| Device |
software |
1 |
2019 |
| Drug |
som230 |
1 |
2012 |
| Drug |
sonovue |
1 |
2017 |
| Drug |
sorafenib (200 |
1 |
2006 |
| Drug |
sorafenib (200/400mg bid)/taxotere iv |
1 |
2006 |
| Drug |
sorafenib (nexavar) |
1 |
2008 |
| Dietary Supplement |
soy |
1 |
2007 |
| Drug |
soy isoflavone nutritional supplements |
1 |
2005 |
| Drug |
soy supplement |
1 |
2005 |
| Drug |
soybean oil soft gel |
1 |
2012 |
| Device |
spaceoar system |
1 |
2012 |
| Device |
spect-ct |
1 |
2016 |
| Other |
spect-ct imaging |
1 |
2009 |
| Procedure |
spect ct |
1 |
2018 |
| Device |
spectracure p18 system |
1 |
2017 |
| Other |
spectrophotometry |
1 |
2011 |
| Procedure |
spectroscopy |
1 |
2015 |
| Radiation |
sr-89 |
1 |
2006 |
| Drug |
sr31747a |
1 |
2005 |
| Radiation |
stad |
1 |
2018 |
| Drug |
stage 1 group 1: abiraterone acetate |
1 |
2008 |
| Drug |
stage 1 group 2: abiraterone acetate |
1 |
2008 |
| Drug |
stage 2: abiraterone acetate |
1 |
2008 |
| Drug |
stage 3: abiraterone acetate |
1 |
2008 |
| Drug |
stage 3: glucocorticoid |
1 |
2008 |
| Drug |
stage 4: abiraterone acetate |
1 |
2008 |
| Drug |
stage 4: glucocorticoid |
1 |
2008 |
| Radiation |
standard-care simulation |
1 |
2018 |
| Drug |
standard adt (androgen deprivation therapy) |
1 |
2016 |
| Radiation |
standard arm |
1 |
2010 |
| Procedure |
standard biopsy |
1 |
2018 |
| Dietary Supplement |
standard broccoli soup |
1 |
2013 |
| Other |
standard care/exercise |
1 |
2018 |
| Behavioral |
standard cbt |
1 |
2017 |
| Radiation |
standard external beam irradiation |
1 |
2007 |
| Procedure |
standard follow-up care |
1 |
2009 |
| Procedure |
standard imaging |
1 |
2007 |
| Radiation |
standard imrt |
1 |
2011 |
| Other |
standard nccn counseling |
1 |
2016 |
| Other |
standard nccn counseling/oncotype dx results |
1 |
2016 |
| Drug |
standard of care adt / (hmb / arginine / glutamine) |
1 |
2012 |
| Drug |
standard of care for metastatic prostate cancer |
1 |
2019 |
| Radiation |
standard of care imrt (photon) |
1 |
2018 |
| Device |
standard of care mri |
1 |
2019 |
| Radiation |
standard of care proton therapy |
1 |
2018 |
| Drug |
standard of care, enzalutamide |
1 |
2018 |
| Other |
standard practice education |
1 |
2017 |
| Procedure |
standard prostate biopsy |
1 |
2020 |
| Other |
standard prostate cancer education presentation |
1 |
2016 |
| Behavioral |
standard prostate cancer information websites |
1 |
2013 |
| Radiation |
standard radiation treatment |
1 |
2011 |
| Radiation |
standard radiotherapy |
1 |
2014 |
| Procedure |
standard rarp |
1 |
2019 |
| Radiation |
standard salvage radiation treatment (ssrt) |
1 |
2011 |
| Procedure |
standard transrectal 12 core biopsy |
1 |
2019 |
| Procedure |
standard transrectal ultrasound (trus) guided biopsy |
1 |
2016 |
| Device |
standard ultrasound guided prostate biopsy |
1 |
2014 |
| Other |
standardized care pathways |
1 |
2017 |
| Behavioral |
standardized educational flyer |
1 |
2017 |
| Other |
standardized exercise intervention program |
1 |
2011 |
| Drug |
statin, such as simvastatin, atorvastatin, rosuvastatin, pravastatin) |
1 |
2016 |
| Procedure |
stellate ganglion block |
1 |
2014 |
| Radiation |
stereotactic ablative body radiation |
1 |
2013 |
| Radiation |
stereotactic ablative body radiation (sbrt) |
1 |
2019 |
| Radiation |
stereotactic ablative body radiotherapy (sabr) 35-50 gy |
1 |
2020 |
| Radiation |
stereotactic ablative body radiotherapy (sabr) 35-50 gy/5 |
1 |
2020 |
| Radiation |
stereotactic ablative radiotherapy (sabr) |
1 |
2019 |
| Radiation |
stereotactic body radiation therapy (sbrt) (cohort b) |
1 |
2019 |
| Radiation |
stereotactic body radiation therapy (sbrt) radiation for prostate cancer utilizing the elekta versa |
1 |
2019 |
| Radiation |
stereotactic body radiation therapy (sbrt) radiation for prostate cancer utilizing the elekta versa/agility system. |
1 |
2019 |
| Radiation |
stereotactic body radiation therapy for oligometastases |
1 |
2014 |
| Radiation |
stereotactic body radiation therapy with integrated boost |
1 |
2013 |
| Radiation |
stereotactic body radiosurgery (sbrt) |
1 |
2017 |
| Radiation |
stereotactic body radition (sbrt) |
1 |
2017 |
| Radiation |
stereotactic body rt with mr-guided boost |
1 |
2013 |
| Radiation |
stereotactic fractionation |
1 |
2014 |
| Radiation |
stereotactic radiation |
1 |
2013 |
| Radiation |
stereotactic radiosurgical boost |
1 |
2014 |
| Radiation |
stereotactic radiotherapy |
1 |
2015 |
| Radiation |
stereotactic, ultra-fractionated radiotherapy |
1 |
2016 |
| Radiation |
stereotatic radiotherapy |
1 |
2017 |
| Drug |
steroids switch |
1 |
2016 |
| Diagnostic Test |
sthlm3 |
1 |
2018 |
| Drug |
sti571 (glivecâ®) |
1 |
2011 |
| Diagnostic Test |
stockholm3-test |
1 |
2019 |
| Device |
stratangs |
1 |
2016 |
| Behavioral |
strength training |
1 |
2018 |
| Behavioral |
strength training group |
1 |
2008 |
| Behavioral |
stretching control group |
1 |
2014 |
| Drug |
strontium-89 |
1 |
2005 |
| Radiation |
strontium chloride sr |
1 |
2004 |
| Drug |
su5416 |
1 |
2001 |
| Drug |
suba-itraconazole |
1 |
2018 |
| placebo |
subcutaneous injection saline placebo |
1 |
2018 |
| Drug |
sufentanil |
1 |
2010 |
| Drug |
sulfamethoxazole |
1 |
2017 |
| Behavioral |
supervised |
1 |
2014 |
| Behavioral |
supervised 1:1 exercise |
1 |
2014 |
| Behavioral |
supervised exercise training |
1 |
2014 |
| Behavioral |
supervised physical activity |
1 |
2017 |
| Behavioral |
supervised physical activity/behavioral counseling |
1 |
2017 |
| Behavioral |
supervised physical activity/exercise counseling |
1 |
2017 |
| Behavioral |
supervised/home based exercise |
1 |
2014 |
| Behavioral |
support |
1 |
2011 |
| Procedure |
support group therapy |
1 |
2008 |
| Device |
suprapubic tube ex 2 day |
1 |
2016 |
| Device |
suprapubic tube ex 5 day |
1 |
2016 |
| Procedure |
surgery/with imrt-igrt |
1 |
2010 |
| Device |
surgery: transperineal focal laser ablation (tpla) |
1 |
2019 |
| Drug |
surgical castration |
1 |
2015 |
| Device |
surgisis male sling |
1 |
2009 |
| Behavioral |
surviving online workshop |
1 |
2009 |
| Other |
swedish massage therapy |
1 |
2017 |
| Procedure |
systematic light exposure |
1 |
2018 |
| Other |
systemic therapy |
1 |
2016 |
| Procedure |
systemic trus guided biopsy |
1 |
2017 |
| Radiation |
t gating kv intrafraction monitoring |
1 |
2012 |
| Device |
tablet |
1 |
2015 |
| Behavioral |
tai ji quan training |
1 |
2018 |
| Behavioral |
tailored newsletters |
1 |
2013 |
| Drug |
tak-573 |
1 |
2019 |
| Biological |
taking of urines |
1 |
2009 |
| Drug |
talabostat mesylate |
1 |
2019 |
| Drug |
talabostat mesylate/pembrolizumab |
1 |
2019 |
| Drug |
tamsulosin |
1 |
2019 |
| Drug |
tamsulosin and |
1 |
2005 |
| Drug |
tamsulosin and/or dutasteride |
1 |
2005 |
| Drug |
tandutinib |
1 |
2006 |
| Drug |
tap-144-sr(3m) |
1 |
2012 |
| Drug |
tap-144-sr(6m) |
1 |
2012 |
| Drug |
tarceva |
1 |
2006 |
| Procedure |
targeted |
1 |
2020 |
| Procedure |
targeted biopsies guided by a fusion of mri |
1 |
2014 |
| Procedure |
targeted biopsies guided by a fusion of mri/ultrasound- images |
1 |
2014 |
| Procedure |
targeted biopsies of the prostate |
1 |
2013 |
| Procedure |
targeted biopsies using magnetic resonance imaging guiding |
1 |
2016 |
| Procedure |
targeted biopsy |
1 |
2013 |
| Radiation |
targeted focal hdr brachytherapy |
1 |
2016 |
| Procedure |
targeted prostate biopsy |
1 |
2018 |
| Procedure |
targeted/standard prostate biopsy |
1 |
2020 |
| Biological |
tarp dendritic cell vaccine |
1 |
2009 |
| Biological |
tarp peptide vaccine |
1 |
2009 |
| Drug |
tas3681 |
1 |
2015 |
| Drug |
taselisib |
1 |
2015 |
| Drug |
tasquinimod 0.25 mg; 0.5 mg |
1 |
2012 |
| Drug |
tasquinimod 0.25 mg; 0.5 mg; 1.0 mg |
1 |
2012 |
| Drug |
taxol |
1 |
2002 |
| Drug |
taxotere iv |
1 |
2006 |
| Drug |
taxotereâ® |
1 |
2012 |
| Drug |
tazemetostat |
1 |
2019 |
| Biological |
tcm |
1 |
2018 |
| Biological |
tcm/ goserelin acetate/ bicalutamide |
1 |
2018 |
| Biological |
tcm/goserelin acetate/abiraterone acetate |
1 |
2018 |
| Biological |
tcrzeta-cd19t-expressing t-lymphocytes |
1 |
2019 |
| Device |
tds-im electroporation device |
1 |
2015 |
| Drug |
tecemotide (l-blp25) |
1 |
2011 |
| Radiation |
technetium tc 99m methylene diphosphonate |
1 |
2009 |
| Behavioral |
technology |
1 |
2017 |
| Behavioral |
telephone based counseling |
1 |
2014 |
| Behavioral |
telephone delivered education only |
1 |
2009 |
| Behavioral |
telephone implementation intention |
1 |
2011 |
| Behavioral |
telephone interpersonal counseling |
1 |
2009 |
| Behavioral |
testing |
1 |
2020 |
| Other |
testosterone (androgelâ®) with the 5î±-reductase inhibitor dutasteride |
1 |
2009 |
| Drug |
testosterone cypionate 100 mg |
1 |
2018 |
| Drug |
testosterone cypionate 100 mg/ml |
1 |
2018 |
| Drug |
testosterone gel |
1 |
2007 |
| Drug |
testosterone injection |
1 |
2010 |
| Drug |
testosterone transdermal gel |
1 |
2007 |
| Drug |
testosterone undecanoate |
1 |
2019 |
| Drug |
tetrathiomolybdate |
1 |
2005 |
| Behavioral |
text |
1 |
2018 |
| Behavioral |
text/email message |
1 |
2018 |
| Biological |
tf(c)-klh conjugate vaccine |
1 |
1999 |
| Drug |
thalidomide (thado) |
1 |
2005 |
| Biological |
the 23- valent pneumococcal vaccine |
1 |
2008 |
| Drug |
the intrathecal morphine injection |
1 |
2013 |
| Drug |
the intravenous patient-controlled analgesia |
1 |
2013 |
| Biological |
the ppv23 vaccine (pneumovax) |
1 |
2008 |
| Device |
the tranbergcls|thermal therapy |
1 |
2018 |
| Drug |
theophylline |
1 |
2009 |
| Biological |
therapeutic autologous dendritic cells |
1 |
2001 |
| Biological |
therapeutic autologous lymphocytes |
1 |
2002 |
| Other |
therapeutic education |
1 |
2018 |
| Behavioral |
therapeutic education program |
1 |
2014 |
| Behavioral |
therapeutic educational program |
1 |
2020 |
| Procedure |
therapeutic lymphadenectomy |
1 |
2014 |
| Drug |
therapeutic testosterone |
1 |
2000 |
| Biological |
therapeutic vaccine |
1 |
2018 |
| Biological |
thomsen-friedenreich antigen |
1 |
1999 |
| Drug |
thoracic epidural analgesia (tea) |
1 |
2011 |
| Procedure |
three-dimensional ultrasound-guided biopsy |
1 |
2016 |
| Behavioral |
three in-person sessions |
1 |
2016 |
| Drug |
tipifarnib |
1 |
2000 |
| Drug |
tivantinib |
1 |
2012 |
| Drug |
tivozanib |
1 |
2013 |
| Drug |
tk1258 |
1 |
2009 |
| Other |
tobacco cessation counseling |
1 |
2017 |
| Drug |
tok-001 |
1 |
2009 |
| Other |
tomato rich diet |
1 |
2010 |
| Drug |
tomivosertib (eft508) |
1 |
2018 |
| Radiation |
tomotherapy |
1 |
2018 |
| Drug |
tookad soluble 4 mg |
1 |
2017 |
| Drug |
tookad soluble 4 mg/kg |
1 |
2017 |
| Drug |
tookad vtp |
1 |
2019 |
| Drug |
toremifene |
1 |
2001 |
| Drug |
toremifene citrate |
1 |
2005 |
| Drug |
torisel |
1 |
2009 |
| Drug |
total androgen suppression (tas) with bicalutamide |
1 |
2006 |
| Drug |
total androgen suppression (tas) with goserelin acetate |
1 |
2006 |
| Drug |
trabectedin |
1 |
2003 |
| Other |
traditional pre-test genetic counseling |
1 |
2017 |
| Procedure |
trans-perineal mri targeted biopsy |
1 |
2018 |
| Procedure |
trans-rectal mri targeted biopsy |
1 |
2018 |
| Procedure |
trans rectal ultrasound |
1 |
2019 |
| Procedure |
trans rectal ultrasound guided prostate biopsy |
1 |
2019 |
| Drug |
transdermal estradiol |
1 |
2005 |
| Drug |
transdermal oestradiol |
1 |
2005 |
| Drug |
transdermal testosterone |
1 |
2018 |
| Biological |
transgenic lymphocyte immunization vaccine (tli) |
1 |
2003 |
| Device |
transperineal device will be used |
1 |
2008 |
| Procedure |
transperineal prostate biopsy |
1 |
2010 |
| Radiation |
transperineal template guided mapping biopsy, multiparametric mri, hemiablative focal brachytherapy |
1 |
2015 |
| Procedure |
transperineal, mri-guided, prostate biopsy |
1 |
2015 |
| Device |
transrectal apt device |
1 |
2008 |
| Device |
transrectal apt device/transperineal device will be used |
1 |
2008 |
| Procedure |
transrectal prostate biopsy (trb): |
1 |
2015 |
| Procedure |
transrectal prostate biopsy with ultrasonography. |
1 |
2013 |
| Procedure |
transrectal random biopsy of the prostate |
1 |
2015 |
| Device |
transrectal shear wave elastography of the prostate |
1 |
2015 |
| Procedure |
transrectal u |
1 |
2019 |
| Device |
transrectal ultrasound |
1 |
2015 |
| Device |
transrectal ultrasound-guided prostate biopsy |
1 |
2017 |
| Device |
transrectal ultrasound (bk medical pro focus ultraview 2202 system) |
1 |
2013 |
| Procedure |
transrectal ultrasound scan of prostate |
1 |
2017 |
| Device |
transurethral catheter ex 5 day |
1 |
2016 |
| Procedure |
transverse versus vertical closure |
1 |
2011 |
| Diagnostic Test |
tranversus abdominis plane block |
1 |
2018 |
| Biological |
trastuzumab emtansine |
1 |
2015 |
| Drug |
trc253 |
1 |
2016 |
| Drug |
treatment with tookad vtp |
1 |
2006 |
| Other |
treatmentchoice decisional tool |
1 |
2017 |
| Drug |
treosulfane |
1 |
2007 |
| Drug |
triapine |
1 |
2003 |
| Drug |
tributyrin |
1 |
1999 |
| Drug |
tricom (prostvac-f |
1 |
2006 |
| Drug |
tricom (prostvac-v |
1 |
2006 |
| Biological |
tricom vaccine |
1 |
2005 |
| Biological |
tricomâ„¢ |
1 |
2004 |
| Device |
trigrid delivery system |
1 |
2018 |
| Drug |
trilostane |
1 |
2005 |
| Drug |
trimethoprim |
1 |
2017 |
| Drug |
trimethoprim/sulfamethoxazole |
1 |
2017 |
| Procedure |
trimix injection with doppler ultrasound |
1 |
2007 |
| Drug |
triptorelin (decapeptylâ®) |
1 |
2009 |
| Drug |
triptorelin 11.25 mg |
1 |
2012 |
| Drug |
triptorelin embonate (inn) |
1 |
2008 |
| Drug |
triptorelin embonate 22.5 mg |
1 |
2012 |
| Drug |
triptorelin pamoate (pamorelinâ® la 11.25 mg) |
1 |
2010 |
| Drug |
triptorelin pamoate 11.25mg |
1 |
2012 |
| Biological |
trovax |
1 |
2007 |
| Drug |
trpv6 calcium channel inhibitor sor-c13 |
1 |
2018 |
| Procedure |
trus |
1 |
2016 |
| Procedure |
trus-biopsy |
1 |
2015 |
| Device |
trus-guided biopsy |
1 |
2015 |
| Device |
trus-robot |
1 |
2016 |
| Device |
trus fusion guided prostate biopsy |
1 |
2019 |
| Device |
trus probe |
1 |
2008 |
| Procedure |
trus/fusion biopsy |
1 |
2016 |
| Device |
trusbx |
1 |
2019 |
| Drug |
trx518 |
1 |
2019 |
| Other |
ttns |
1 |
2020 |
| Procedure |
tumor biopsy |
1 |
2018 |
| Radiation |
tumor boost irradiation |
1 |
2017 |
| Radiation |
tumor irradiation |
1 |
2017 |
| Other |
tumor marker detection in lymph nodes |
1 |
2010 |
| Biological |
tumor rna transfected dendritic cells |
1 |
2005 |
| Dietary Supplement |
turmeric |
1 |
2017 |
| Behavioral |
type of decision aid |
1 |
2007 |
| Drug |
ulixertinib |
1 |
2015 |
| Procedure |
ultrasound- images |
1 |
2014 |
| Other |
ultrasound-based cancer-specific images |
1 |
2010 |
| Procedure |
ultrasound elasticity imaging |
1 |
2017 |
| Device |
ultrasound guided prostate exam using soc ultrasound system |
1 |
2017 |
| Device |
ultrasound image-guided ablation device |
1 |
2016 |
| Device |
ultrasound transperineal prostate biopsy |
1 |
2017 |
| Device |
ultrasound/mri |
1 |
2019 |
| Other |
undergo hrv |
1 |
2015 |
| Other |
undergo hrv/wear accelerometer to assess therapy complications |
1 |
2015 |
| Device |
urethral catheter loaded with beacon transponders |
1 |
2019 |
| Other |
urinary pca3 test using progensaâ® pca3 assay kit (gen-probe) |
1 |
2012 |
| Diagnostic Test |
urine |
1 |
2018 |
| Procedure |
urine sample |
1 |
2017 |
| Other |
urine sampling |
1 |
2019 |
| Biological |
urine test |
1 |
2018 |
| Diagnostic Test |
urine/plasma biomarkes. |
1 |
2018 |
| Behavioral |
urological intervention |
1 |
2014 |
| Device |
uronav guided biopsy |
1 |
2016 |
| Device |
urostationâ® |
1 |
2014 |
| Device |
us fusion-guided prostate biopsy |
1 |
2014 |
| Behavioral |
usual care (uc) |
1 |
2017 |
| Behavioral |
usual care observational control |
1 |
2016 |
| Other |
usual care with attention |
1 |
2016 |
| Behavioral |
usual care/nci website |
1 |
2018 |
| Other |
usual diet |
1 |
2019 |
| Biological |
utomilumab |
1 |
2017 |
| Biological |
uv1 synthetic peptide vaccine |
1 |
2013 |
| Biological |
uv1 synthetic peptide vaccine/gm-csf |
1 |
2013 |
| Biological |
vaccine vehicle only |
1 |
2006 |
| Drug |
val201 |
1 |
2014 |
| Drug |
valacyclovir in combination with brachytherapy |
1 |
2013 |
| Drug |
vandetanib |
1 |
2008 |
| Behavioral |
vegetable intake education |
1 |
2011 |
| Drug |
velcade tm (bortezomib) for injection |
1 |
2003 |
| Drug |
veliparib |
1 |
2012 |
| Drug |
venetoclax |
1 |
2018 |
| Procedure |
venographic occlusion of spermatic veins |
1 |
2008 |
| Other |
vert system |
1 |
2016 |
| Drug |
verteporfin |
1 |
2017 |
| Drug |
veru-111 |
1 |
2018 |
| Drug |
veru-944 |
1 |
2018 |
| Procedure |
vienna nomogram prostate biopsy protocol |
1 |
2012 |
| Drug |
vinblastine sulfate |
1 |
2002 |
| Drug |
vinflunine |
1 |
2007 |
| Drug |
vinorelbine |
1 |
2005 |
| Drug |
vinorelbine oral formulation |
1 |
2006 |
| Device |
visualase thermal therapy |
1 |
2013 |
| Device |
visualase thermal therapy system |
1 |
2011 |
| Other |
visually enhanced prostate cancer educational presentation |
1 |
2016 |
| Dietary Supplement |
vitamin b12 |
1 |
2005 |
| Dietary Supplement |
vitamin b6 |
1 |
2018 |
| Drug |
vitamin d supplementation |
1 |
2007 |
| placebo |
vitamin e placebo |
1 |
2000 |
| Dietary Supplement |
vitamin e supplement |
1 |
2008 |
| Radiation |
vmat focal therapy boost to dil |
1 |
2017 |
| Drug |
vmd-928 300-mg capsules |
1 |
2018 |
| Other |
volume controlled ventilation |
1 |
2018 |
| Radiation |
volumetric modulated arc therapy |
1 |
2012 |
| Radiation |
volumetric modulated arc therapy (vmat) |
1 |
2012 |
| Radiation |
volumetric modulated arc therapy (vmat)/high-dose rate (hdr) radiotherapy |
1 |
2012 |
| Drug |
voluven (hydroxyethyl starch 130 |
1 |
2011 |
| Drug |
voluven (hydroxyethyl starch 130/0,4) |
1 |
2011 |
| Drug |
vt-464: given orally once daily in 28-day cycles |
1 |
2014 |
| Drug |
vt-464: given orally once daily in 28 day cycles |
1 |
2015 |
| Drug |
vt-464: given orally twice daily in 28-day cycles |
1 |
2014 |
| Biological |
w_pro1 |
1 |
2020 |
| Behavioral |
waitlist control |
1 |
2017 |
| Behavioral |
walking exercise |
1 |
2009 |
| Behavioral |
walking football training |
1 |
2019 |
| Behavioral |
walking intervention |
1 |
2012 |
| Other |
walnuts |
1 |
2019 |
| Procedure |
wb-mri |
1 |
2018 |
| Other |
wear accelerometer to assess therapy complications |
1 |
2015 |
| Behavioral |
web-based counseling |
1 |
2016 |
| Behavioral |
webchoice |
1 |
2008 |
| Drug |
weekly cabazitaxel |
1 |
2012 |
| Behavioral |
weight loss |
1 |
2007 |
| Behavioral |
weight maintenance program |
1 |
2017 |
| Behavioral |
weight training |
1 |
2009 |
| Genetic |
western blotting |
1 |
2007 |
| Dietary Supplement |
western diet |
1 |
2008 |
| Behavioral |
wetness management |
1 |
2013 |
| Drug |
white button mushroom extract |
1 |
2008 |
| Diagnostic Test |
whole-body magnetic resonance imaging |
1 |
2018 |
| Diagnostic Test |
whole-body planar |
1 |
2015 |
| Diagnostic Test |
whole-body planar/pelvic spect/ct scan |
1 |
2015 |
| Radiation |
whole-gland hdr brachytherapy |
1 |
2016 |
| Procedure |
whole-mount sectioning of the prostate |
1 |
2008 |
| Radiation |
whole-pelvic radiotherapy (wprt) |
1 |
2011 |
| Diagnostic Test |
whole body contrast enhanced computer tomography |
1 |
2018 |
| Diagnostic Test |
whole body non-contrast mri |
1 |
2018 |
| Behavioral |
whole grain rye |
1 |
2011 |
| Radiation |
whole pelvic radiotherapy |
1 |
2018 |
| Radiation |
whole pelvis radiotherapy |
1 |
2018 |
| Device |
with computed tomography (ct) (pet |
1 |
2015 |
| Procedure |
with imrt-igrt |
1 |
2010 |
| Device |
with magnetic resonance imaging (mri) (pet |
1 |
2015 |
| Other |
withdrawal of antiandrogen therapy |
1 |
1999 |
| Other |
without dexmedetomidine |
1 |
2018 |
| Behavioral |
written decision aid |
1 |
2013 |
| Behavioral |
written exercise guidelines |
1 |
2015 |
| Behavioral |
written information |
1 |
2017 |
| Drug |
wst 11 -mediated -vtp |
1 |
2009 |
| Drug |
wst09 |
1 |
2006 |
| Radiation |
xrt |
1 |
1999 |
| Drug |
xtandi |
1 |
2017 |
| Drug |
yervoy injectable product |
1 |
2019 |
| Drug |
ym 155 |
1 |
2007 |
| Other |
yoga |
1 |
2017 |
| Behavioral |
yoga therapy |
1 |
2015 |
| Other |
you decide |
1 |
2008 |
| Drug |
zactima (vandetanib) |
1 |
2007 |
| Drug |
zd1839 |
1 |
2005 |
| Drug |
zd4054 (zibotentan) |
1 |
2006 |
| Drug |
zd4054 22.5 mg |
1 |
2003 |
| Drug |
zd6474 (vandetanib) |
1 |
2008 |
| Drug |
zimberelimab |
1 |
2020 |
| Drug |
zoladex (or lupron) |
1 |
2008 |
| Drug |
zoladex â® |
1 |
2015 |
| Drug |
zoladex goserelin implant |
1 |
2011 |
| Drug |
zolderonic acid (zometa) |
1 |
2007 |
| Drug |
zoledronate |
1 |
2016 |
| Drug |
zoledronate therapy |
1 |
2010 |
| Drug |
zoledronic acid (zometa) |
1 |
2005 |
| Drug |
zoledronic acid 20mg tablets |
1 |
2008 |
| Drug |
zolpidem |
1 |
2018 |
| Drug |
zyc300 (zyc300 with cyclophosphamide pre-dosing) |
1 |
2006 |